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ABSTRACT
The potency order of prostanoid EP receptor agonists which inhibited fMLP-stimulated 
superoxide generation and stimulated c AMP generation by human neutrophils were found 
to be consistent with the EP2 receptor subtype. However, evaluation of prostanoid 
receptor antagonists showed that AH 6809 (prostanoid DP and EPi receptor antagonist), 
specifically and selectively antagonised PGE2 -mediated inhibition of superoxide 
generation. Furthermore, PGE2-stimulated cAMP elevation in human neutrophils was 
also antagonised by AH 6809 with a similar potency. The results suggested that contrary 
to the existing classification of prostanoid EP receptors, AH 6809 antagonises an EP2 - 
mediated response. However, it is unclear whether this neutrophil prostanoid EP 
receptor subtype may represent a novel subtype or a human homologue of the classical 
EP2  receptor. Studies investigating the presence of ‘EPn’ receptors on rabbit peripheral 
blood neutrophils were inconclusive, therefore the species specificity and distribution of 
the *EPn* receptor are unclear.
The signal transduction pathway utilized by this neutrophil prostanoid EP receptor, 
termed *EPn\  appeared to be via stimulation of adenylate cyclase and cAMP elevation. 
In addition, cAMP increases in the neutrophil may modulate neutrophil function by 
attenuating influx-dependent increases in [Ca2+]i associated with neutrophil activation,
but had no effect on the release of Ca2+ ions from intracellular stores.
‘EPn* receptors mediating cAMP elevation were also present on human monocytes and 
the human promyelocytic cell line (HL-60) as defined by AH 6809 antagonism of PGE2 . 
However, AH23848B (EP4  receptor antagonist) non-competitively antagonised the 
PGE2 -mediated cAMP increase, suggesting that human monocytes may also express 
prostanoid EP4  receptors.
Therefore, inhibitory prostanoid ‘EPn* receptors are present on human neutrophils and 
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1.1 Leukocytes in host defence
Immunity is the body’s defence system, its protective mechanisms recognise and 
eliminate or neutralise foreign or abnormal materials. These immune responses are 
provoked by microbial infection and damaged or abnormal cells. The cells of the immune 
system are leukocytes normally found in the circulation, but migrate to all parts of the 
body to perform this host defence (Brent, 1992).
There are two main types of immune response, specific and non-specific. The former 
requires prior exposure to specific foreign substances (antigens), and recognition of 
antigen by leukocytes of the lymphocytic lineage on subsequent exposure. Non-specific 
immune responses, commonly known as the inflammatoiy response, are mounted against 
all foreign materials and do not require pre-exposure or recognition of antigenic 
determinants (Van Arsdel, 1992).
1.1.1 Leukocytes and inflammation
Inflammation is triggered during the initial exposure to a foreign substance (before 
specific immunity is activated) and in response to any tissue injury. The purpose of the 
inflammatory response is to bring leukocytes to the site of injury to destroy or inactivate 
the foreign material and prepare the way for tissue repair (Van Arsdel, 1992). 
Neutrophils are the earliest leukocytes to arrive at the scene and provide the first line of 
defence. When the cause of the insult is successfully eliminated, the acute inflammation 
remains localised and quickly resolves. If the material is not eliminated, the inflammation 
persists and leads to the recruitment of monocytes and lymphocytes into the inflamed 
area. A granuloma is subsequently formed to isolate the inflammogen, but if it is not 
completely effective, develops into a chronically inflamed lesion. Chronic inflammatory 
conditions such as rheumatoid arthritis (Van Arsdel, 1992), asthma (Kay, 1986), 
inflammatory bowel disease (Yamada & Grisham, 1991) and psoriasis (Christophers et 
al.y 1982) are characterized by periods of regression and repair, punctuated by further 
acute inflammatory episodes involving leukocyte (neutrophil, monocyte and lymphocyte)
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infiltration and activation.
The leukocytes which perform host defence are of an aggressive destructive nature which 
need to be highly regulated to protect the host, without inflicting tissue damage and 
inflammation on the host. Dysfunction of these regulatory processes leads the 
inappropriate and excessive leukocyte activation, as occurs in acute inflammation (adult 
respiratory distress syndrome, ARDS, Windsor et al.y 1993), chronic inflammation 
(rheumatoid arthritis, Van Arsdel, 1992) and autoimmune diseases (systemic lupus 
erythematous disease, Isenberg, 1992). Amongst the most potentially destructive 
leukocytes are the ‘professional phagocytes’ such as monocytes, eosinophils and 
neutrophils.
1.1.2 The role of the neutrophil in inflammation
The neutrophil is an end-stage cell incapable of division with a short life-span (half-life of 
approximately 12 hours in the circulation, McAfee e ta l.y 1976), and limited protein 
synthetic capacity. Although the neutrophil is generally associated with acute 
inflammation, it has a surprisingly wide range of responses which can cause considerable 
tissue damage. In addition, neutrophil function is regulated by a wide range of 
endogenous and exogenous agents.
Circulating neutrophils normally make only transient contact with endothelial cells lining 
the post capillary venules, by rolling along the luminal surface of the endothelial cells, 
after which, neutrophils detach themselves and return to the general blood flow. 
Neutrophil rolling involves labile interactions between complementary selectin adhesion 
molecules expressed on the plasma membranes of the neutrophils and endothelial cells 
(Lawrence & Springer, 1991). However at sites of inflammation, neutrophils migrate 
out of the circulation into the extravascular tissue in response to inflammatory agents 
released as a result of the trauma, to eliminate the inflammogen. The sequence of events 
in neutrophil activation in inflammation is illustrated in Fig 1.1 and described below.
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The process of neutrophil extravascular migration is believed to consist of 3 sequential 
steps. The first step is the initial tethering of the neutrophils to the endothelial cells in the 
vicinity of the inflammatory insult, by interacting with different selectin adhesion 
molecules, such as E-selectin. Endothelial cells do not constitutively express E-selectin 
molecules and requires de novo protein synthesis. Inflammatory cytokines such as tumor
necrosis factor-a (TNFa) and interleukin-1 (IL-1), and lipopolysaccharide (LPS), a
constituent of bacterial cell walls, however stimulate E-selectin expression by endothelial 
cells (Lawrence & Springer, 1991). The selectin-mediated tethering brings neutrophils 
into the proximity of chemoattractants (discussed in the next section) released from or 
displayed by endothelial cells for the second step of the migration process-neutrophil 
activation. These chemoattractants stimulate neutrophils to activate their surface 
expression of MAC-1 (CD 1 lb/CD 18) integrin molecules, the complimentary ligand for 
the ICAM-1 integrin adhesion molecule expressed by endothelial cells which mediates 
firm leukocyte-endothelial cell adhesion (Larson & Springer, 1990). IL-1 and TNFa also
upregulate the expression of ICAM-1 (Lawrence & Springer, 1991), which facilitates the 
integrin mediated adhesion which stops the neutrophils rolling. Chemoattractant- 
stimulated neutrophil integrin activation is due to a conformational change of the 
expressed integrin receptor and is not dependent on upregulation of additional integrins. 
Neutrophil activation by chemoattractants causes a simultaneous shedding of selectin 
adhesion molecules (Kishimoto et al.y 1989), and is required for the next step of 
neutrophil migration. However, integrin receptor interactions between neutrophils and 
endothelial cells are required for the final step, neutrophil diapedesis, the process of 
transmigration from the intravascular lumen via the inter-endothelial junctions into the 
extravascular tissue to reach the site of tissue damage (Arfors et al., 1987).
After passing through the endothelial barrier, neutrophils migrate towards the 
inflammatory stimulus, down a concentration gradient, by a process called chemotaxis. 
On encountering the cause of the inflammation, neutrophils will attempt to destroy the
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foreign matter by releasing degradative enzymes such as P-glucuronidase from their
azurophilic granules and the generation of toxic reactive oxygen metabolites (ROM) by 
activation of NADPH-oxidase (commonly known as the respiratory burst). Particulate 
stimuli such as bacteria and tissue debris are engulfed by neutrophils into discrete 
intracellular pockets called phagosomes. The contents are destroyed by fusion of 
granules with the phagosome and the emptying of the enzymes into the pocket, and by 
the release of ROM into the lumen of the phagosome by NADPH-oxidase located in the 
phagosome membrane. Neutrophils also generate proinflammatory factors which can 
recruit, prime and activate other leukocytes, such as leukotriene B4  (LTB4 , Ford- 
Hutchinson et al., 1980) and platelet activating factor (PAF, Lotner et al., 1980) by 
activating phospholipase A2  (PLA2 ). Neutrophils can synthesize proteins, such as 
interleukin- 8  (IL-8 ) on stimulation by cytokines (Strieter et a l., 1990) and during 
phagocytosis (Bazzoni et al.9 1991). ‘Frustrated phagocytosis’ by neutrophils may 
contribute to the tissue damage, when neutrophils are unable to completely engulf 
particulate stimuli and tissue debris. ROM and proteolytic enzymes are then released into 
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1.1 Illustration of the sequence of events involved in neutrophil activation at sites of acute inflammation
1.1.3 Effect of inflammatory mediators on neutrophil function
Neutrophils can be activated by a range of endogenous stimuli in addition to bacterial- 
derived agents such as the tripeptide formyl-methionyl-leucyl-phenylalanine (fMLP). 
Endogenous inflammatory mediators such as phospholipid derived LTB4  and PAF 
released from neutrophils (Wymann et al., 1987), and products from the activation of the 
complement cascade, the peptide complement factor C5a (Hugli & Chenoweth, 1981). 
More recently, a group of chemotactic cytokines (chemokines) have been discovered 
(reviewed by Oppenheim et a l., 1991), the first one described was the neutrophil 
selective chemokine interleukin- 8  (IL-8 ). Subsequently more neutrophil selective 
chemokines have been discovered such as ENA-78 (epithelial neutrophil activating 
peptide 78) and neutrophil-activating peptide-2 (NAP-2). Another family of monocyte 
and eosinophil selective chemokines has also been discovered, whose members include 
monocyte chemotactic peptide 1,2 and 3 (MCP-1, -2 and -3) and RANTES (reviewed by 
Oppenheim et al., 1991).
Neutrophil activation stimulated by these chemoattractants, C5a, LTB4 , IL- 8  and fMLP, 
is mediated by specific receptors for these stimuli on the plasma membrane. The 
receptors are the classical rhodopsin type of G protein coupled receptors, with 7- 
transmembrane spanning domains (Holmes eta l., 1991). Activation of neutrophil 
chemoattractant receptors stimulates increases in intracellular calcium, chemotaxis, 
degranulation and the respiratory burst (Snyderman & Uhing, 1992, and Baggiolini & 
Kemen, 1992).
IL- 8  may be the most important endogenous neutrophil chemoattractant in inflammation, 
as IL- 8  is generated by a wide variety of cell types. Leukocytes such as monocytes, 
lymphocytes and neutrophils synthesise IL- 8  (Gregory eta l., 1988, Walz eta l., 1987, 
Strieter et al., 1990, respectively), as do non-immune cells, including fibroblasts (Van 
Damme etal., 1989), synovial cells (Watson et a l., 1988a,b), chondrocytes (Lotz et a l . ,
1992) and endothelial cells (Schroder & Christophers, 1989). In addition, IL- 8  may play
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an important role in neutrophil emigration, as endothelial cells present IL- 8  molecules on 
their luminal surface (Rot, 1992), which would activate rolling or adherent neutrophils. 
Studies have shown that endogenous IL- 8  may regulate neutrophil migration by inducing 
selectin shedding to facilitate spreading and transmigration (Huber et al., 1991), and anti- 
IL- 8  monoclonal antibodies inhibit neutrophil emigration in the rabbit (Sekido et al.,
1993).
Cytokines other than the chemokines, for example, IL-1, TNFa and granulocyte-
macrophage colony stimulating factor (GMCSF) may also regulate neutrophil activation, 
but they differ from chemokines in several ways. The receptors for interleukin 1 (IL-1), 
(TNFa) and granulocyte-macrophage colony stimulating factor (GMCSF) are type I
membrane glycoproteins containing a single transmembrane domain (Taniguchi, 1995). 
However, DL-1 does not appear to have a direct effect on the neutrophil. IL-1 stimulated 
neutrophil activation in vivo may be mediated via induction of IL- 8  generation (Watson et 
al., 1988a). In contrast, TNFa and granulocyte-macrophage colony stimulating factor
(GMCSF) directly influence neutrophil activation. They are unable to elicit a response 
from neutrophils in vitro themselves, but prime neutrophils to be more readily activated 
and more responsive to subsequent stimulation by the direct neutrophil stimuli described 
above (Khwaja et al., 1992). The exact mechanism involved in the priming of 
neutrophils however is not clear, although a role for phospholipase D and phosphatidic 
acid has been suggested (Bauldry etal., 1991), and may be involve the generation of 
PAF (DeNichilo et al., 1991, Stewart et al., 1991). In addition, the cytokines, TNFa
and GMCSF, and the bacterial cell wall derived lipopolysaccharide (LPS), are able to 
stimulate hydrogen peroxide generation by adherent (to endothelial cells and basement 
membrane proteins such as fibrinogen), but not suspended neutrophils (Nathan, 1987). 
The ability of TNFa and GMCSF to stimulate neutrophils directly therefore, may depend
on interactions between their receptors, the cytoskeleton and adhesion molecules on 
adhesion to endothelial cells and extracellular proteins (Nathan, 1987).
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1.1.4 Modulators of neutrophil activation
Modulation of neutrophil activation would be an attractive therapeutic target as a treatment 
of inflammatory conditions where there is excessive or inappropriate neutrophil 
recruitment and activation. Several approaches are available to modulate leukocyte 
activation which are applicable to neutrophils:-
a) Preventing the activation of leukocytes with antagonists of specific leukocyte 
stimuli, for example IL- 8  receptor antagonists
b) Modulating signal transduction pathways regulating leukocyte function by 
inhibiting stimulatory signal transduction pathways or stimulating/enhancing inhibitory 
intracellular second messengers such as cAMP
1.1.4.1 Inhibition of neutrophil activation with antagonists of specific neutrophil
stimuli
There are a large number of exogenous and endogenous stimuli which are able activate or 
prime neutrophils (see section 1.1.3). However, the type of stimuli present at an 
inflammatory site depends on the cause of the inflammation, for instance, bacterial 
infection or tissue damage, and the location of the injury, such as the skin or the lung. 
Any combination of inflammatory mediators could be present. Therefore, inhibiting 
neutrophil activation by antagonising single specific stimuli may only be effective in a 
limited range of inflammatory responses. The stimuli involved would not be the same in 
every disease and may not be known in some inflammatory conditions, hence, 
antagonists of specific neutrophil stimuli may not be therapeutically useful.
1.1.4.2 Inhibition of neutrophil activation by modulating intracellular transduction 
pathways
The neutrophil chemoattractants, such as fMLP and C5a, stimulate G protein coupled 
receptors to activating the classical activation pathway involving phospholipase C
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activation. This pathway activates protein kinase C and elevates intracellular calcium 
levels (Cockcroft & Gomperts, 1985). Activation of these signal transduction molecules 
leads to activation of the neutrophil stimulating degranulation and the respiratory burst.
There are also intracellular signal transducer molecules which inhibit leukocyte activation. 
The most ubiquitous and most well known inhibitory second messenger is cyclic 3\5*- 
adenosine monophosphate (cAMP). Adenylate cyclase catalyses the formation of cAMP 
from adenosine trisphosphate (ATP), whilst cAMP is inactivated by phosphodiesterases 
by conversion to 5* adenosine monophosphate. Cell-permeable analogues of cAMP such 
as dibutyryl cAMP, or agents which elevate endogenous cAMP levels either by activating 
adenylate cyclase (forskolin) or inhibiting phosphodiesterase (isobutylmethyl xanthine, 
IBMX), inhibit neutrophil activation (Lad etal., 1985, Nourshargh & Hoult, 1986, Lad 
et a l., 1985). Therefore, agents which elevate cAMP may be potentially anti­
inflammatory.
1.1.4.3 Inhibition of neutrophil activation by phosphodiesterase inhibitors
There at least 5 subtypes of phosphodiesterase for which cAMP is a substrate, and 
isoforms exist within individual PDE subtypes (reviewed by Beavo, 1990), but the type 
IV cAMP-specific PDE is found in most leukocytes. Inhibitors of the type IV isozyme 
suppress leukocyte activation in vitro and cause relaxation of smooth muscle, and are 
therefore potentially anti-inflammatory and bronchodilatory (Torphy & Undem, 1991). 
Several selective type IV PDE inhibitors have been developed for the treatment of asthma 
but exhibited antidepressant activity in clinical trials (Watchel, 1983). These side effects 
may be attributable to the lack of selectivity of the inhibitors for the different isozymes of 
type IV PDEs.
1.1.4.4 Inhibition of neutrophil activation by stimulators of adenylate cyclase
There are at least 8  different isoforms of the mammalian adenylate cyclase (Kruprinski et 
al., 1992), but the isoform present in human leukocytes has not been identified.
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Forskolin is a direct-acting non-selective stimulator of adenylate cyclase (De Souza et al., 
1983), and also lacks potency. Therefore development of a selective activator of the 
neutrophil adenylate cyclase may be difficult to achieve. However, neutrophils and other 
leukocytes express plasma membrane receptors for substances which suppress their 
activation, for example, adenosine (Cronstein et al., 1983), adrenergic agents (Lad et a l. , 
1985), histamine (Burde et al., 1990) and prostaglandins (Bourne et al., 1971). These 
inhibitory mediators may act as endogenous physiological modulators of leukocyte 
activation. The development of selective agonists for these inhibitory receptors may 
represent another approach for the development of novel anti-inflammatory agents. 
These inhibitors may be more useful as anti-inflammatory agents as they are not as 
specific as the antagonists of leukocyte stimuli. They may encounter the problems of 
selectivity associated with modulators which act intracellularly, such as phosphodiestase 
inhibitors, but these may be more easily identified and overcome. The pharmacological 
characterization of receptors on the plasma membrane is more readily performed in intact 
cells, as opposed to intracellular targets which would require extensive biochemical 
isolation and purification before characterization could be performed.
The receptor-orientated agonistic approach is perhaps the more amenable to. 
pharmacological investigation and intervention, and has been undertaken in the studies 
presented in this thesis on the human neutrophil. Although the neutrophil may not be 
most important cell in inflammation, it is perhaps the most suitable leukocyte for such a 
study. Neutrophils are the most numerous of the leukocytes in the circulation, and their 
responses in vitro are comparatively simple, have a rapid onset and short duration 
compared to lymphocytes, monocytes and eosinophils. The majority of the 
pharmacological analysis performed in the present study will be performed using human 
neutrophils but will be extended to other leukocytes.
One of the best known inhibitors of leukocyte activation are the E-type prostaglandins, as 
initially reported by Gordon et al. (1976), who demonstrated inhibition of T-lymphocyte 
activation by PGE2 in vitro. Subsequently, the immunomodulatory effects of PGE2  have
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been observed in lymphocytes, monocytes and neutrophils in vitro and in vivo (reviewed 
by Kunkel & Chensue, 1984). However contradictory reports of proinflammatory 
effects of prostaglandins have also been described, but it is unclear whether these are 
attributable to different prostanoid receptor subtypes (reviewed by Goodwin, 1991). In 
addition, the classification of prostanoid receptors has been conducted in other tissues 
and subtypes of prostanoid receptors have been identified (Gardiner & Collier, 1980 and 
Kennedy etal., 1982). In spite of this, leukocyte inhibitory prostanoid receptors have not 
been pharmacologically characterized prior to the initiation of this study.
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1 .2 Prostaglandins and their receptors
1.2.1 Historical and general background
The term “eicosanoids” encompasses the unsaturated lipids derived from C2 0  
polyunsaturated fatty acid precursors, the most common being arachidonic acid (C20:4 n- 
5). They can divided into two groups; those formed via the cyclo-oxygenase pathway, 
namely the prostanoids (prostaglandins and thromboxanes) and the products of the 
lipoxygenase metabolic route (leukotrienes, lipoxins and hydroxy-fatty acids).
Prostaglandins are oxygenated polyunsaturated 20-carbon fatty acids containing a 
cyclopentane ring (a characteristic of the theoretical parent structure prostanoic acid). 
Thromboxanes, on the other hand, contain an oxane ring, and may be regarded as 
derivatives of thrombanoic acid.
The biological activity of prostaglandins was first discovered in the 1930s as a factor 
found in human semen and sheep vesicular gland which stimulated smooth muscle and 
lowered blood pressure (Goldblatt, 1933, and Von Euler, 1934). Von Euler (1936) 
characterised this factor as a hydroxylated unsaturated fatty acid, and the name 
prostaglandin was conferred on the assumption that it originated from the prostate gland.
Prostaglandins (PGs) are not synthesised and stored like most hormones, but are 
synthesised de novo by almost all mammalian cells and act locally as autocoids. They are 
generated in response to a wide range of stimuli; physiological, such as hormone receptor 
activation, and pathological, such as mechanical trauma. There are three series of 
naturally occurring PGs, l-,2- and 3- according to the fatty acid precursor (constituents 
of membrane phospholipids) they are derived from. The numerical subscript indicates 
the number of double bonds in the alkyl chain. The 1-series is derived from eicosatrienoic 
acid (C 20:3 n-6)> the 2 -series from eicosatetraenoic acid (C 20:4 n-6 more commonly known 
as arachidonic acid) and the 3-series from eicosapentaenoic acid (C20:5 n-3)- The PGs of 
2 -series i.e. derived from arachidonic acid are predominant in mammalian tissue and their
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synthetic route is shown in Fig 1.2.
1.2.2 Classification of prostanoid receptors
The prostanoids are ubiquitously present in the mammalian body, capable of exerting a 
wide spectrum of biological actions on different tissues, organs and cells and proposed to 
have pathophysiological roles such as inflammatory and peripheral vascular diseases. 
Prostanoids have a multiplicity of target tissues and are able to elicit a wide range of 
responses, some of which are opposing in the same tissue such as contraction and 
relaxation of smooth muscle but at different concentrations (Gardiner & Collier, 1980). 
These observations have hampered the progress of prostaglandin research investigating 
the involvement of individual prostanoids and their receptors in inflammatory processes 
and pathology of diseases such as ARDS, asthma, inflammatory bowel disease, psoriasis 
and arthritis.
Hence, the classification of prostanoid receptors in general was imperative to determine 
which responses were attributable to which receptors. Such a classification would also 
lead to the discovery of selective agonists and antagonists which would reciprocally aid 
receptor classification, and provide possible therapeutic starting points for the discovery 
of potential drugs to treat these diseases.
Two different approaches were undertaken to form a preliminary classification of 
prostanoid receptors. Coleman et al. (1984) conducted a systematic search of a wide 
range of tissues to identify those which they believed had a homogeneous receptor 
population. This was achieved by applying two criteria; the tissues should respond with 
either a relaxation or contraction (not both) to each prostanoid agonist, and secondly in 
each tissue, one naturally occurring prostanoid was considerably more potent. These
preliminary studies identified specific receptors for PGE2 , PGF201 and TXA2 . The
incorporation of data from studies on platelets (human and guinea-pig) led to the proposal 
of the existence of five distinct receptor types for PGD2 , PGE2 , PGF2 a> PGI2 and
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TXA2 - The nomenclature proposed for this classification was that prostanoid receptors 
be termed P-receptors and the prostanoid which was most potent at the receptor indicated 
by a prefix, for instance, DP, EP, FP, IP and TP receptors for PGD2 , PGE2 , PGF2a>
PGI2  and TXA2 respectively. Subdivisions of the receptors were indicated by numerical 
subscript, for example, EPi, EP2 , EP3 , etc.
The other approach (Gardiner & Collier, 1980) used a limited number of tissues 
(guinea-pig trachea and human bronchial muscle). Responses of these respiratory 
tissues to PGEi, PGE2 , PGF2a, PGF2 B, PGI2 and 3 synthetic prostanoid agonists
(TR4161, TR4367 and TR4752) were classified as contractile/stimulant (x),
relaxant/inhibitory (\j/) or “irritant” (co) (they induced cough in cats). These receptors
were later subdivided (Gardiner, 1986) on the basis of agonist potency orders in a 
wider range of tissues (respiratory and non-respiratory), and the activity of the ligands; 
U46619 (thromboxane mimetic) and SC 19220 (EP receptor antagonist). The
contractile prostanoid receptors were subdivided into Xi receptors (agonist U46619),
%2 receptors (agonist PGF2a/PGD2) and X3 (agonist PGE2/antagonist SC 19220). The
relaxant receptor (y) was also subdivided as agonist potency orders for PGEi, PGE2 ,
PGI2 and butaprost (EP receptor agonist, TR4979) were different for inhibition of 
human platelet aggregation and vasodilation (Copas et al., 1981).
The activity of a prostanoid in a tissue does not necessarily indicate that its specific 
receptor is present in the tissue. Only the use of selective antagonists can determine 
this, as shown by AH19437 (TP receptor antagonist) antagonism of U46619 at TP 
receptors and the weaker effects of other prostaglandins at this receptor. This illustrates 
the promiscuity of prostanoids and their receptors and why the Coleman et al. 
classification was more easily understood and universally adopted. The Gardiner & 
Collier approach used a limited number of tissues which clearly contained
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heterogeneous prostanoid receptor populations, and the classification was not easily 
transferable from respiratory tissues to other organs.
Selective agonists and antagonists have however been identified using these criteria, 
such as the EP1/EP3 selective agonist sulprostone and AY23626 (Coleman et a l., 
1987). Their use has clarified the preliminary classifications of both Coleman et al. and 
Gardiner which in turn led to the development of more selective ligands. This self- 
perpetuating process has evolved into the classification which is currently recognised 
today as being as unambiguous and pharmacologically correct as possible. It is largely 
based on the Coleman et al. classification both in terms of nomenclature and approach 
and the most recent version published in the IUPHAR Receptor Compendium 
(Coleman et al., 1994b) and summarised in Table 1.1.
1.2.3 Pharmacological characterization of receptors
Receptors can be classified on the basis of a variety of criteria; molecular information 
about the receptors themselves and their genes; second messenger/signal transduction 
pathways and by their pharmacological profiles. The most informative and accessible 
rationale in the field of prostaglandin research, as can be observed from the previously 
described characterization of prostanoid receptors, is the pharmacological classification 
of receptors. This method of receptor classification relies upon the interpretation of the 
effects of agonists and antagonists on the functional response of the tissue under 
investigation. A variety of methods can be adopted in the pharmacological 
classification of receptors but their usefulness is dependent on the availability of 
selective agonists and antagonists. The approaches undertaken in the present study are 
outlined below:
1.2.3.1 Receptor classification using relative agonist and antagonist potency 
ratios
When the rank order of the potency of a series of agonists in two different tissues is
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found to be similar, the presence of the same receptor in both tissues is indicated, as is 
the case when an antagonist exhibits a similar potency. If two tissues express different 
receptors, a difference in the relative agonist potency ratio and/or antagonist potency 
would be expected. More quantitative and unequivocal evidence would be an 
estimation of the affinity constant from its pA2 value (the negative logarithm to the base 
1 0  of the concentration of the antagonist which causes a two-fold shift of the control 
agonist concentration-effect curve). If an antagonist is competitive (and reversible), 
this value is equal to the affinity constant of that antagonist at that receptor , that is, 
when the slope is unity in the corresponding Schild plot (Jenkinson et al.9 1995). 
However, it is possible for an antagonist to exhibit the same affinity at two different 
receptors, hence the ideal situation would be to have data with both agonists and 
antagonists.
1 .2.3.2 Quantitative analyses of agonist concentration-effect data
The overall response induced by an agonist in a tissue is determined by two properties; 
its affinity for the receptor (how well it binds to the receptor) and its efficacy (the ability 
of the resultant agonist-receptor complex to elicit a response in that particular tissue). 
These parameters provide more quantitative information about the agonist and the 
complementary receptor and may provide more effective direction of chemical effort in 
the synthesis of novel agonist probes for a given receptor with the required properties, 
that is; affinity and efficacy which govern potency, and selectivity. Furthermore, 
estimates of agonist efficacy could increase our understanding of the transduction 
pathway linking activation of the receptor to the observed response, such as 
amplification of the initial signal through multiple biochemical coupling steps. In the 
case of the neutrophil, the range of functions which can be modulated by these 
pharmacological agents, the degrees of inhibition, and the quantitation of their effects 
on second messengers would provide knowledge of the ‘cross-talk’ between 
stimulatory and inhibitory signals within the neutrophil and how they influence cellular 
function.
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Fig 1.2 Synthetic pathway for PGE2 and other prostaglandins from 
arachidonic acid.
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Receptor Type Endogenous Ligand Selective Agonist Selective Antagonist
DP PGE>2 BW 245C
ZK 110841
PGE2  See Table 3.1
w FP PGF2 a Fluprostenol
Cloprostenol
Prostalene
IP PGI2  Cicaprost
Iloprost
Octimibate
TP TXA2  U44609
U46619 
SQ 26655








Table 1.1 Classification of prostanoid receptors. Extracted from the IUPHAR Classification of Prostanoid Receptors (Coleman et al
1994). Prostanoid EP receptors discussed in further detail in Chapter 3.
1.3 Characterization of neutrophil inhibitory receptors using superoxide generation
as a functional assay
1.3.1 Requirements of a functional assay for the characterization of neutrophil
inhibitory receptors
In order to characterize receptors mediating inhibition of neutrophil activation, a suitable 
functional assay is required which fulfils certain criteria:-
1. The assay system must be sensitive to inhibition by the agents under 
investigation.
2. The functional assay should be simple, reproducible, of short duration and 
easily quantified to reduce the likelihood of degradation of the agents being studied.
3. It also desirable that the biological response used in the assay be physiological 
relevant, considered pro-inflammatory and destructive, and its suppression considered 
to be anti-inflammatory.
Most in vitro neutrophil activation assays occur rapidly and last a few minutes, such as 
superoxide generation, degranulation, polarisation and phagocytosis. Others, for 
instance, chemotaxis and IL- 8  synthesis, have a considerably longer time course 
(hours). However the time course of neutrophil responses is also dependent on the 
type of stimulus used. In general, soluble stimuli, like C5a and fMLP, elicit more 
rapid neutrophil responses than particulate stimuli, including immune complexes and 
opsonised particles. Particulate stimuli require ingestion to activate neutrophils, whilst 
soluble stimuli activate neutrophils directly via plasma membrane receptors.
Superoxide generation in neutrophils is rapidly induced by fMLP and has been widely 
used for investigating the inhibitory effect o f adenosine receptor (Cronstein et a l. ,
1983), p-adrenergic receptor (Lad et al., 1985) and histamine receptor (Burde et al., 
1990) agonists, in addition to prostaglandins (Gryglewski et al., 1987). Superoxide
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generation is easily and more accurately quantified spectrophotometrically by measuring 
the reduction of ferricytochrome C (Nauseef et al., 1983). Other less direct protocols 
measure hydrogen peroxide, a distal product of the same pathway, e.g. with scopoletin 
(reviewed by Hayes & Fletcher, 1990). Thus, fMLP-stimulated superoxide generation 
using ferricytochrome C was chosen in the present study for the characterization of 
inhibitory prostaglandin receptors in human neutrophils.
1.3.2 Human neutrophil NADPH-oxidase - the superoxide anion generation complex
NADPH-oxidase catalyses the one electron reduction of oxygen to superoxide (O2’ ) 
using NADPH as the electron donor (reviewed by Babior, 1978 a,b). The formation of 
superoxide anions through this system is the initial step leading to the generation of all 
reactive oxygen metabolites by neutrophils, such as hydrogen peroxide (H2 O2 ), the
hypochlorite ion (CIO") and the hydroxyl radical (OH ). In the resting neutrophil, the 
NADPH-oxidase complex is disassembled with components dispersed in the plasma 
membrane and in the cytosol. On stimulation, the cytosolic components translocate to 
the membrane to assemble the active oxidase. Electrons are donated by NADPH to a 
flavoprotein functioning as NADPH dehydrogenase and passed on to the terminal 
oxidase, cytochrome bsss, which reacts with O2 to produce 0 2 “ (Fig 1.3).
The stoichiometry of the formation of superoxide anions is:
202 + NADPH - 2 0 2“ + NADPH ^  + H*
The oxidase components are the best characterized of the NADPH-oxidase complex; 
cytochrome bsss is a heterodimer consisting of a small haeme carrying subunit (a
chain) of 22 kDa (p22ph°*) and a large highly glycosylated subunit (P chain) of 91kDa
(gp9lPhox). A 22kDa G protein, RaplA, is closely associated with cytochrome bssg 
(Quinn et al., 1989) and colocalises with cytochrome bsss in the plasma membrane and 
also within specific granules (Quinn et al., 1992), which suggests that this complex
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may be formed during activation. The two cytosolic components, p47Phox and 
p67Phox, with molecular weights of 47kDa and 67kDa respectively are essential for 
oxidase activity. Protein kinase C-dependent phosphorylation of p47Phox correlates 
with the association of p47Phox with the cytoskeleton and the translocation of p47Phox 
and p67Phox to the plasma membrane (Nauseef et al., 1991). Protein kinase C may 
represent an activation signal used by receptor-mediated stimuli e.g. fMLP to induce 
NADPH-oxidase activation. In chronic granulomatous disease (CGD), the NADPH- 
oxidase is defective and the leukocytes are unable to generate superoxide anions
resulting in abnormal responses. The cause of the defect are mutations of the a  (< 5%)
or |3 (« 55%) subunit of cytochrome bsss or the cytosolic factors p47Phox (« 35%) and
p67Phox (< 5%) (reviewed by Morel et al., 1991), thus demonstrating that all four of 
these components are required for the formation of the active oxidase. The NADPH 
dehydrogenase component(s) is less well characterized, and the nature and identity of 
this electron carrier linking NADPH to cytochrome bsss is more controversial. It has 
been identified as a FAD-binding flavoprotein, and some evidence suggests that the 
NADPH dehydrogenase is localised in the cytosol in resting cells and its translocation 
to the membrane during activation is dependent on the presence of p47Phox (Umei et 
al., 1991).
1.3.3 Reactive oxygen metabolites formed from superoxide anions by neutrophils
Superoxide anions generated by NADPH-oxidase can be modified by neutrophils to 
form different and more microbicidal reactive oxygen metabolites e.g.hydrogen 
peroxide (H2 O2 ), hypochlorite anions (CIO"), the hydroxyl radical (OH ) and 
chloramines.
Hydrogen peroxide is formed either by the spontaneous dismutation of superoxide 
anions or can be catalysed by superoxide dismutase:
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202” + 2H+ -  H20 2 + 0 2
Myeloperoxidase released from the neutrophil azurophil granules catalyses the 
oxidation of halide ions by hydrogen peroxide into hypohalite ions which are are also 
bactericidal. As the most abundant halide anion in neutrophils is the chloride ion Cl“, 
the hypochlorite ion is formed:
Cl" + H20 2 -  C1CT+ H20
These hypochlorite ions react with amines to form chloramines which are powerful 
oxidising agents and the most toxic ROM derived from the respiratory burst. In 
addition to this the hydroxyl radical, OH - may also be formed from 0 2~ (Weiss e ta l .,
1977 and Tauber et al., 1977) although the precise mechanism is unclear. Superoxide 
anions may also react with NO to form peroxynitrite anions (ONOO"), which may 
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Fig 1.3 Organisation of the NADPH-oxidase system of the human 
neutrophil: transition from the resting state to the activated state. In
unstimulated neutrophils (resting state) the oxidase is dormant and dissociated with 
components distributed in the cytosol and plasma membrane. Upon stimulation 
(activated state), the soluble components, p47Phox and p67phox, translocate to the plasma 
membrane and associate with the NADPH flavodehydrogenase (Fp) and cytochrome bsss 
(p22phox and p9lPhox). RaplA, a ras-related G protein, is closely associated with 
cytochrome bsss-
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1.4 Aims of this thesis
The aims of this thesis are to pharmacologically characterize the prostanoid EP receptors 
mediating inhibition of leukocyte activation in vitro using the following approaches:
1. Characterize the inhibitory prostanoid EP receptors of human neutrophils using 
fMLP-stimulated superoxide generation as the functional assay with a range of selective 
agonists and antagonists.
2. Determine whether cAMP elevation is the second messenger pathway utilized by 
this inhibitory prostanoid EP receptor in the human neutrophil.
3. Further determine whether EP receptor agonist-mediated cAMP elevation 
modulation of [Ca2+]i is involved in the regulation of human neutrophil activation by 
comparing the effects of EP receptor agonists and phosphodieserase inhibitors on fMLP- 
stimulated increases in [Ca2+]i.
4. Investigate the inhibitory profile of PGE2  on human neutrophil activation by 
comparing its potency and efficacy as an inhibitor of superoxide generation, 
degranulation and shape change stimulated by a range of agonists.
5. Further determine the profile of the inhibitoiy effect of PGE2 on other leukocytes 
by characterizing the prostanoid EP receptors present on human peripheral blood 
monocytes and undifferentiated HL-60 cells (a human promyelocytic cell line) and the 









Butaprost: m ethyl( 1 r ,2 r , 3r)-3 -h ydroxy-2 -[ ( 1 E ,4 r )-4  -hydroxy-4 -(1-
propylcyclobutyl)-l-butenyl]-5-oxocyclopentaneheptenoate
Glaxo Wellcome Research generously supplied:-
AH 6809: 6-isopropoxy-9-oxoxanthene-2-carboxylic acid
AH13205: (+/-)-trans-2-4 [4-( 1 -h ydroxy hexyl)p henyl] -5-oxocyclopen tanehep tanoic
acid
AH23848B: (lcc[z],2p ,5a )-(± )-7 -(5 -[ {(1, l*-biphenyl)-4-yl}m ethoxy]-2-[4-
moipholinyl]-3-oxocyclopentyl)-4-heptenoic acid
BW 245C: 5-(6-carboxyhexyl)-l-(3-cyclohexyl-3-hydroxypropyl)hydantoin
BW A8 6 8 C: 3 -b e n z y l-5  -[ 6 -c a r b o x y h e x y  1]-1 -[ 2-c y c l o h  ex y 1-2-
hydroxyethylamino] hydantoin
GR63799X: (1r-[1oc{Z},2P{ R * } ,3a]-4-(benzoylamino)phenyl-7-(3-hydroxy-2-[2- 
hydroxy-3-phenoxypropoxy]-5-oxocyclopentyl)4-heptenoate


















octenyl]-5-oxocyclopentaneheptanoate (purchased from Cascade 1994 
onwards).
SC 19220: l-acetyl-2-(8-chloro-l 0,1 l,dihydro-benz[fc,/][l,4]oxazepine-10-
carbonyl)hydrazine
All other prostaglandins were bought from Cascade Biochem Ltd, Reading. Structures 
of most widely used prostanoids shown in Figs 2.1, 2.2 and 2.3.








Research Biochemicals International (RBI®) supplied:-
RO 20-1724: (4-(3-butoxy-4-methoxy-4-methoxybenzyl)-2-imidazolidinone)
Rolipram: 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidinone synthesised “in
house” at Astra Chamwood.
Calbiochem supplied: -
Milrinone: 1,6-dihydro-2-methyl-6-oxo(3,4*-bipyridine)-5-carbonitrile
2 . 1 . 1 .4 Other reagents
Cytochalasin B, ferri-cytochrome C (type IV), digitonin, dimethyl sulphoxide (DMSO), 
econazole, formyl-methionyl-leucyl-phenylalanine (fMLP), gluteraldehyde, MOPS (3- 
[N-morpholino]propanesulfonic acid), superoxide dismutase (SOD), human recombinant
C5a, forskolin, p-dinitrophenyl-P-d-glucuronide, Percoll, Triton X-100 and zymosan A
were obtained from Sigma (Poole, Dorset). H -89 {N -[2-((/?-
bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, HC1), and SQ 22,536 (9- 
(tetrahydro-2’-furyl)adenine) obtained from Calbiochem. Fura-2am was supplied by 
Molecular Probes Inc (Eugene, Oregan). Human recombinant EL- 8  (72 amino acid form) 
was obtained from Advanced Protein Products, Brierley Hill, West Midlands, and C 16 
platelet activating factor (PAF) from Cascade Biochem Ltd, Reading. Sterile 0.9% saline 
and 3.8% sodium citrate solutions were from Phoenix Pharmaceuticals. Heparin 
(Monoparin) and EDTA tubes (Monovette) were bought from Evans. Dextran T500 was 
bought from Pharmacia. Polymorphprep™, Lymphoprep™ and Nycoprep™ 1.068g 
from Nycomed U.K., Birmingham and Monopoly Resolving Medium from Flow 
Laboratories. Hank’s buffered salt solution (HBSS) and all culture products were from 
Imperial and Gibco. Phosphate buffered saline (PBS) tablets from Oxoid. Sagatal and 
Euthatal anaesthetics (both pentobarbitone sodium) were obtained from Rhone Merieux 
and Saffan™ (an anaesthetic steroid) was supplied by Pitman-Moore. Sodium caseinate
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was purchased from Difco. All other laboratory reagents were of analytical grade and 
obtained from Fisons Scientific Equipment.
2.1.2 Stimuli and priming agents
Human recombinant C5a stock solutions (1(MM) and IL-8 stock solutions (lOjig ml-1) 
were prepared in 0.1% HSA in PBS, whilst Ci6 PAF was dissolved in distilled water at 
10-2M. All stocks were stored at -20°C and dilutions made in buffer containing 0.1% 
HSA. fMLP stock solutions (10-2M in DMSO) were also stored at -20*C.
2.1.3 Opsonisation of zymosan
Fresh human serum was prepared by placing uncoagulated blood in a clean glass 
universal bottle (up to 20ml per bottle) which was allowed to stand for 2h at room 
temperature. The clot was freed (‘rimming’) from the walls of the vessel with an 
autoclaved glass Pasteur pipette at lh and 2h to allow the clot to contract The universal 
was centrifuged (lOOOg, 10 min, 20’C) and the serum placed in a sterile 50ml 
polypropylene centrifuge tube.
Zymosan A (yeast cell wall particles from Saccharomyces cerevisiae) was suspended in 
sterile PBS (5mg ml-1), vortex-mixed and the suspension passed through a 23 gauge 
needle to disperse aggregates. After centrifugation (lOOOg, 5 min, 20*C) the zymosan 
was resuspended in freshly prepared human serum at 15mg ml-1 with rigorous pipetting 
in a sterile 13.5ml conical polystyrene centrifuge tube and incubated in a shaking water- 
bath at 37°C for 30 min. The suspension was washed twice by centrifuging (lOOOg, 5 
min, 20°C) resuspending in fresh PBS and finally resuspended in PBS at lOmg ml-1 and 
the suspension once again passed through a 23 gauge needle. This suspension as stored 
at 4*C until required, and vortex-mixed before diluting. The opsonised zymosan was 


































































Fig 2.4 Structures of Phosphodiesterase Inhibitors
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2.2 Preparation of human neutrophils
Neutrophils were isolated from blood donated by healthy male and female members of 
the human volunteer panel of Astra Charnwood or members of the Department of 
Pharmacology, School of Pharmacy and Pharmacology, University of Bath. Venous 
blood (100ml from each donor) was collected in 50ml syringes from the antecubital vein 
with 21 gauge venepuncture sets (Vygon) and anticoagulated with heparin (10U ml-i 
blood, Monoparin) in the Department of Clinical Pharmacology, Astra Charnwood, 
Research and Development Laboratories, Loughborough or the Medical Centre, 
University of Bath.
The neutrophils were isolated using aseptic techniques in Class II cabinets. Initial 
experiments used Monopoly Resolving Medium as the separating medium; however due 
to its inconsistent supply its use was discontinued and Polymorphprep was used in all 
subsequent experiments.
2.2.1 Polymoiphprep /Mono-Poly Resolving Medium
Heparinised blood was layered onto Monopoly Resolving Medium (MPM) in the ratio of 
4ml blood : 3ml MPM in 13.5ml polystyrene conical centrifuge tubes (Sterilin) and 
centrifuged (300g, 20°C) for 45 min. With Polymorphprep as the separating medium, 
5ml heparinised blood was layered onto 3.5ml Polymorphprep in 13.5ml polystyrene 
conical centrifuge tubes (Sterilin) and centrifuged (450-470g, 20°C) for 25 min. Both of 
these methods resulted in two bands of leukocytes; the upper band contained 
mononuclear cells and platelets whilst the lower band was composed of granulocytes, 
suspended over a pellet of erythrocytes. Thus, both allowed the one-step separation of 
polymorphonuclear leukocytes (PMN) from human blood.
The mononuclear leukocyte band was discarded with the plasma and then the lower 
granulocyte band from tubes from individual donors were collected and pooled in 4x 
50ml conical polypropylene centrifuge tubes and diluted with an equal volume of RPMI
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1640 (buffered with sodium bicarbonate at 2 g H ) and supplemented with penicillin 
(100U ml*1) and streptomycin (lOOjig ml-1). These tubes were centrifuged (400g, 20°C) 
for 1 0  min, the supernatant discarded and contaminating erythrocytes removed by 
hypotonic lysis (20ml cold 0.2% NaCl, 30s followed by 20ml 1.6% NaCl). Following 
centrifugation (400g, 20*C) for 10 min, the cell pellet was gently resuspended in 5ml 
RPMI 1640. The granulocytes were counted and viability assessed by Trypan Blue 
exclusion (viability >99%). The purity of the cell preparation was examined 
microscopically on cytospin preparations with Wright’s stain and was typically >95% 
neutrophils, the remainder consisted of eosinophils and monocytes. There was no 
apparent difference in the purity or function of the cells isolated using Monopoly 
Resolving Medium and Polymorphprep. The cells were maintained at room temperature 
rolling on a Coulter Roller in RPMI 1640 at lxlO7 ml-1 or less.
2.2.2 Lymphoprep Method
Venous blood was taken (100ml) and heparinised as described in 2.2 and then 
centrifuged (400g, 6  min) at room temperature. The platelet rich plasma was removed 
and the residual pellet was diluted to 200ml with RPMI 1640 (HEPES buffered,
supplemented with penicillin 100U ml'1, streptomycin 100(ig ml' 1 and fungizone l|ig  ml' 
!) in a 75cm2  culture flask and mixed gently. The diluted blood was gently layered on to
Lymphoprep in 50ml conical centrifuge tubes in the ratio of approximately 30ml diluted 
blood : 15ml Lymphoprep and centrifuged for 30 min (250g) at room temperature. The 
single band of mononuclear cells and all the supernatant above the erythrocyte pellet were 
removed with a plastic Pasteur pipette, and the pellets gently mixed and pooled (2 into 1). 
Warmed 6 % dextran (500,000 MWt.) in saline (5ml) was added to each tube, the volume 
made up to 50ml with saline and the contents gently and thoroughly mixed and allowed to 
stand for 30 min at room temperature. The leukocyte rich supernatant above the 
sedimented erythrocytes was collected, centrifuged (400g, 10 min, 20’C) and the 
contaminating erythrocytes removed by hypotonic lysis (10ml ice-cold 0.2% NaCl for
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30s followed by 10ml 1.6% NaCl). After centrifugation (400g, 10 min, 20'C), the cells 
were resuspended in 5ml HBSS (Ca2+/Mg2+ free, pH 7.2-7.4, 0.1% BSA), counted and 
viability assessed microscopically by Trypan blue exclusion.
2.2.3 The Percoll Method
The method used in this study is based on that described by Haslett etal.t (1985), with 
modifications made by members of Division of Gastroenterology, University Hospital, 
Nottingham, who routinely use this method. Venous blood was taken as described in
2.2 and anti-coagulated with 3.8% sodium citrate (Phoenix Pharmaceuticals) in the 
proportion 1:10 v/v citrate to blood. A maximum of 40ml blood was collected in each 
50ml polypropylene centrifuge tube, and the tubes were centrifuged (400g, 20 min, 
20°C). The platelet rich plasma (PRP) was aspirated and centrifuged (lOOOg, 15 min, 
20° C) to generate platelet poor plasma (PPP) which was put aside for making the Percoll 
gradients and resuspending the leukocytes. Meanwhile 6 ml of warmed 6 % dextran 
(MWt 500,000) in 0.9% saline was added to each cell pellet, the volume made up to 50ml 
with sterile saline and the contents of the tube was gently and thoroughly mixed by 
inversion and rocking. This was then allowed to stand vertically at room temperature for 
30 min to sediment the erythrocytes. The leukocyte rich supernatant was removed and 
centrifuged (400g, 10 min, 20°C), and the cell pellet gently resuspended in 2-3ml 
autologous PPP in a 13.5ml polystyrene conical centrifuge tube. This was underlayered 
with 2ml freshly prepared 42% Percoll (previously diluted to 90% with sterile saline) in 
PPP which was in turn underlayered with 2ml freshly prepared 51% Percoll (previously 
diluted to 90% with sterile saline) in PPP using an autoclaved 223mm glass Pasteur 
pipette. The gradient was centrifuged (223g, 10 min, 20*C) and resulted in an upper 
band of mononuclear cells located at the plasma/42% Percoll interface and a lower band 
of PMN at the 42% Percoll/51% Percoll interface. The plasma and upper band was 
discarded and the PMN collected, diluted with PPP and centrifuged (400g, 10 min, 
20*C). Any residual erythrocytes were removed by hypotonic lysis (10ml ice-cold 0.2% 
NaCl for 30s followed by 10ml 1.6% NaCl) and 2-3 drops of PPP. After centrifugation
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(400g, 10 min, 20°C) the cells were resuspended in 5ml PPP and Trypan Blue exclusion 
used for microscopic determination of viability and counting.
2.3 Preparation of rabbit neutrophils
2.3.1 Isolation of rabbit peritoneal neutrophils
New Zealand White rabbits (male and female) weighing between 3.5-4.5kg were 
anaesthetised with 2ml Saffan™ (0.9% w/v alphaxolone and 0.3% w/v alphadolone 
acetate) administered in a bolus injection via an ear vein, and then given an intraperitoneal 
injection of 50ml 0.5% sodium caseinate in sterile PBS using a 19 gauge needle. The 
rabbits were allowed to regain consciousness and returned to their cages. The next day 
(approximately 18h later) the rabbits were killed with an intravenous bolus injection of 
Euthatal (pentobarbitone sodium, 400mg per rabbit) via an ear vein and the peritoneal 
cavity lavaged with 50ml PBS containing heparin (20U ml-t). The cell suspension was 
centrifuged (400g, 10 min) and any contaminating erythrocytes were removed from the 
pellet by hypotonic lysis (10ml ice-cold 0.2% NaCl for 15s, followed by 10ml 1.6% 
NaCl). After centrifugation (400g, 10 min) the cells were resuspended in PBS 
containing 0.9mM CaCl2 and 0.5mM MgCl2 at 2xl07 ml-i. The cells were found to be
>80% neutrophils in each case and viability as determined by Trypan Blue exclusion was 
>95%.
2.3.2 Isolation of rabbit peripheral blood neutrophils
New Zealand White rabbits (male, 3.5-4.5kg) were anaesthetised with Sagatal 
(pentobarbitone sodium, 150mg per rabbit) via an ear vein and anaesthesia maintained 
with supplements of Sagatal (pentobarbitone sodium, 15mg ml-* in saline) via the same 
route. The throat was shaved and the carotid artery cannulated with a cannula (size 3Fg) 
flushed through with heparinised saline (10U ml-i). Arterial blood was collected in 50ml 
polypropylene syringes containing 3.8% sodium citrate in the ratio 8 ml citrate : 32ml 
blood and decanted into 50ml conical centrifuge tubes, after which the animal was
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sacrificed with a bolus injection of Euthatal (400mg per rabbit, i.v.).
The neutrophils were isolated from the citrated arterial blood as described by Haslett et al. 
(1987). The tubes were centrifuged (300g, 20 min, 20*C) and the platelet rich plasma 
(PRP) generated was collected in 50ml centrifuge tubes and centrifuged (2000g, 15 min, 
20°C) to generate platelet poor plasma (PPP). Meanwhile, 8 ml of warmed 6 % dextran 
(MWt 500,000) in sterile saline was added to the pellet of each 40ml citrated blood (in 
each tube) and the volume made up to 50ml with sterile saline. Each tube was then mixed 
gently and thoroughly by inverting and rolling and allowed to stand for 30 min (20*C) to 
sediment the erythrocytes. The leukocyte rich supernatant was collected in 50ml 
centrifuge tubes, centrifuged (400g, 20°C) and the pellet resuspended in 2-3ml 
autologous PPP and transferred to a 13.5ml polystyrene conical centrifuge tube. Each 
cell suspension was underlayered with 2ml 43% freshly prepared Percoll (diluted to 90% 
with saline) in PPP which was in turn underlayered by 53% Percoll (diluted to 90% with 
saline) in PPP. A gradient tube as just described, was prepared for every 40ml citrated 
blood collected and centrifuged (275g, 10 min, 20*C) and resulted in a band of 
mononuclear cells and platelets at the plasma/43% Percoll interface (top) and a wider 
band of PMN at the lower 43%/53% Percoll interface just above an erythrocyte pellet. 
The upper band of mononuclear cells and platelets was discarded and the lower band 
collected in a 50ml centrifuge tube and centrifuged (400g, 10 min, 20°C). Contaminating 
erythrocytes were removed by hypotonic lysis (10ml ice-cold 0.2% NaCl for 15s, 
followed by 10ml 1.6% NaCl) and 1-2 drops of autologous PPP. After centrifugation 
(400g, 10 min, 20°C) the cells were resuspended in 5ml autologous PPP, and a 20|il 
aliquot used for counting and assessment of viability by Trypan Blue exclusion. The cell 
preparations were examined microscopically and found to contain approximately 90% 
neutrophils.
2.4 Preparation of human monocytes
Venous blood was collected as described for the isolation of neutrophils except that the
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blood was collected into 11 Monovette EDTA tubes (9ml per tube) and the isolation of 
monocytes performed aseptically in a Class II flow cabinet. 1 ml of 6 % dextran 
(500,000 MWt.) in 0.9% saline was added to the contents of each tube and gently mixed. 
The tubes were allowed to stand vertically at room temperature for 30-40 min and the 
leukocyte rich plasma collected. 4.5-5.0ml of the leukocyte rich plasma was gently 
layered over 2.5ml Nycoprep 1.068 in 13.5ml polystyrene conical centrifuge tubes and 
the gradients centrifuged (600g, 15 min, 20°C).
The uppermost 1ml of plasma from each gradient was centrifuged in micro-centrifuge 
tubes (10,000rpm, 6  min, 20°C) to generate PPP. The broad band of monocytes at the 
plasma/Nycoprep interface was collected in a 50ml polypropylene centrifuge tube and 
centrifuged (400g, 10 min, 20°C). The cells were washed twice in 15ml 5% autologous 
PPP in 0.9% saline with centrifuging (50g, 10 min, 20*C) to reduce the number of 
contaminating platelets to final ratio of 1 monocyte:2-8 platelets. The purity of the 
leukocyte preparation was approximately 90% monocytes, the remainder of which were 
lymphocytes. The monocytes were maintained in 10ml 5% autologous PPP/saline rolling 
on a Coulter roller at room temperature until required.
2.5 Undifferentiated human promyelocytic leukaemia cells (HL-60)
HL-60 cells (ECACC, Porton Down) were maintained at a cell density of between 1x105  
and lx l0 6 ml- 1 in RPMI 1640 (buffered with sodium bicarbonate 2g l-1, supplemented 
with penicillin 100U ml-1, streptomycin lOOpg ml-1 and 10% heat inactivated FCS) in 
162cm2 culture flasks (100ml) at 37°C and 5% CO2 in an incubator.
2.6 Leukocyte functional assays
2.6.1 Superoxide assay
2.6.1.1 Human neutrophils
The neutrophils were removed from the Coulter Roller and centrifuged (400g, 20*C, 10
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min) and resuspended at lxlO7 ml- 1 in PBS containing 0.9mM CaCh and 0.5mM
MgCl2 - The cells were preincubated with the antagonists at 5x l0 6 ml- 1 on a coulter roller
for 60 min at room temperature prior to addition of the agonists/inhibitors. The assays 
were performed in 7 5 mm x 1 2 mm polypropylene round bottomed centrifuge tubes with a 
final assay volume of 1ml (lxlO6 neutrophils ml-1) in the presence of glucose (final assay 
concentration 1 ImM). The experiments were performed in the presence of cytochalasin 
B (fungal metabolite from Helminthosporium dematioideum), which disrupts the 
cytoskeleton of the cell and enables the release of superoxide anions into the supernatant. 
Cytochalasin B (final assay concentration 5pg ml*1) was added simultaneously with the 
agonists (unless otherwise stated) at 37°C in a shaking water bath, followed by ferri- 
cytochrome C (horse heart, type VI, final assay concentration 0.085mM). 5 min after 
addition of the agonists, fMLP was added (final assay concentration 10*7M) and 
incubated for a further 5 min. All treatments were performed in duplicate. The reaction 
was terminated by removing the tubes from the water bath and centrifuging the tubes 
(4*C, 10 min, lOOOg).
An aliquot of each supernatant (300|il) was placed in 96 well cell culture plates and the 
absorbance read at 550nm on a Multiskan Mark II microplate reader (Flow Laboratories). 
The absorbances were zeroed on the SOD (90U ml-1) samples which represented 100% 
inhibition. The effect of the inhibitors were determined as % inhibition of the fMLP 
response; and if antagonists were present, the antagonist/fMLP response was used as the 
reference.
2.6.1.2 Use of inhibitors in superoxide assay
The assay protocol used was as described in 2.6. Phosphodiesterase inhibitors and 
prostaglandin agonists or other inhibitors were simultaneously added (37°C), 5 min prior 
to fMLP stimulation.
For the experiments using divalent cation chelators, the cells were centrifuged (400g,
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20*C, 10 min) and resuspended in 10ml PBS (Ca2+/Mg2+ free) containing ImM EGTA 
and left rolling on a Coulter Roller for 20 min at room temperature prior to centrifuging 
(400g, 20*C, 10 min) and resuspension in PBS (Ca2+/Mg2+ free) for the assay. The 
cations where added to the appropriate tubes just prior to the addition of the neutrophils 
(lxlO6 ml- 1 per sample) as were the chelators, and the assay performed as described in 
2 .6. 1. 1.
2.6.1.3 Superoxide generation stimulated by other agonists and priming agents
The stimulation period chosen for opsonised zymosan was 15 min at 37*C in the absence 
of cytochalasin B (5|ig ml-1), and 5 min for C5a in the presence of cytochalasin B (5|ig 
ml-1).
Priming of superoxide generation with PAF (2xlO-7M) used a 5 min preincubation period 
(37#C) prior to addition of the stimulus, with cytochrome C already present in the tubes 
but cytochalasin B was omitted as the priming effect was more pronounced in its 
absence.
2.6.1.4 fMLP-stimulated superoxide generation by rabbit neutrophils elicited from 
the peritoneal cavity and from peripheral blood
The superoxide assay was performed in the presence of cytochalasin B (5jig ml-1) using 
10-7M  fMLP as the stimulus with 2xl06 (elicited) or 1x106 (peripheral blood) neutrophils 
ml- 1 in each tube.
2.6.2 Measurement of cAMP generation
2.6.2.1 Human neutrophils
Human neutrophils were isolated as described in 2.2.1, and the cells from 2-3 donors 
were pooled just prior to the experiment. The neutrophils (2 x l0 7 ml-1) were 
preincubated with the non-selective phosphodiesterase inhibitor IB MX (5xlO-4 M) in
65
PBS/Ca/Mg and llmM  glucose for 5 min at 37*C prior to aliquoting (IOOjj.1) into pre- 
warmed 1.5ml microcentrifuge tubes containing 50|il stimulus in a shaking water-bath set 
at 37*C. The tubes were gently shaken for 5 min and then the reaction stopped by the 
addition of 50pl 20% perchloric acid. The tubes were removed from the water-bath, 
capped, vortex-mixed and then placed on ice for at least 15 min. After which the tubes 
were centrifuged for 30s ( 1 0 ,0 0 0 g) and the supernatants (~2 0 0 jil) removed into fresh 
1.5ml microcentrifuge tubes which were capped and stored at -70*C until required for 
extraction of the cAMP. All treatments were performed in duplicate unless otherwise 
stated.
2.6.2.2 Undifferentiated HL-60 cells
For the generation of cAMP, cells were removed from the incubator and placed in 50ml 
polypropylene conical centrifuge tubes and centrifuged (200g, 5 min, 20°C) and washed 
once in RPMI 1640 (buffered with sodium bicarbonate 2g l-i, supplemented with 
penicillin 100U ml-i, streptomycin lOOjig ml-i) before resuspending in 5ml PBS/Ca/Mg. 
The cells were counted on a Technicon Junior cell counter (Bayer Diagnostics, 
Basingstoke) and viability determined by Trypan Blue exclusion (>90%). The cells were 
diluted to 2 x l0 7 ml-i and in some experiments incubated with antagonists at room 
temperature rolling in polystyrene 7ml bijoux for 25 min. Thereafter, IBMX was added 
and incubated with the cells for 5 min at 37#C. Aliquots of the IBMX/HL-60 suspension 
(lOOjil) were then added to pre-warmed 1.5ml micro-centrifuge tubes containing 50|il of 
vehicle of stimulus and incubated for a further 10 min. The final assay concentration of 
HL-60 cells was lxlO 6 per determination and IBMX was 5xlO-4 M. The reaction was 
stopped by the addition of 50|il 20% perchloric acid (ice-cold) and the samples treated, 
stored and extracted as described for human neutrophils (2 .6 .2 .1 ).
2.6.2.3 Human peripheral blood monocytes
The cells (in 5% autologous PPP/saline) were centrifuged (50g, 10 min, 20*C) and 
resuspended in PBS/Ca/Mg at 4x l0 6 ml-i and incubated for 25 min with the antagonists
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rolling on a Coulter roller at room temperature. IBMX (final assay concentration 5x10- 
4 M) and indomethacin (final assay concentration 3xl0-6M) were added and incubated 
with the cells for 5 min at 37’C. Aliquots of the cell suspension (100|il, lxlO 5 
monocytes) were added to pre-warmed 1.5ml microcentrifuge tubes containing 50jil 
prostaglandin or vehicle and gently shaken on a water-bath (37°C) for 5 min. The 
reaction was stopped by the addition of 50jil 20% perchloric acid (ice-cold) and the 
samples treated, stored and extracted as described for human neutrophils (2 .6 .2 .1 ).
2.6.2.4 Rabbit peripheral blood neutrophils
The assay was performed as described for human neutrophils i.e. 45 min preincubation 
with antagonists at room temperature, 5 min preincubation with IBMX (37*C) followed 
by stimulation with prostaglandins for 5 min (37*C) in a final volume of 150|il. The 
reaction was stopped by the addition of 50|il 20% ice-cold perchloric acid. However a 
lower concentration of cells (0 .5-lx l0 6 per determination was used as the yield from 
each rabbit was low, but the cells from individual rabbits were used and not mixed. The 
reaction was stopped by the addition of 50jxl 20% perchloric acid (ice-cold) and the 
samples treated, stored and extracted as described for human neutrophils (2 .6 .2 .1 ).
2.6.3 Extraction of cAMP
The cAMP samples were defrosted and allowed to come up to room temperature prior to 
extraction. An equal volume (200jil) of a 1:1 freshly prepared mixture of tri-n- 
octylamine and l,l,2-trichloro-l,2,2-trifluoro-ethane (Freon) was added to each tube, 
capped and thoroughly vortex-mixed (at least 10s) and centrifuged for 1.5 min at 
10,000g. This resulted in a trilayer of liquids in each tube, only the uppermost layer 
(extracted cAMP) was collected and placed in a fresh 1.5ml microcentrifuge tube. An 
aliquot of this extract was diluted in cAMP assay buffer and assayed for cAMP content
2.6.4 Assay of cAMP
a) Initial experimental samples were assayed by 3H-RIA (Amersham TRK.432) in
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1.5ml micro-centrifuge tubes using 25|il volumes of samples, standards and reagents. 
The unbound 3H-cAMP in 50|il of supernatant was measured after addition of 4ml 
Optiphase scintillant in a Packard Tricarb Scintillation Counter using a count time of 4 
min.
b) Most of the experimental samples were assayed using 125I-SPA RIA (Amersham 
RPA.538) a dual range scintillation proximity assay (SPA) system. All samples unless 
otherwise stated were assayed unacetylated. The RIA was performed in Packard 96 well 
plates using 50|il volumes of samples, standards and all reagents. The plates were heat- 
sealed, shaken and stood for 10-30h before counting on a Topcount counter with a count 
time of 5 min per well.
2.6.5 Fura-2 loading cells for spectrophotofluorimetry
These experiments were performed at the School of Pharmacy and Pharmacology, 
University of Bath, where the donors were volunteers from the members of the 
department and the neutrophils isolated using Lymphoprep as described in 2.2.2. 
Neutrophils were resuspended in HBSS (without Ca2+ or Mg2+ ions) containing 0.1% 
BSA (~5xl07 ml-1) and loaded with Fura-2am (2|iM, 2.5|il of 5mM stock in DMSO per 
5ml cell suspension) at 37°C for 30 min in the dark with intermittent shaking, essentially 
a modification of the method of Murphy et al. (1991). The cells were washed once in 
HBSS (pH 7.2-7.4, without Ca2+ or Mg2+ ions), viability assessed by Trypan Blue 
exclusion and resuspended in HBSS (pH 7.2-7.4, without Ca2+ or Mg2+ ions) 
containing 0.1% BSA supplemented with 100|iM CaCl2  at 5 x l0 6 ml-1. The cell
suspensions were maintained on ice and aliquots taken for fluorimetry measurements 
after gentle mixing by inversion when required.
All the measurements of changes in intracellular calcium were performed on a PTI dual 
excitation dual emission fluorimeter (Photon Technology Instruments). A cuvette stirrer 
and a circulator were fitted, enabling the contents of the cuvettes (quartz) to be maintained
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at 37*C and constantly stirred.
The experiments were performed at 37’C in a quartz cuvette using a constantly stirred 
2ml aliquot of the neutrophil suspension (5xl06 ml-1) in the presence of ImM MgCl2  and 
ImM CaCl2 unless otherwise stated. The responses of the cells used at the beginning 
and the end of each experimental day were identical.
2.6.6 Determination of intracellular calcium levels using spectrophotofluorimetry
2.6.6.1 Measurement of neutrophil [Ca2+]i
The excitation wavelengths were set at 340nm (1A) and 380nm (2A), and emission was 
measured at 510nm. The fluorescence output was converted to [Ca2+]i after calibration 
by using the equation described by Grynkiewicz et al. (1985) as shown below:-
[ ]i Fmix-F  c- Sb2 
where F represents the fluorescence measurement ( 1 A/2 A ratio), Fmax and Fmin 
fluorescence in the obtained by the addition of 80p.l of digitonin (4mg ml-1, 70% 
ethanol/H2 0 ) in the presence of ImM extracellular Ca2+ ions and the further addition of 
80|il EGTA (lOOmM, preceded by 40jxl 2M NaOH) respectively, Kca is the apparent 
dissociation constant for Ca2+ binding with Fura-2 and Sf2/Sb2 is the dilution correction
factor determined from the ratio of the fluorescence of free Fura-2 and Ca2+-bound Fura- 
2 measured using the 2A signal.
All of the experiments were performed in the presence of ImM MgC^ and ImM CaCl2  
unless otherwise stated. The cells were incubated with vehicle, PGE2  or rolipram for 5 
min at 37*C prior to stimulation with fMLP. Monitoring of [Ca2+]i commenced 40s prior
to the addition of fMLP to obtain a baseline measurement, and monitored for up to 5 min 
after the addition of fMLP.
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2.6.7 Readdition of extracellular calcium ions
Experiments involving the re-addition of Ca2+ ions were based on the method described 
by Clementi etal. (1992). The cells were incubated with vehicle, PGE2 or rolipram, 
ImM MgCl2 , O.lmM CaC^ and ImM EGTA for 5 min at 37*C prior to the addition of 
buffer or fMLP (0.1 |iM). After which, 2mM CaCh (in 20|il, 70s after buffer/fMLP) 
was added using a Hamilton syringe via the injection port to allow continuous recording.
2.6.8 Measurement of Mn2+ ion influx
Mn2+ influx was measured as the quenching of intracellular fura-2 excited at 360nm, the 
isobestic point for Ca2+ ions, and emission measured at 510nm (Murphy & Westwick, 
1992). At this excitation wavelength, the presence of Ca2+ ions does not interfere with 
Mn2+-induced quench of fura-2. Calibration was performed by expressing the agonist- 
induced response as percentage quench (AUC) compared to that achieved by ionomycin 
(2xlO-fiM). [Ca2+]i was measured simultaneously using the 340nm excitation and 
510nm emission wavelengths. Vehicle, PGE2 or rolipram were added and incubated at 
37*C for 5 min prior to the addition of buffer, fMLP or ionomycin. MnCl2 (0.1-ImM) 
was added 40s after the addition of the stimulus. The baseline was monitored for 40s 
prior to stimulation, and the signal monitored for up to 5 min after stimulation.
2.6.9 Degranulation as measured by P-glucuronidase release
Essentially the conditions used for the P-glucuronidase release assay from human
neutrophils were identical to those used for superoxide generation except for the omission 
of ferri-cytochrome C from the assay system. After the samples were centrifuged 
(lOOOg, 10 min, 4°C), lOOjil of the supernatants were removed for assay of
p-glucuronidase content and the remainder was discarded. The cell pellets were lysed by 
the addition of 1ml 0.1% Triton X-100 (Sigma) in saline (0.1% BSA), vortex-mixed and
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incubated at 37*C for 20 min. Cell debris was removed by centrifugation (lOOOg, 10 
min, 4’C) and 100|il of the cell lysates were assayed for p-glucuronidase content.
Assay of P-glucuronidase enzyme activity in lOOjil of supernatant or cell lysate was
measured as the consumption of the substrate p-dinitrophenyl-P-d-glucuronide (600}il of
5mM stock) in 0.1M acetate buffer (pH 4.5) at 37“C overnight (at least 16h). The 
reaction was stopped by the addition of 300jil of 0.8M glycine buffer (pH 10.4). The 
samples were mixed and 300(il aliquots were placed in 96 well plates and the absorbance 
of the resultant colour (yellow dinitrophenol) was determined at 405nm using a Multiskan 
Mark II plate reader.
Results were expressed initially as % of total cellular P-glucuronidase content (A405nm
in supernatant added to A405nm in pellet) released, effects of inhibitors expressed as % 
inhibition of fMLP response.
2.6.10 Neutrophil shape change (Polarisation)
2.6.10.1 Shape change assay
Neutrophils are exquisitely sensitive to becoming polarised and is the first visible sign of 
activation. This can occur as a result of many stimuli; contact with extremely low 
concentrations of priming agents, e.g. endotoxin (Haslett et al., 1985). Rough handling, 
repeated temperature changes and prolonged contact with large numbers of other 
neutrophils on sedimentation can also induce a shape change in neutrophils. The 
preparation of neutrophils for shape change assays therefore requires extreme care and 
special procedures as described in 2.2.3.
The neutrophils were finally resuspended in HBSS (Ca2 +/M g2+ free, 0.35% sodium 
bicarbonate, lOmM MOPS) at lx l0 7 ml-i for the assay.
The assay was based on the protocol described by Haston & Shields (1985) and used by
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Cole and co-workers, Department of Gastroenterology, University of Nottingham. In 
this study, it was performed in triplicate in 12mm x 75mm polypropylene tubes with a 
final assay volume of 1ml HBSS containing lOmM MOPS, 0.9mM CaCl2  and 0.5mM
MgCl2 , inhibitor, lxlO 6 neutrophils and the stimulus. The neutrophils were added
penultimately, the stimulus being the last addition. The tubes were capped and placed in 
an incubator (37#C) for 30 min. The reaction was stopped by the addition of 1ml 2.5% 
glutaraldehyde in PBS and the tubes left to stand at room temperature for at least 30 min. 
The tubes were vortex-mixed and then centrifuged (lOOOg, 10 min, 20°C) and the cells 
washed twice by resuspending the pellets in PBS, vortex-mixing and centrifugation 
(lOOOg, 10 min, 20*C). The cells were finally resuspended in 1ml PBS and stored at 
4°C for up to 4 weeks, but vortex-mixed and allowed to come up to room temperature 
prior to analysis.
2.6.10.2 Microscopic determination of neutrophil shape change
Microscopic examination of the fixed neutrophils was determined essentially as described 
by Haston & Shields (1985). The cell suspensions were mounted in a double chamber 
Neubaur haemocytometer and 200 neutrophils from each sample were counted as either 
unpolarised (perfectly spherical) or polarised (exhibiting pseudopodia and or not 
spherical in shape), and % polarisation determined for each sample.
2.6.10.3 Flow cytometric determination of neutrophil polarisation
The samples were transferred to Becton Dickenson 12mm x 75mm polystyrene centrifuge 
tubes as recommended for use with the Coulter Elite flow cytometer. The flow cytometer 
settings used were as follows:-
The samples were vortex-mixed and when the flow rate of the cytometer was stabilised at 
between 60-120 events/second, forward light scatter and right angle light scatter data 
capture was initialised. Forward light scatter is a measurement of cell size which would 
increase when a neutrophil becomes polarised and exhibits pseudopodia, whilst right
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angle (side) scatter indicates the degree of granularity of the cell which would not change. 
The data capture settings were gated on a negative control containing unpolarised cells 
(basal, approximately 4% polarised) and a positive treatment (maximally stimulated, 
fMLP Ixl0-7M) which contained >95% polarised neutrophils and exclude erythrocytes 
and leukocytes other than neutrophils. This was especially important as fixing cells with 
gluteraldehyde can change the size of cells compared with fresh cells. The flow 
cytometer was programmed to analyse 6000 events within the whole (unpolarised and 
polarised) neutrophil region in terms of forward light scatter and the results for each 
sample were expressed as % polarised within the gated region.
There was a close degree of correlation between the 2 methods of counting (Fig 2.5, 
r=0.994, p<0.05, n=33 determinations (Cole and co-workers reported r=0.994, 
p<0.001). All samples were counted on the Elite Flow Cytometer which was more 
accurate; 6000 events counted instead of 2 0 0  per sample, it was also objective and was 
considerably less labour intensive and time consuming (1 - 2  min per sample compared to 
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Fig 2.5 Correlation between manual and flow cytometric analysis of 
human neutrophil shape change. Comparison of the quantitation of human 
neutrophil shape change, as determined by manual counting ( 2 0 0  cells per sample 
counted) flow cytometric determination (6000 cells per sample) using the “Elite” flow 
cytometer (Coulter). Correlation determined using 33 samples, with correlation co­
efficient of R=0.994.
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2.7 Analysis of data
2.7.1 Analysis of agonist activity
Activity of agents were expressed as negative logarithm base 10 of the molar 
concentration of the agent producing 50% of own maximum response, i.e. a pJAso] value 
as described by Jenkinson et al. (1995). For agents which do not have a clear maximum 
effect, negative logarithm base 10 of the molar concentration of the agent giving 50% 
maximum response obtainable in the assay, i.e. p[ICso] or p[ECso] values were 
calculated (Jenkinson et al., 1995).
2.7.2 The Operational Model of Agonism
The potency orders of the EP agonists in the superoxide and cAMP assays could not be 
compared directly as some of the agonists were partial in the cAMP assay. The effects of 
mathematically increasing receptor reserve were simulated using the Operational Model 
(Leff et al.y 1990) in both assays in order to compare agonist potency orders.
The mathematical form of the Operational Model
Emz [A ]n 
~ (Ka+[A])"+'c’[A]'
The Operational Model is described by the above equation, with E representing the 
tissue response to a given agonist concentration [A]), as the agonist equilibrium
dissociation constant and % defining the model definition of the efficacy of an agonist in a
tissue for the agonist under study. Em (the maximum pharmacological effect that can be 
generated in a particular system, i.e. by a “full agonist”) and n (the slope of the 
transducer relation, a measure of the sensitivity with which a particular system transduces 
AR the agonist-receptor complex into E). Fig 2.6 (upper panel) shows the 
concentration-effect (E/[A]) curves for full and partial agonists in a low receptor reserve
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system. If the receptor reserve is increased as shown in Fig 2.6 (lower panel), the 
maximum effect of the full agonist is unchanged as it is already maximal and the curve 
simply left-shifts. With the same increase in receptor reserve, the partial agonists are 
now able to achieve the same maximum effect of the full agonist and also shift to the left
The affinity (pKa) and efficacy (x) of the partial agonists were estimated by applying the 
Operational Model (Leff et al., 1990) by comparison of a partial agonist with a full 
agonist (i.e. PGE2). An increase in receptor reserve was simulated by increasing (x) by a
factor of 1 0 0  for the partial agonists to render them full agonists and allowing the 
corresponding changes in p[Aso] for the full agonists in both the superoxide and cAMP 
assays. The potency orders of the agonists in both assays were then compared.
2.7.3 Analysis of antagonist activity
E/[A] curve data from 5 experiments for PGE2 or BW 245C inhibition of fMLP 
superoxide generation in the absence and presence of AH 6809 were fitted to the Hill 
equation (i) of the form:
E =  ------  (0
[Ax ]m+ [A]”
in which a, [A 5 0] and m are the asymptote, location and slope parameters respectively.
[A50] values were assumed to be logio-normally distributed and they were estimated as 
such and quoted as p[Aso] (-logiotAso]) values.
The E/[A] data describing the 5 curves were fitted to a modified form of the Schild 
equation (ii) (Black etal ., 1985), where [Asoc] is a control [A50], [B] is the concentration 
of AH 6809, Kb is its equilibrium dissociation constant and n is the Schild plot slope.
1 0 sol=:log 10[A5 0 ] 10O "b [^] ! K b )  dO
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Additional goodness-of-fit analysis was performed on the pKs estimate for AH 6809 
from the Schild analysis with the slope unconstrained and constrained to unity, using 
PGE2 as the agonist as described by Leff & Giles (1992).
2.7.4 Statistical Analyses of Data
The data was analysed for statistical significance using paired Student’s t-test unless 
otherwise stated. Significance was determined by 95% confidence limits i.e. P<0.05, and 
indicated in figures and tables as * for P<0.05, ** for P<0.01 and *** for P<0.001. 
Probabilities are reported for each comparison with the control group, so type I error 
rates may exceed those reported in the text.
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Fig 2.6 Illustration of the effect of receptor reserve on the responses 
of full and partial agonists according to the Operational Model. The upper 
panel shows the responses of a full agonist (continuous line) and two partial agonists 
with different efficacies (dashed and dotted lines) in a low receptor reserve system. . 
When the receptor reserve is increased to a sufficient level as to allow the partial agonists 
to achieve the same maximum response as the full agonist as shown in the lower panel, 
the maximum response of the full agonist is unchanged as it is already maximal, and the 
E/[A] curve is simply left-shifted. Correspondingly, the E/[A] curves of partial agonists 




OF PROSTANOID EP RECEPTORS MEDIATING 
INHIBITION OF HUMAN NEUTROPHIL
ACTIVATION
3.1 INTRODUCnON
3.1.1 Classification of E-Type prostaglandin (EP) receptors
Amongst the prostanoids, PGE2 is arguably the prostanoid with the widest spectrum of 
biological activities; affecting the reproductive, cardiovascular, nervous and respiratory 
systems and the gastro-intestinal tract. Some of the most profound effects of PGE2 are on 
inflammatory and immune responses. There has been much speculation as to the 
pathophysiological role of PGE2 as both pro-inflammatory and anti-inflammatory effects 
have been described (Kunkel & Chensue, 1984). Despite the degree of interest in PGE2 , the 
EP receptors on the cells involved in inflammation and immunological responses are perhaps 
some of the least well characterized.
The classification of prostanoid EP receptors is based primarily on the effects of agonists and 
antagonists on smooth muscle preparations, as are most pharmacological receptor 
classifications. At present, the EP receptor is the only prostanoid receptor for which there is 
unequivocal evidence for subdivision and is outlined in Table 3.1.
The naturally occurring agonists, PGE2  and PGEi, are equiactive and neither shows 
selectivity between the EP receptor subtypes (Coleman e ta l ., 1987). One of the most 
definitive agonists is sulprostone (EP1/EP3 selective) (Bunce etal., 1990), which is active at 
EPi and EP3 receptors in the nanomolar concentration range. In contrast, sulprostone is 
greater than 1000 times less potent than PGE2 at EP2 receptors (Coleman et al., 1987). 
Butaprost is also widely used, although it is less potent as an agonist (active in the 
micromolar concentration range), it is more selective, showing agonism only at the EP2  
subtype (Gardiner, 1986).
There is a lack of selective antagonists for the EP receptor subtypes, hence the 
characterization of prostanoid EP receptors relies heavily upon the use of agonist potency
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orders. There are only antagonists described for the EPi receptor subtype, i.e. SC 19220 
and AH 6809 show a similar activity to each other at EPi, EP2 and EP3 receptors (Coleman 
etal.y 1987), antagonising EPi receptors with pA2 values of 5.4 and 6 . 8  respectively. The 
pA2 values for SC 19220 at both EP2 and EP3 receptors were <4.0, similarly the pA2  
values in the same tissues were <5.0 for AH 6809.
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Receptor Subtype Selective Agonist Selective Antagonist pA2
EPi Sulprostone 6S C 19220 5.2-5.6
61 AH 6809 6 .4-7.0
EP2  2AH13205/3Butaprost None
EP3 4Sulprostone/5GR63799X None
EP4  None 7AH23848B 5.4
Table 3.1 Classification of prostanoid EP receptor subtypes, selective 
agonists and antagonists. The data was obtained from the following publications; 
*Dong etal., 1986,2Nials etal., 1993, 3Gardiner, 1986, 4Coleman etal., 1987,5Bunce 
etal., 1990, 6Coleman etal.,  1985, 7Coleman etal., 1994a. UAH 6809 is also a 
prostanoid DP receptor antagonist (see Fig 1.2).
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3.1.2 Prostanoid receptors on human neutrophils
Numerous publications have documented the anti-inflammatory effect of the naturally 
occurring prostaglandins; PGEi, PGE2 and PGD2 on isolated human neutrophils, such as 
inhibition of degranulation, superoxide generation, adhesion and injury to endothelial cells, 
(Bourne et al., 1971, Lad et al., 1985, Chopra & Webster, 1988, Hecker et al., 1990). 
There have been conflicting reports of the ability of prostacyclin (PGI2) and the IP agonist, 
iloprost, to inhibit human neutrophil activation (Boxer et al., 1980, Gryglewski et al., 1987, 
Riva etal., 1990, Hecker et al., 1990). The evidence, however, suggests that IP agonist 
inhibition of human neutrophil adhesion to endothelial cells may be due to an effect on the 
endothelial cell rather than the neutrophil (Boxer et al., 1980 and Riva et al., 1990). Weak 
inhibition of superoxide generation by PGI2 and iloprost has only been observed by some 
groups; and then only at very high concentrations (Gryglewski et al., 1987 and Hecker et al., 
1990) compared to the activity at other IP receptors such as on the human platelet (Dong et 
al., 1986, Keery & Lumley, 1988).
PGEi and PGE2 in common with other inhibitors of human neutrophil activation, such as p-
adrenergic agonists (Nielson, 1987), also induced cAMP accumulation; and this has been 
proposed as a common mechanism of action. This is supported by the ability of dibutyryl 
cAMP (a cell-permeable analogue of cAMP) to inhibit neutrophil degranulation and 
superoxide generation (Bourne et al., 1972).
Intravenous infusion of PGEi into humans also inhibits fMLP-stimulated lysosomal enzyme 
release from neutrophils ex vivo (Fantone et al., 1981) demonstrating a direct anti­
inflammatory effect of systemic prostaglandins on human neutrophils. This supports the 
observations made in animal models of the anti-inflammatory effects of stable prostaglandins 
(Rampart & Williams, 1986).
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However, there has been little effort to pharmacologically characterize these human 
neutrophil prostanoid receptors. The generally accepted view, that the human neutrophil EP 
receptors are of the EP2  subtype is based largely on circumstantial evidence, for instance 
PGEi and PGE2 inhibit neutrophil activation and increase cAMP levels, and EP2  receptors 
are positively linked to adenylate cyclase (Coleman et al., 1990 and Yeardley et al., 1993).
Few binding studies of human neutrophil prostanoid receptors have been reported. There is 
only one detailed binding study on PGD2 and PGE2 receptors in human neutrophils (Rossi & 
O’Flaherty, 1989). PGD2 and PGE2 bound to distinct sites; and described the presence of 
two binding sites for PGE2 and one for PGD2 . For PGE2 , there was a high affinity site 
(Kd=10 9M; 150 specific binding sites/cell) and a low affinity site (Kd=10-7M; 5800 specific 
binding sites/cell), whilst there were 5100 binding sites for PGD2 with a Kd of 1.3xl0-gM. 
The authors suggested that the measured high affinity Kd values correlated with the inhibitory 
concentrations of the prostaglandins. However, this is unlikely to be the case for PGE2 as 
with the majority of tissues the agonist occupancy curve is positioned to the right of 
functional E/[A] curve. Since the vast amount of literature on PGE2 inhibition of human 
neutrophil activation, including the authors* own PGE2 -mediated inhibition of enzyme 
release, the position of E/[A] curve for PGE2  (the p[Aso]) is to the right of the high affinity 
Kd, and therefore does not correlate with a binding constant Kd of 10-9M. The Kd of 10*7M 
for the lower affinity site for PGE2 binding may be more consistent with the functional PGE2  
data, and the higher affinity site may represent either a higher affinity state of the same 
receptor or another EP receptor. No synthetic prostanoid antagonists or selective agonists 
were used to displace the labelled PGD2 or PGE2 binding, only unlabelled PGD2 and PGE2 .
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3.1.3 Aims
The objectives of this chapter were:-
1. To conduct a rigorous pharmacological characterization of the inhibitory prostanoid 
receptors present on human neutrophils, using inhibition of fMLP-stimulated superoxide 
generation as the functional assay.
2. To establish the relationship between prostanoid EP receptor agonist mediated 
inhibition of fMLP-stimulated neutrophil superoxide generation and cAMP elevation.
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3.2 RESULTS
3.2.1 Effect of prostanoid EP agonists on superoxide generation by human neutrophils
There was little superoxide (O2-) generation from unstimulated human neutrophils (less than 
0.1 nmol O2" 106 neutrophils-i); but fMLP (10-7 M)-stimulated neutrophils generated 
9.910.5 nmol O2” 106 neutrophils-i (n=30). PGE2  and PGEi inhibited fMLP (10-7M)- 
stimulated superoxide generation with similar potency; p[Aso] values were 7.210.1 (n=30) 
and 6.810.1 (n=4) respectively, and achieved the same maximum response (Fig 3.1). The 
EP2  selective agonists AH13205, 11-deoxy PGEi, butaprost and viprostol were also 
inhibitors, as were the other agonists with described activity at EP2  receptors; 16,16-dimethyl 
PGE2  (EPi>EP2 ) and misoprostol (EP2/EP3 selective) -see Table 3.2. The concentration- 
effect curves of these agonists as inhibitors of superoxide generation are shown in Fig 3.1 
and Table 3.2.
EPi and EP3 selective agonists were weak inhibitors of fMLP-stimulated superoxide 
generation compared with their activity at EPi and EP3 receptors (Fig 3.1). Sulprostone 
(EP1/EP3 selective), M&B 28,767 and GR 63799X (EP3 selective agonists) (Lawrence et 
al., 1992, Bunce etal., 1990 respectively) failed to reach above 50% inhibition at the highest 
concentration tested (Table 3.2). No concentration-effect (E/[A]) curves could be generated 
for these agonists.
The metabolites and breakdown products of the PGE compounds were also active although 
less potent than the parent compounds, PGEi and PGE2  (Table 3.2). The most potent were 
PGEo (13,14-dihydro-PGEi), PGAi and PGA2 followed by PGBi and PGB2 ; whilst 
13,14-dihydro-15-keto-PGE2 was virtually inactive.
3.2.2 Effect of prostanoid DP, IP and TP receptor agonists
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The naturally occurring DP receptor agonist PGD2 and the selective synthetic agonist BW 
245C (Giles et al., 1989) also inhibited superoxide generation with PLA50] values of 7.8±0.1 
(n=7) and 8.4±0.2 (n=6 ) as shown in Fig 3.2. The potent IP receptor agonists cicaprost and 
iloprost (Dong etal., 1986) were weak inhibitors of fMLP-stimulated superoxide generation 
compared with their potency at IP receptors. The maximum effect of cicaprost was -30% at 
10-5M (n=3) and p[Aso] of iloprost was <5.0 (n=3). The E/[A] curves are shown in Fig 3.2.
The TP agonist U46619 had little effect when tested up to 10-6M (n=2).
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A g o n is t  - lo g io  [A 5 0 ] M M ax % I n
p g e 2 7.2±0.1 8718 30
PGEj 6 .8 ±0 . 1 8317 4
11 -Deoxy PGEi (EP2) 6 . 1±0 . 2 9612 7
AH13205 (EP2) 5.5±0.2 9512 7
Butaprost (EP2) 5.0±0.3 68122 3
Viprostol (EP2) 8.2±0.3 7612 4
17-Phenyl-trinor PGE2 (EPi>EP2) 4.9±0.1 6116 7
16,16-Dimethyl PGE2 (EP1/EP3) 5.910.3 7315 4
Sulprostone (EP1/EP3 ) <4.0 1515 (10-4M) 3
M&B 28,767 (EP3>EP2) 4.610.1 3912 3
GR 63799X (EP3) <4.5 18-45 (3xl0-5M) 2
Misoprostol (EP^Ps) 6.310.4 7815 3
PGA! 6.310.2 9013 3
p g a 2 5.810.2 9613 3
PGBi 5.110.2 76114 4
p g b 2 5.210.2 73111 4
PGE0  (13,14-dihydro PGEi) 6 .2 1 0 . 2 8414 3
15-keto-13,14-dihydro PGE2 <4.8 19-64 (10-4M) 2
Table 3.2 Comparison of the potency of prostanoid EP agonists as 
inhibitors of fMLP (10*7 M)-stimulated superoxide generation by human 
neutrophils. Human neutrophils (106 ml-1) were preincubated with the agonists for 5 
min (37°C) in the presence of cytochalasin B (5|ig ml-1) prior to stimulation with fMLP 
(5 min, 37°C). Results shown are the mean±s.e.m p[Aso] (-logio [Aso]M) and 
maximum inhibition achieved (% I) of the number of experiments indicated for each 
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Fig 3.1 Effect of PGE2 , PGEi and prostanoid EP receptor agonists 
on fMLP (10-7M)-stimulated superoxide generation by human neutrophils.
Neutrophils (106 ml-1) were preincubated with EP receptor agonists and cytochalasin B 
(5|ig ml-1) for 5 min (37°C) prior to stimulation with fMLP for 5 min (37°C). The same 
PGE2 data is shown in both panels for comparison. Results shown are mean±s.e.m % 
inhibition of fMLP-stimulated superoxide response for each agonist of the number of 
experiments indicated in the figure legends performed in duplicate.
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Fig 3.2 Effect of PGD2 , selective DP receptor agonist, BW 245C, 
and selective IP receptor agonists, cicaprost and iloprost, on fMLP (10* 
7M)-stimulated superoxide generation by human neutrophils. Neutrophils 
(106 ml-i) were preincubated with DP or IP receptor agonists in the presence of 
cytochalasin B (5|ig ml-i) for 5 min (37“C) prior to stimulation with fMLP for 5 min 
(37 *C). Results shown are mean±s.e.m % inhibition of fMLP-stimulated superoxide 
response for each agonist of the number of experiments indicated in the figure legends 
performed in duplicate.
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3.2.3 Effect of prostanoid DP and EP receptor antagonists on PGE2
The EPi selective antagonist SC 19220 (pA2 5.4) (lO-MO^M) did not antagonise the PGE2  
E/[A] curve (n=3). There was a slight nonsignificant leftward shift of the PGE2  curve in the 
presence of 10-4M SC 19220 (Fig 3.3).
AH 6809, the other EPi antagonist (pA2 of 6 . 8  - Coleman et al., 1987), produced a 
concentration-dependent (10-7M - 3xl0-6M) rightward shift of the PGE2 E/[A] curve (Fig
3.4). There was no statistical difference in the goodness-of-fit (residual sum of squares) of 
the unconstrained Schild analysis compared with the analysis performed constraining the 
slope to unity, F i,3=0.119, (P>0.05, degrees of freedom=l) (Leff & Giles, 1992). The 
pKfl value estimated using a modified Schild analysis, was 7 .1±0.1 (data from n=5 donors) 
with the slope was constrained to unity.
This pKfi value was calculated from the earliest experiments conducted with AH 6809 on 
PGE2 -inhibition of O2" generation. Subsequent experiments using 10-5M AH 6809
performed over the duration of this entire study (5 years) using a wider range of blood 
donors showed that the degree of antagonism observed was extremely variable and was 
consistently lower than that predicted from the pKe value of 7.1 (Fig 3.5). A more accurate 
estimate of a pA2  value may actually be closer to 6.0 than 7.1 as the concentration-ratio (CR) 
was 1.3±0.11ogio units (n=6 8 ). However in some donors, the degree of antagonism 
observed using 10-5M AH 6809 was similar to 3xlO-6M, suggesting that a ‘wall* existed 
limiting the amount of antagonism obtainable. Such a situation may arise if more than one 
receptor for PGE2 coexists in the neutrophil mediating inhibition of fMLP-stimulated 
superoxide generation, and only one of which is antagonised by AH 6809. Variability of the 
relative expression of these AH 6809-sensitive and insensitive prostanoid EP receptors 
between individuals may explain the diversity of AH 6809 antagonism in the different
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neutrophil preparations.
AH 6809, up to 10-5M, and under these experimental conditions did not stimulate O2" 
generation. However, fMLP-stimulated O2” generation was increased in the presence of AH 
6809 (10-5M) to 147±6% of the control fMLP response (n=6 8 ). This apparent enhancement 
was variable and had no correlation with the degree of antagonism of PGE2 observed in each 
experiment (Fig 3.5, n=6 8 ).
As AH 6809 is also a DP receptor antagonist, another DP antagonist was evaluated to 
determine whether the inhibitory effect of PGE2 was mediated at the DP receptor. The 
selective and potent DP receptor antagonist BW A8 6 8 C (pA2 9.3, Giles et a l ., 1989) was 
without effect on the PGE2 E/[A] curve (n=5) at 10-7M, a concentration which caused a 
2.4±0.3 logio unit rightward shift of the PGD2 E/[A] curve (n=5) (Fig 3.6). BW A8 6 8 C 
(10-7M) also had no effect on the antagonism of the PGE2  E/[A] curve by 10-5M AH 6809 
(n=3) (Fig 3.7). The weak EP4  receptor antagonist AH23848B (pA2 4.9-5.4, Coleman et 
al., 1994a) depressed the control fMLP superoxide response at 3xl0-5M by 77.9±4.0% 
(n=3), but not at 10 5M (106±18% of control fMLP response, n=3). AH23848B (10*5M) 
had no effect on the PGE2 E/[A] curve (n=3) (Fig 3.8). The control PGE2 p[Aso] was 
7.5±0.2 (maximum inhibition of 86.3±1.8%, n=3) compared to 7.4±0.1 (maximum 
inhibition of 80.7±3.5%, n=3) in the presence of AH23848B (10-5M). AH23848B is more 
potent as a TP receptor antagonist (Brittain et al., 1984) but the structurally related compound 
GR 32191B, also a TP receptor antagonist (pA2 8.2-8.8 in human platelets, Lumley et al., 
1989), had no effect on fMLP stimulated superoxide generation itself (3xl0-6M, n=2) and 
did not affect the PGE2 inhibition curve (3xl0-6M, n=2).
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Fig 3.3 Effect of prostanoid EPi receptor antagonist, SC 19220 (10- 
5M and 10*4 M) on PGE2 -mediated inhibition of fMLP (10-7 M )-stim uIated
superoxide generation by human neutrophils. Neutrophils (106 ml-1) were 
preincubated with SC 19220 (60 min, room temperature) prior to addition of PGE2 and 
cytochalasin B (5|ig ml-1) for 5 min (37°C) and then stimulated with fMLP for 5 min 
(37-C). Results shown are mean±s.e.m % inhibition of fMLP-stimulated superoxide 
response of 3 separate experiments performed in duplicate.
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Fig 3.4 Effect of prostanoid DP/EPj receptor antagonist AH 6809 
(10*7 -3xl0*6 M) on PGE2 -mediated inhibition of fMLP (10-7 M )-stim ulated
superoxide generation by human neutrophils. Neutrophils (106 ml-1) were 
preincubated with AH 6809 (60 min, room temperature) prior to addition of PGE2  and 
cytochalasin B (5jig m l1) for 5 min (37‘C) and then stimulated with fMLP for 5 min 
(37*C). Results shown are mean±s.e.m % inhibition of fMLP-stimulated superoxide 
response of 5 separate experiments performed in duplicate. Inset shows the 
corresponding modified Schild plot as described in the text, where A and B represent the 
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Fig 3.5 Variability of AH 6809 (10’5 M) antagonism of PGE2 -
mediated inhibition of fMLP (10-7 M)-stimulated superoxide generation by 
human neutrophils (upper panel), and lack of correlation between AH 
6809 antagonism  and enhancem ent of fMLP (10~7 M )-s t im u la te d  
superoxide generation (lower panel). Results show AH 6809-potentiation of 
fMLP-stimulated superoxide generation (control fMLP response=100%) plotted against 
AH 6809 (10-5M) antagonism of PGE2 expressed as the concentration ratio (CR) 
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Fig 3.6 Effect of prostanoid DP receptor antagonist BW A8 6 8 C 
(10*7 M) on PGE2 (upper panel) and PGD2 (lower panel)-m ediated
inhibition of fMLP (10-7 M)-stimulated superoxide generation by human 
neutrophils. Neutrophils (106 ml-1) were preincubated with BW A8 6 8 C (60 min, 
room temperature) prior to addition of prostaglandins and cytochalasin B (5|ig ml-1) for 5 
min (37*C) and then stimulated with fMLP for 5 min (37#C). Results shown are 
mean±s.e.m % inhibition of fMLP-stimulated superoxide response of 5 separate 
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Fig 3.7 Effect of prostanoid DP receptor antagonist BW A8 6 8 C 
(10-7M) on AH 6809 (10*5M) antagonism of PGE2-mediated inhibition of 
fMLP (10*7M)-stimulated superoxide generation by human neutrophils.
Neutrophils (106 ml-1) were preincubated with BW A8 6 8 C+/-AH 6809 (60 min, room 
temperature) prior to addition of PGE2 and cytochalasin B (5jig ml-1) for 5 min (37*C)
and then stimulated with fMLP for 5 min (37°C). Results shown are mean±s.e.m % 
inhibition of fMLP-stimulated superoxide response of 3 separate experiments performed 
in duplicate.
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Fig 3.8 Effect of prostanoid EP4 receptor antagonist AH23848B  
(10-5M ) on PGE2-mediated inhibition of fMLP (10~7M )-stim ulated
superoxide generation by human neutrophils. Neutrophils (106 ml-i) were 
preincubated with AH23848B (60 min, room temperature) prior to addition of 
prostaglandins and cytochalasin B (5|ig ml-i) for 5 min (37*C) and then stimulated with 
fMLP for 5 min (37°C). Results shown are meanis.e.m % inhibition of fMLP- 
stimulated superoxide response of 3 separate experiments performed in duplicate.
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3.2.4 Specificity and selectivity of AH 6809 antagonism
The adenosine A2  receptor agonist, NECA, and the direct activator of adenylate cyclase, 
forskolin, both inhibited fMLP stimulated superoxide generation. The p[A5 o] value for 
NECA was 7.9±0.1 and the pICso was <4.5 for forskolin (p[Aso] was not calculated as no 
clear maximum was reached at 3xlO-5M). The maximum inhibition reached by NECA and 
forskolin were 85.3±3.5% and 43.0±6.0% respectively (at 3xlO-SM, n=3 for both). AH 
6809 at 10-5M had no effect on the E/[A] curves of NECA (p[A5o]=7 .9 ±0 . 1 , maximum 
inhibition of 77.3±1.0%) or forskolin (pIC5o<4 .5 , maximum inhibition of 37.0±3.0%) 
shown in Fig 3.9 (n=3 for both). This concentration of AH 6809 did however cause a 
rightward shift of the E/[A] curve of the EP2  selective agonist AH13205, although the shift 
was not parallel (Fig 3.10). An approximately 20 fold parallel rightward shift of the lower 
part of the AH 13205 curve was observed at 10-5M AH 6809 (n=3), but at AH13205 
concentrations of 10-5M and higher, less antagonism was observed.
AH 6809 under the same conditions antagonised BW 245C inhibition of fMLP-stimulated 
superoxide generation (Fig 3.11) with a pA2 value of 6.6±0.1 (slope=1.0±0.1, n=3
experiments). The selective prostanoid DP receptor antagonist BW A8 6 8 C (10-7M) also 
























Fig 3.9 Effect of AH 6809 (10-5 M) on adenosine receptor agonist 
NECA (upper panel) and direct adenylate cyclase stimulator forskolin 
(lower panel)-mediated inhibition of fMLP (10-7M)-stimuIated superoxide 
generation by human neutrophils. Neutrophils (106 ml*1) were preincubated with 
AH 6809 (60 min, room temperature) prior to addition of inhibitors and cytochalasin B 
(5pg ml*1) for 5 min (37°C) and then stimulated with fMLP for 5 min (37’C). Results 
shown are mean±s.e.m % inhibition of fMLP-stimulated superoxide response of 3 









5 -4 37 689
[AH 13205] (log10 M)
Fig 3.10 Effect of AH 6809 (10-5M) on selective EP2 receptor agonist 
AH13205-mediated inhibition of fMLP (10*7 M )-stim ulated superoxide 
generation by human neutrophils. Neutrophils (106 ml-1) were preincubated with 
AH 6809 (60 min, room temperature) prior to addition of AH13205 and cytochalasin B 
(5pg ml-1) for 5 min (37°C) and then stimulated with fMLP for 5 min (37°C). Results 
shown are mean±s.e.m % inhibition of fMLP-stimulated superoxide response of 3 
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Fig 3.11 Effect of AH 6809 (3xHMM-3xlO-5M) (upper panel) and BW 
A8 6 8 C (10-7M) (lower panel) on BW 245C-mediated inhibition of fMLP 
(10*7M )-stim ulated superoxide generation by human neutrophils.
Neutrophils (106 ml-1) were preincubated with AH 6809 or BW A8 6 8 C (60 min, room 
temperature) prior to addition of BW 245C and cytochalasin B (5|ig ml*1) for 5 min 
(37’C) and then stimulated with fMLP for 5 min (37#C). Results shown are mean±s.e.m 
% inhibition of fMLP-stimulated superoxide response of 3 (AH 6809) and 4 (BW 
A8 6 8 C) separate experiments performed in duplicate.
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3.2.5 Effect of PGE2 and EP agonists on cAMP accumulation in human neutrophils
PGE2  stimulated increases in cAMP accumulation in human neutrophils in the presence of 
5xl(MM IBMX (Fig 3.12), by 7.5±3.0 pmol cAMP 106 neutrophils*1 (n=21) above basal 
levels of 1.2±0.2pmol cAMP 106 neutrophils*1 (n=21) with a p[Aso] of 6.8±0.1 (n=21). 
Other EP receptor agonists 11-deoxy PGEi, misoprostol, AH13205 and also PGAi also 
increased cAMP accumulation (Fig 3.12). In individual experiments 11-deoxy PGEi and
misoprostol were full agonists compared to PGE2 with a maximum response, a = l. The
p[A50] values for 1 1 -deoxy PGEi and misoprostol were 5.6±0.2 and 5.210.2 respectively 
(n=4 for both). However PGAi (p[A5o]=6 .3 ! 0 .2 ) and AH13205 (p[A5o]=5.810.1) were
found to be partial agonists with a  values of 0.6210.04 and 0.3410.03 respectively
compared with PGE2 response, a = l, which were significantly lower than PGE2 , p<0.05 for 
both (n=3).
3.2.6 Application of the Operational Model to EP agonist data in superoxide and cAMP 
assays
The experimental potency orders (using p[Aso] values), of the prostanoid EP agonists PGE2 , 
PGAi, AH13205, misoprostol and 11-deoxy-PGEi in the fMLP-stimulated superoxide 
assay and the cAMP assay were different (Table 3.3). However, the analysis was 
complicated by the partial agonist activity of AH13205 and PGAi compared with PGE2 in 
the cAMP assay.
After application of the Operational model to the same experimental data in both superoxide 
and cAMP assays to simulate an increase in receptor reserve; all the agonists reached the 
same maximum response and the potency orders in the 2 assays was similar. The latter 
suggests that prostanoid EP agonists inhibited fMLP-stimulated superoxide generation and
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stimulated cAMP elevation by activating the same receptor.
3.2.7 The effect of AH 6809 and AH23848B on PGE2 stimulated cAMP accumulation by 
human neutrophils
AH 6809 (10-5M) had no effect on basal cAMP levels compared to control neutrophils which 
were 0.7±0.1 and 0.810.1 pmol 106 neutrophils1 respectively (n=ll). AH 6809 (10-5M) 
did however antagonise PGE2 stimulated cAMP accumulation by human neutrophils (Fig
3.13), the rightward shift was 1.310.1 logio units n= ll which approximated to a pA2 value 
of 6.3. This was consistent with the observed antagonist activity of AH 6809 (at 10*5M) 
against PGE2 inhibition of fMLP-stimulated superoxide generation by human neutrophils.
AH23848B (3xl0-5M) had no effect on basal cAMP levels compared to human neutrophils 
which were 0.810.2 and 1.010.1 pmol 106 neutrophils- 1 respectively (n=3). Neither did 
AH23848B (3xl0-5M) produce a rightward shift of the PGE2 cAMP stimulation curve (Fig
3.13), the DR was 0.110.1 log 10 units (n=3), indicating that AH23848B did not antagonise 
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Fig 3.12 Effect of PGE2 and prostanoid EP receptor agonists on cAMP 
levels in human neutrophils. Neutrophils (3x10 6 per determination) were 
preincubated with IBMX (5xlO-4M, 5 min, 37#C) prior to stimulation with prostanoid 
agonists (5 min, 37°C). Results shown are the mean±s.e.m cAMP increase for each 
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Fig 3.13 Effect of AH 6809 (10-5M) (upper panel) and AH23848B 
(3xlO -5 M) (lower panel) on PGE2 -stimulated cAMP accumulation by 
human neutrophils. Neutrophils (2xl0 7 ml-1) were preincubated with the 
antagonists for 3 min (room temperature) followed by the addition of IBMX (5xl(MM, 
5 min, 37’C) prior to stimulation with prostanoids (5 min, 37°C). Results shown are 
the mean±s.e.m cAMP increase normalised with respect to the control PGE2  maximum 




p[A50] 7.2 6.3 6.3 6.1 5.5
cAMP PGE2>PGAi>AH13205«1 1-deoxy PGEi ^misoprostol
p[A50] 6.8 6.3 5.8 5.6 5.2
a  1.0 0.62 0.34 1.0 1.0
After Simulation
Superoxide PGE2>PGAi«misoprostol® 11 -deoxy PGEi>AH13205
p[A50] 9.2 8.3 8.3 8.1 7.5
cAMP PGE2>PG Ai® 11 -deoxy PGEi®misoprostol>AH 13205
p[A5q] 8.8 7.6 7.6 7.2 6.9
a  1.0 1.0 1.0 1.0 1.0
Table 3.3 Application of Operational Model of Agonism to EP agonist data 
in human neutrophil superoxide and cAMP assays. An increase in receptor reserve 
was simulated in the experimental data using the Operational Model in order to render all the 
agonists full for comparison of agonists potency orders.
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3.3 DISCUSSION
The results presented in this chapter suggest that the prostanoid EP receptor mediating 
inhibition of fMLP stimulated superoxide generation by human neutrophils to be 
pharmacologically distinct from the prostanoid EP2 receptor. Initial characterization showed 
that this inhibitory EP receptor exhibited an agonist potency order consistent with the EP2  
subtype. In addition to this, the same agonist potency order was obtained for cAMP 
accumulation in human neutrophils suggesting both functions were mediated by the same 
receptor. However, AH 6809 (an EPi/DP receptor antagonist) antagonism of PGE2  
inhibition of fMLP-stimulated superoxide generation by the human neutrophil appears to 
differentiate it from the EP2 receptor according to the existing classification.
3.3.1 Inhibitory prostanoid EP receptors on human neutrophils
In the present study, human neutrophils were shown to express prostanoid EP and DP 
receptors; activation of which inhibited 0 2 “ generation stimulated by fMLP. The presence of 
these inhibitory prostanoid receptors on human neutrophils is confirmed by others on the 
activity of PGEi, PGE2 and PGD2 on 0 2 “ generation, LTB4 release and degranulation by 
human neutrophils (Ney & Schror, 1991; Wheeldon & Vardey, 1993). Inhibition of fMLP- 
stimulated O2" generation by the selective IP (cicaprost and iloprost) and TP (U46619) 
receptor agonists was only observed at high concentrations compared with those selective for 
their respective receptors (Dong et al., 1986). This suggested that neither receptor was 
present on human neutrophils and is supported by the findings of others (Hecker et a/., 
1990, Wheeldon & Vardey, 1993). Inhibitory effects of IP and TP receptor agonists on 
human neutrophil activation may therefore be mediated by interacting with DP and/or EP 
receptors.
The activity profile and potency order of the wide range of prostanoid EP agonists tested
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suggest that the inhibitory receptor on the human neutrophil is of the EP2 subtype. The range 
of compounds tested in this study is an expansion on the preliminary reported data (Li et al., 
1993) and more extensive than those more recently published in the literature (Wheeldon & 
Vardey, 1993, Armstrong & Talpain, 1994, Talpain et al., 1994). Similar agonist potency 
orders have been reported for the more widely used agonists; AH13205, butaprost, 11-deoxy 
PGEi, misoprostol and sulprostone as inhibitors of opsonised zymosan stimulated-LTB4  
generation (Wheeldon & Vardey, 1993) and fMLP-stimulated O2" formation (Armstrong & 
Talpain, 1994) by human neutrophils.
In addition, this study has established that the same agonist potency order exists in the human 
neutrophil for inhibition of O2” generation and stimulation of cAMP accumulation. This 
provides further evidence for the human neutrophil prostanoid EP receptor as being similar to 
the EP2  subtype as the signal transduction pathway for the EP2 receptor is cAMP (Coleman 
e ta l ., 1990 and Yeardley e ta l ., 1993). Additional quantitative information on agonist 
activity was obtained from the cAMP measurements, as some of the agonists were partial 
agonists in this second messenger assay, i.e. PGAi and AH 13205. In contrast, all the 
prostanoid EP agonists including PGAi and AH13205 were apparently full agonists in the 
O2” functional assay. In other ‘EP2-receptor’ containing preparations such as the rabbit ear 
artery; AH13205 is a full agonist (Nials etal., 1993). However, in the human myometrium, 
PGE2 , butaprost and AH13205 stimulate cAMP elevation via an EP 2-receptor; but notably 
AH13205 is a partial agonist. Using the Operational Model (Leff etal., 1990), the affinity 
and efficacy of the partial agonists could be estimated which further characterized and 
quantified the properties of the agonist at the neutrophil prostanoid EP receptor. Conclusive 
proof of these partial agonists AH 13205 and PGAi acting at the same receptor as PGE2 
could only be provided by partial agonist-full agonist interaction experiments with PGA 1 or 
AH13205 with PGE2 (full agonist). However, the poor potency of these partial agonists and
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the precision of the cAMP assay do not permit such a study. In addition, the apparent 
partiality of PGAi and AH13205 may be explained by the model proposed by Szabadi 
(1977); in which an agonist can activate two functionally antagonistic receptor populations. 
However, the agonist potency orders obtained for the prostanoid EP agonists in the cAMP 
assay after simulation of increased receptor reserve do suggest that both PGAi and AH13205 
are truly partial agonists.
The EPi selective antagonists SC 19220 and AH 6809 were tested to further confirm the EP2  
identity deduced from agonist potency information. As would have been expected from the 
classification, SC 19220 (up to lO^M) had no effect on PGE2 inhibition of 0 2 “ generation, 
although this high antagonist concentration did appear to cause a leftward shift of the PGE2  
curve. Taking into account the weakness of SC 19220 as an EPi receptor antagonist (pA2
5.4), the possibility of a non-specific effect cannot be excluded. Coleman e td . y (1987) also 
showed SC 19220 did not antagonise PGE2 induced relaxation of the cat trachea, an EP2  
receptor containing tissue, up to a concentration of lO^M (pA2 <4.0).
Coleman etal. (1987) also reported that AH 6809 had no antagonist activity at 10-5M (pA2  
<5.0) in the cat trachea. These observations were the basis of the EP receptor antagonist 
profile of SC 19220 and AH 6809, and are upheld to the present time. However, few 
studies have actually used SC 19220 and AH 6809 to confirm agonist potency information 
on EP2  receptors. The characterization of EP2 receptors relied upon the activity of the EP2  
agonists butaprost and AY-23626 (EP2/EP3 selective, available in limited supply, but now 
exhausted), and inactivity of sulprostone (EP1/EP3 selective). Antagonists were only used to 
differentiate between EPi and EP3 receptors as sulprostone was an agonist at both subtypes. 
Unexpectedly and contrary to the established classification, AH 6809 concentration- 
dependently caused a rightward shift of the PGE2  neutrophil superoxide inhibition E/[A]
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curve and the PGE2 cAMP stimulation curve in the human neutrophil. This suggests that AH 
6809 antagonises a response mediated via an EP2 receptor.
The possibility of AH 6809 antagonism of PGE2 being mediated at the DP receptor was 
excluded, as the more selective and potent DP receptor antagonist BW A8 6 8 C (at 10-7M) had 
no effect on the PGE2 inhibition of O2" generation. The same concentration of BW A8 6 8 C 
(1 0 -7M) produced over 1 0 0  fold rightward shift of the PGD2  curve which was consistent 
with its pA2  value of 9.3 at the DP receptor. Neither was the antagonism of PGE2  by 10-5M 
AH 6809 (a concentration which produced the maximum rightward shift of the PGE2  curve 
of 20-30 fold) affected by the presence of BW A8 6 8 C (10-7M), further confirming that DP 
receptors did not contribute to the inhibitory effect of PGE2 or its antagonism by AH 6809. 
AH 6809 under the same assay conditions, did however antagonise DP receptor mediated 
inhibition of fMLP-stimulated O2" generation, causing rightward shifts of the E/[A] curves of 
BW 245C. This was consistent with the degree of antagonism of BW245C observed by 
Wheeldon & Vardey (1993) also using fMLP-stimulated O2” generation in human 
neutrophils as the assay system.
Further confirmation of the human EP2 receptor antagonistic activity of AH 6809 was the 20- 
fold rightward shift of the AH13205 curve by AH 6809 (10-5M). The antagonism was 
restricted to the lower part of the AH 13205 curve which may reflect on the lack of potency of 
AH13205 as a prostanoid EP agonist; since even the control AH 13205 E/[A] curve steepened 
at concentrations of > 10-5M. These results suggest that AH 13205 had non-specific effects 
on neutrophil function, and/or perhaps had effects on another inhibitory receptor at > 10-5M.
The specificity of the AH 6809 antagonism was confirmed by its lack of effect on another (a 
non-prostanoid) inhibitor of human neutrophil activation, the adenosine A2 receptor agonist 
NECA (Cronstein etal., 1988). Neither did AH 6809 antagonise forskolin (the direct
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activator of adenylate cyclase, De Souza et al., 1983) inhibition of fMLP stimulated 
superoxide generation. Thus, AH 6809 was not acting indiscriminately and generally 
antagonising inhibitors of neutrophil activation; nor was it acting intracellularly post­
activation of adenylate cyclase. These data support the specificity of AH 6809 as a 
prostanoid receptor antagonist, as it does not appear to interfere with the non-prostanoid 
receptors or the other components downstream of adenylate cyclase involved in inhibition of 
fMLP-stimulated 0 2 “ generation. AH 6809 (10-5M) also antagonised PGE2-stimulated 
cAMP accumulation by 1.3 log 10 units i.e. similar to the degree of antagonism observed in 
the 0 2 “ assay, thereby providing yet more evidence for AH 6809 acting selectively at the 
prostanoid EP receptor.
Prostanoid receptor-selective antagonism by AH 6809 was not however observed by Talpain 
et al. (1994). They observed AH 6809 (10-5M) antagonism of NECA inhibition of fMLP- 
stimulated O2” generation which was equal to if not greater than that observed using PGE2 as 
the agonist. This obviously contradicts the findings presented here. There are however 
several methodological differences which may account for this. In the experiments presented 
in this thesis, the agonist potencies were similar to that published by a variety of other 
researchers (Gryglewski etal., 1987, Hecker etal., 1990, Ney & Schror, 1991) all of which 
were performed in the absence of phosphodiesterase inhibitors, and similar to those of 
Talpain etal. (1994) in the presence of the non-selective phosphodiesterase inhibitor IBMX. 
In the absence of IBMX, Talpain etal. (1994) found the agonists were less potent and few 
agonists reached a clear maximum response, partly because agonist concentrations of 10-5M 
were not exceeded. Another difference is that the pre-incubation time for the agonists used in 
the present study were 5 min compared to 10 min (Talpain etal., 1994) at 37°C prior to 
stimulation with fMLP. The time course of PGE2~stimulated cAMP accumulation in this 
study was optimal at 5 min, either in the presence or absence of phosphodiesterase inhibition 
(see chapter 4), and in some experiments was slightly lower at 10 min compared to 5 min.
I l l
This suggests that in terms of adenylate cyclase activation, the pre-incubation period of 5 min 
was optimal for PGE2 to ensure maximal elevation of cAMP levels on stimulation of O2” 
generation. In addition to this, the fMLP-stimulation period used in this study was 5 min, 
and not the 10 min adopted by Talpain et al. (1994). Nielson (1987) showed that fMLP- 
stimulated O2” generation by human neutrophils was biphasic; the first phase was terminated 
by 5-6 min and inhibited by isoprenaline, thereafter the second phase was initiated and the 
rate of O2” generation was increasing at 10 min and not inhibited by isoprenaline. In 
addition, the inhibitory effect of isoprenaline on fMLP-stimulated O2” generation was more 
pronounced after 5 than 15 min stimulation. Therefore only the first phase of fMLP- 
stimulated 0 2 “ generation was inhibited by P-agonists (increases in cAMP). Nielson
demonstrated that PGE2 had a similar effect, although it was less potent than isoprenaline as 
an inhibitor. These observations could account for the differences observed between the 
present study and that of Talpain et al., in terms of potency and effectiveness of the agonists. 
Thus, in the latter, the assay conditions were not optimal for the study of these compounds.
AH 6809 enhanced fMLP-stimulated 0 2 “ generation in this present study, suggesting a 
stimulatory or priming effect on neutrophil function; but did not stimulate 0 2 “ generation 
itself. AH 6809 enhancement of fMLP-stimulated O2" generation by human neutrophils has 
subsequently been reported by Talpain et al. (1994). Stimulatory effects of AH 6809 in other 
tissues have been noted over a similar concentration range, such as spasmolytic activity on 
smooth muscle unrelated to its prostanoid receptor blocking activity observed by Coleman 
(1987). There have been many activities reported at these high concentrations of AH 6809 
(>lxl0-5M); for instance antagonism of thromboxane synthase, antagonism of prostanoid TP 
receptors (Keery & Lumley, 1988) and inhibition of phosphodiesterase activity in mast cells 
(IC50 2.6x10 5M) although it is unclear which isoform is involved (Keery & Lumley, 1988). 
Inhibition of phosphodiesterase activity may explain AH 6809-mediated potentiation of
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prostacyclin and NECA inhibition of human platelet aggregation (Keery & Lumley, 1988). 
This effect is the exact opposite to that observed by Talpain et al. (1994) in the human 
neutrophil. If an inhibition of phosphodiesterase does occur it may contribute to the lack of 
rightward shift of the PGE2 O2” inhibition curve by 10-5M AH 6809 observed in some 
donors.
More recently, AH 6809 (10-5M) antagonism of PGE2-induced relaxation of the rabbit ear 
artery, an EP2 -receptor mediated response (Humbles et al.> 1991), has been observed 
(personal communication from George Smith, Astra Chamwood, 1995). However 
antagonism was not observed in all preparations, and the degree of antagonism was small (<
0.5 logio units). Consequently, this effect of AH 6809 may not be attributable to antagonism 
of the EP2 receptor, but to a non-prostanoid effect Of AH 6809 as observed in other smooth 
muscle preparations (Coleman, 1987).
As EP2 and EP4 receptors mediate similar functions in many tissues, such as relaxation of 
smooth muscle; the effect of the EP4  receptor antagonist AH23848B on PGE2  was evaluated 
in the neutrophil. AH23848B is a more potent TP receptor antagonist (pA2 7.8-8.3, Brittain 
eta l.y 1984) than an EP4  receptor antagonist (Coleman et a l., 1994a). Initially, due to its 
lack of potency, AH23848B was evaluated at 3xl0-5M, which would give approximately a 
logio unit rightward shift of agonists at EP4  receptors according to its literature pA2 value 
(Coleman et al., 1994a). However, under the assay conditions used, this concentration of 
AH23848B reduced the control fMLP O2” response to a level too small to quantify the effect 
of inhibitors accurately. Thereby, suggesting that AH23848B had a non-specific effect on 
neutrophil O2” generation or agonist activity at another inhibitory receptor on the human
neutrophil. A lower concentration (10-5M) which did not affect the control fMLP response 
did not antagonise the inhibitory effect of PGE2 on fMLP-stimulated 0 2 “ generation or
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PGE2-stimulated cAMP accumulation. However, the lack of potency of this compound as an 
EP4  receptor antagonist does not preclude the presence of EP4  receptors on human 
neutrophils. Armstrong & Talpain (1994) reported however that AH23848B at 3xlO-5M did 
not significantly reduce PGE2 stimulated cAMP generation in human neutrophils which 
supports the lack of EP4  receptors on human neutrophils. Indeed, Talpain etal. (1994) 
reported that lower concentrations of AH23848B (10-5 M) increased fMLP-stimulated 
superoxide generation by human neutrophils and increased the potency of PGE2 , butaprost 
and NECA as inhibitors of fMLP-stimulated O2" generation. This effect on PGE2 was not 
observed in the present study, which again may be accounted for by differences in protocol. 
Talpain et al. used a 10 min (37°C) pre-incubation period for the antagonists prior to addition 
of the agonists, whilst in this study the cells were pre-incubated for up to 60 min at room 
temperature to insure equilibrium had been reached. This is especially important in view of 
the low potency of some of the antagonists such as AH23848B, compared to the agonists. 
However the enhancement of the effects of other inhibitors of neutrophil activation observed 
by Talpain etal. (1994) may suggest AH23848B is a partial agonist, but this was rejected as 
AH23848B enhanced rather than inhibited fMLP-stimulated 0 2 “ generation. However in the 
present study, the converse was observed at 3xl0-5M, which suggests that AH23848B may 
have some agonist activity although it is unclear which receptor is involved. This is not 
entirely unexpected as AH23848B has agonist activity at EP4 receptor in the rabbit saphenous 
vein (Lydford et al., manuscript in preparation).
In addition, this study has shown, as have others (Wheeldon & Vardey, 1993 and Armstrong 
& Talpain, 1994), that the EP2 selective agonist AH13205 was just 30 fold less potent than 
PGE2  on the human neutrophil. This potency difference is consistent with the presence of 
EP2  receptors and the absence of EP4  receptors, as AH13205 is 11,000 less potent than 
PGE2  in EP4  receptor containing tissues (Coleman et al., 1994a). However, as there are no
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reported selective agonists or more potent selective antagonists, for this most recently 
described subtype, the EP4  receptor; the presence of EP4  receptors on human neutrophils 
cannot be conclusively demonstrated.
This study has shown that contrary to the established classification, AH 6809 is an antagonist 
at the human EP2  receptor and not a selective EPi or DP receptor antagonist The data from 
the human neutrophil provides evidence that this EP receptor may be different to other 
species or perhaps represents a novel subtype. However, the lack of detailed information in 
the literature on the actions of AH 6809 in EP2 receptor containing tissues especially human, 
means that experimental differences cannot be excluded. This is especially important in the 
context that EP2 and EP4  receptors can mediate similar responses in the same tissue; and at 
the time when AH 6809 was described as an EPi selective antagonist (Coleman et al., 1987), 
EP4  receptors were unknown. So it is possible that the lack of antagonism observed at EP2 
receptor containing tissues could be due to the presence of EP4 receptors masking any 
antagonism. Differences in experimental protocol could also have masked AH 6809 
antagonism of EP2 receptors, for instance if AH 6809 was added to the tissue to block any 
effects of DP and EPi receptors in the tissue prior to testing any EP agonists, the EP2 
receptors could also have been blocked. In addition, in some preparations AH 6809 may 
have activity which precludes clear interpretation of its prostanoid antagonist activity, such as 
platelets and smooth muscle preparations. The use of AH 6809 is also complicated by its 
lipophilicity. AH 6809 is extremely highly plasma protein bound, approximately 97% is 
bound in 4% BSA (Coleman etal., 1990) and therefore non-specific binding to protein and 
diffusion may pose a variable problem between tissue preparations. The lipophilicity of AH 
6809 would present less of a problem for cell preparations, unless there are protein 
supplements or a large number of non-participating cells in the assay.
It can be said then, that the characterization of prostanoid receptors in general is fraught with
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difficulties. Not least because most tissues and cells possess at least two different prostanoid 
receptors, for example, the human neutrophil has EP2 and DP receptors (and possibly EP3), 
the human platelet has DP, IP and TP receptors, the guinea pig trachea has EPi and EP2  
receptors and the rabbit ear artery has EP2 and EP3 receptors.
3.3.2 Biological activity of PGE metabolites
Natural prostaglandins are rapidly metabolised and labile, the plasma half-life of a 
prostaglandin on reaching the blood stream is estimated as less than 1 min. The initially 
formed metabolites are the 15-keto-13,14-dihydro compounds which appear within 1 min 
and have a half-life of about 10 min in the blood. For the PGE compounds this is the
predominant metabolic pathway, and other metabolites are subsequently formed via 0 -
oxidation or co-oxidation, but there is also interconversion between metabolites of the PGE
and PGF compounds. The PGA and PGB compounds are products of non-enzymic 
degradation formed by dehydration of the PGE molecules, by the action of acid and base 
respectively. Their presence in biological samples is generally considered to be artifacts 
formed ex-vivo during storage prior to measurement (Horton, 1979). Nevertheless, an 
enzyme has been identified which can catalyse the isomerisation of PGA 2 to PGC2  (Jones & 
Cammock, 1973) followed by isomerisation to PGB 2 . Thus the indications are that these 
molecules may be formed in vivo; and as the dehydration of PGE moieties into PGA and 
PGB compounds is especially rapid in the presence of albumin, their formation in inflamed 
tissue, such as sites of plasma leakage and oedema, is a distinct possibility. The biological 
activity of PGEo, PGAi, PGA2 , PGBi and PGB2 and other products of PGE metabolism 
and degradation are physiologically and pharmacologically significant. Some of these 
metabolites are also more stable than their parent molecules; these together suggest that the 
duration of the biological activity of PGEi and PGE2 may extend beyond the lifetime of the 
parent Also of significance, is the activity of these metabolites at other prostanoid receptors
116
on leukocytes and in other tissues and how this reflects on the physiological and pathological 
effects of prostaglandins in normal and disease conditions.
3.3.3 Inhibitory prostanoid DP receptors on human neutrophils
Prostanoid DP receptor agonists also inhibit human neutrophil activation, and one of the most 
potent prostanoid agonists evaluated in this study is a DP agonist, BW245C. However, the 
human neutrophil prostanoid DP receptor does not appear to be pharmacologically different 
to the DP receptor found in other tissues (Wheeldon & Vardey, 1993 and the present study) 
in terms of its sensitivity to prostanoid DP agonists or antagonists. There are preliminary 
reports of evidence which suggests subtyping of prostanoid DP receptors, for instance BW 
A8 6 8 C (selective DP receptor antagonist) appearing to interact with 2 receptors in the rabbit 
saphenous vein (Lydford et al., 1994).
In summaty, the pharmacological characterization of the inhibitory prostanoid EP2  receptor 
on the human neutrophil using fMLP-stimulated O2” generation as the assay system has been 
described in this chapter. Furthermore, the same agonist potency order exists for cAMP 
elevation, and PGE2 stimulated increases in cAMP are also inhibited by AH 6809.
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CHAPTER 4
EFFECT OF PGE2 ON cAMP LEVELS IN
HUMAN NEUTROPHILS AND cAMP 
MODULATION OF [Ca2+]j AND SUPEROXIDE
GENERATION
4.1 INTRODUCTION
4.1.1 Modulation of human neutrophil activation by cAMP
Many inhibitors of leukocyte activation, such as phosphodiesterase inhibitors (PDEIs),
prostaglandins D2 and E2 (PGD2 and PGE2 ) and p-adrenoceptor agonists, elicit an
increase in cAMP in the target cell. All of these agents inhibit human neutrophil activation 
and simultaneously elevate cAMP levels. The latter has been proposed as a common 
mechanism of action to explain their inhibitory activities.
Amongst the most intensively studied inhibitors are PGE2  (Gryglewski et al., 1987, 
Rossi & O’Flaherty, 1989, Hecker etal., 1990) and PDEIs (Nielson et al., 1990, Ho et 
al., 1990, Schudt etal., 1991). Both types of agents elevate cAMP levels; PGE2 by 
prostanoid EP receptor mediated activation of adenylate cyclase catalyzing the formation 
of cAMP from ATP, and PDEI’s by inhibiting cAMP metabolism. The 
phosphodiesterase activity in human neutrophils is predominately type IV, the cGMP- 
insensitive cAMP-selective isozyme (Nielson et al., 1990, Wright eta l., 1990). PGE2 
and PDEIs inhibit fMLP-stimulated superoxide (0 2 ~) generation and increase in cytosolic 
free Ca2+ ([Ca2+]i) by human neutrophils. At present, it is unclear if cAMP-elevating 
agents inhibit human neutrophil activation by attenuating stimuli-induced increases in 
[Ca2+]i, and if they do, which mechanisms are involved.
Interestingly, the neutrophil activator, formyl-methionyl-leucyl-phenylalanine (fMLP), 
has been reported to induce a transient (15-30 second) increase in cAMP levels (doubling 
of basal levels). The transience of this fMLP-stimulated cAMP increase is Ca2+- 
dependent and is abolished in the presence of PDEIs (Verghese et al., 1985). However, 
the precise mechanism is unknown, but may represent a physiological process 
implemented by neutrophils to terminate stimulus transduction signals (Verghese et al., 
1985). In which case, cAMP elevation may be a global cellular mechanism utilised by 
both inhibitors (PDEIs and PGE2) and stimulators to attenuate neutrophil activation. The 
inhibitors may exert their suppressive effects by preempting and/or potentiating the
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stimulus (fMLP)-induced cAMP elevation associated with inactivation of cellular 
responses (Verghese et al., 1985).
4.1.2 Role of calcium in human neutrophil activation
Neutrophil activation by receptor-mediated stimuli is invariably associated with an 
increase in cytosolic free Ca2+ ion concentration ([Ca2+]i). An increase in [Ca2+]i is 
essential but not sufficient for activation of neutrophils. fMLP-stimulated degranulation 
and O2" generation is abolished by depleting stored Ca2+ ions and buffering [Ca2+]i with
intracellular Ca2+chelators (O’Flaherty etal., 1991). Indeed, many neutrophil functions 
can be stimulated by agents which do not increase [Ca2+]i including phorbol esters 
(PMA), suggesting that protein kinase C (PKC) activation is also involved in eliciting 
neutrophil responses (Lew et al., 1984, Nielson, 1987).
fMLP, the bacterial peptide, is one of the best known and widely used stimuli in human 
neutrophil function studies. fMLP and the complement fragment C5a are described as 
complete stimuli/secretagogues. They are able to elicit the full range of neutrophil 
responses - aggregation, chemotaxis, exocytosis, 0 2 “ generation and shape change. 
Incomplete stimuli/secretagogues such as LTB4  and interleukin 8  (IL-8 ) are potent 
chemotactic agents, but are extremely poor stimulators of superoxide generation or 
degranulation (Wymann etal., 1987, Baggiolini etal., 1989).
fMLP activates a specific transmembrane receptor coupled to phospholipase C and 
subsequently increases intracellular free calcium levels [Ca2+]i and activates protein
kinase C (PKC). The characteristics of the fMLP-stimulated biphasic increase in [Ca2+]i
are well documented (Sage etal., 1990, Hecker et al., 1990). Following the addition of 
fMLP to neutrophils; there is an immediate rapid transient increase peaking between 10- 
2 0 s which declines into a plateau phase which remains elevated above basal which returns 
only slowly to the unstimulated [Ca2+]i (by approximately 10 min). The first phase has
been attributed to the mobilisation of Ca2+ ions from intracellular endoplasmic stores
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(Lew et al.t 1984, Sage et a i,  1990) as it is unchanged in the absence of extracellular 
Ca2+ ions. The protracted phase is due to the influx of Ca2+ ions via cation channels in 
the plasma membrane and abolished by the removal of extracellular Ca?+ ions (Sage et 
aU  1990).
Initial experiments, measuring changes in [Ca2+]i appeared to show that the onset of 
fMLP-stimulated NADPH-oxidase activation (2.4 seconds) preceded the onset of the 
increase in [Ca2+]i by 2 seconds (Wymann et a l., 1987). This study, as with most 
studies measuring neutrophil [Ca2+]i, used conventional fluorimetry with cell
suspensions in cuvettes. This technique lacks the resolution of the initial changes in 
fluorescence mainly due to the a lag phase in detection of changes in fluorescence 
required for mixing of any additions, such as stimuli to the cell suspensions. However, 
the use of stopped-flow fluorimetry allowed the early subsecond kinetics of fMLP- 
stimulated increases in [Ca2+]i to be determined (Sage et al.y 1990). With the stopped-
flow technique, the onset of fMLP-stimulated increase in [Ca2+]i was found to be 1-1.3 
seconds after fMLP addition. Thus, in the human neutrophil, fMLP-stimulated increases 
in [Ca2+]i precede that of NADPH-oxidase activation; suggesting that increases in [Ca2+h 
may be involved in fMLP-stimulated superoxide generation. Not only does the increase 
in [Ca2+]i precede the respiratory burst; but it also precedes neutrophil degranulation and 
aggregation (Korchak eta l.y 1984a and b). This study showed that fMLP-stimulated 
45Ca uptake (an index of Ca permeability) in neutrophils occurred prior to superoxide 
generation, degranulation and aggregation.
It would appear then that an increase in [Ca2+]i is involved in many if not all neutrophil 
functions, and the modulation of inflammatory stimuli (e.g. fMLP)-induced increases in 
[Ca2+]i would be anti-inflammatory.
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4.1.3 Aims
The aims of this chapter were:-
1. To determine the relationship between PGE2-stimulated cAMP elevation and 
inhibition of human neutrophil activation; by studying how PGE2 and PDEIs alone, and 
in combination, modulate neutrophil cAMP levels and fMLP-stimulated superoxide 
generation.
2. To determine how cAMP elevation modulates increases in cytosolic free calcium, 
an event associated with neutrophil activation; by studying the effect of PGE2 and the 
selective type IV PDEI, rolipram on fMLP-stimulated increases in [Ca2+]i in human 
neutrophils.
3. Establish whether cAMP-elevating agents can modulate Ca2+ and Mn2+ (a Ca2+ 
surrogate) entry in human neutrophils; and whether this could contribute to their 
inhibitory effect on fMLP-stimulated superoxide generation.
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4.2 RESULTS
4.2.1 Effect of PDEIs and PGE2 on cAMP levels in human neutrophils
Rolipram concentration-dependently stimulated small increases in neutrophil cAMP levels 
measured after 5 min stimulation (equal to the pre-incubation period in the superoxide 
assay) (Fig 4.1) and were higher at 10 min. IB MX did not stimulate a significant 
increase in cAMP above basal levels measured after 10 min. Rolipram and IBMX, at 
concentrations which inhibit fMLP-stimulated O2" generation, stimulated small or no 
increase in neutrophil cAMP levels. Significant increases in cAMP were only observed at 
supramaximal inhibitory concentrations of PDEI (Schudt etaL , 1991). In fMLP (10- 
7M)-stimulated neutrophils, rolipram, the selective type IV PDEI increased cAMP levels 
above those in unstimulated cells (Table 4.1). In contrast, the non-selective PDEI, IBMX 
did not increase cAMP levels in either unstimulated or fMLP-stimulated neutrophils 
(Table 4.1).
PGE2  stimulated increases in cAMP levels were measured in the presence of IBMX 
(5xlO-4M) after 2, 5 or 10 min stimulation (n=3) and were not significantly different (Fig 
4.2). In contrast, forskolin was a poor stimulus of cAMP accumulation in human 
neutrophils in the presence of IBMX. Even after 10 min stimulation with forskolin (10- 
4M), the cAMP levels were only 2.13±0.73 pmol cAMP 106 neutrophils- 1 compared with 
basal levels of 0.83±0.23 pmol cAMP 106 neutrophils- 1 (n=6 ). In fMLP (10-7 M)- 
stimulated neutrophils, PGE2 stimulated higher levels of cAMP accumulation (measured 
over the same time course as the superoxide assay) (Table 4.2) but the p[Aso] for PGE2 
was similar in the absence or presence of fMLP (Fig 4.3). The cAMP-potentiating effects 
of fMLP on PGE2~stimulated cAMP accumulation were not as dramatic as those observed 
on rolipram stimulated cAMP increases.
In contrast, cytochalasin B (5pg ml-1) had no effect on cAMP levels in either 
unstimulated or fMLP-stimulated neutrophils (Table 4.2) and did not alter the levels of 
cAMP accumulated on stimulation of human neutrophils by PGE2 (Table 4.2).
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Fig 4.1 Effect of rolipram on human neutrophil cAMP levels 
measured at 5 min and 10 min (upper panel) and IBMX measured at 10 
min (lower panel). Prewarmed neutrophils (106 per determination, 5 min, 37°C) 
were incubated with the PDEIs for 5 min or 10 min. Results shown are the mean±s.e.m 
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Fig 4.2 Time course of PGE2 -stimulated cAMP accumulation by 
human neutrophils. Neutrophils (106 per determination) were preincubated with 
IBMX (5xl0^M, 5 min, 37°C) prior to stimulation with PGE2 for 2, 5 or 10 min (37#C). 
Results shown are meanis.e.m increases in cAMP (pmol 106 neutrophils1) of 3 separate 
experiments performed in duplicate.
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Basal 0.52±0.16 0.4910.17
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Table 4.1 Effect of rolipram and IBMX on cAMP levels of human 
neutrophils stimulated with fMLP (10-7M). Neutrophils (106 per determination) 
were incubated with rolipram or IBMX in the presence of cytochalasin B (5 min, 37*C) 
prior to stimulation with buffer or fMLP (5 min, 37-C). Results shown are the 
mean±s.e.m neutrophil cAMP levels (pmol cAMP 106 neutrophils-1) of 3 separate 
experiments performed in duplicate.
Control CytB fMLP Cyt B/fMLP
Basal cAMP pmol 106  
neutrophils*1
1 .0 2 1 0 . 2 1.1410.09 2.0610.76 2.3510.62
PGE2  max cAMP 
pmol 1 0 6 neutrophils*1 16.7612.84 16.4712.08 42.62113.77 37.06110.55
PGE2 p[A50] 6.8310.19 6.5310.08 6.5810.40 6.9310.16
Table 4.2 Summary of effects of cytochalasin B (5pg ml*i) and fMLP 
(10*7M) on PGE2 cAMP elevation in human neutrophils. Neutrophils (106 
per determination) were preincubated with IBMX (5 x 1 (MM) and PGE2 (5 min, 37*C) in 
the absence or presence of cytochalasin B prior to the addition of buffer or fMLP (5 min, 
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Fig 4.3 PGE2-stimulated cAMP accumulation by human neutrophils - 
effect of cytochalasin B (5pg m l-i) and fMLP (10-7M )-stim ulation .
Neutrophils (106 per determination) were preincubated with IBMX (5 x 1 (MM, 5 min, 
37*C) prior to addition of PGE2 (5 min, 37°C) in the absence or presence of cytochalasin 
B (5|ig ml-i) and stimulated with fMLP or buffer (5 min, 37°C). Results shown are 
meanis.e.m cAMP increase normalised with respect to the PGE2  maximum (=1) for each 
treatment measured after the fMLP stimulation period, of 3 separate experiments 
performed in duplicate.
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4.2.2 Effect of PDEIs and PGE2 on fMLP-stimulated superoxide generation by
human neutrophils
The phosphodiesterase inhibitors (PDEIs), IBMX (non-selective), rolipram and RO 20- 
1724 (both selective for the type IV isoenzyme) inhibited fMLP (10-7M)-stimulated O2” 
generation with p[Aso] values of 5.0±0.2 (n=8 ), 7.4±0.1 (n=4) and 6.9±0.1 (n=6 ) 
respectively. Clear maximum responses were reached by all of these PDEIs, 75.1±2.6% 
by IBMX (5xlO-4M), 72.7±4.3% by rolipram (10-5M) and 72.3±2.6% by RO 20-1724 
(3xl0-5M). Milrinone, however, a type III selective PDEI (Harrison et al., 1986, 
Lindgren etal.y 1990), was a poor inhibitor of fMLP-stimulated Ofc" generation. A clear 
maximum response was not reached even at lO^M (50.0±2.1%, n=3), so a pICso of 
4.2±0.1 was calculated as a p[Aso] could not be estimated. The concentration-effect 
curves for IBMX, rolipram, RO 20-1724 and milrinone inhibition of fMLP-stimulated 
O2” generation by human neutrophils are shown in Fig 4.4.
The effect of combining PGE2  and PDEIs on fMLP-stimulated O2" generation by human 
neutrophils was studied in order to provide evidence for cAMP elevation as the transducer 
pathway via which PGE2 mediates inhibition of neutrophil activation. The PDEIs IBMX
(non-selective) and RO 20-1724 (type IV selective), at SxlO-MxlO^M and 3xlO-8-lxlO- 
5M respectively, concentrations which inhibit fMLP-stimulated O2” generation, 
potentiated PGE2-mediated inhibition of fMLP-stimulated O2" generation. The p[Aso] of 
PGE2  was left-shifted concentration-dependently by IBMX and RO 20-1724 (Fig 4.5 and 
Table 4.3). PGAi (another prostanoid EP receptor agonist)-inhibition of fMLP- 
stimulated O2" generation was similarly potentiated by IBMX (Table 4.4).
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Fig 4.4 Effect of PDEIs; IBMX, rolipram , RO 20-1724 and 
milrinone, on fMLP (10-7M)-stimulated superoxide generation by human 
neutrophils. Neutrophils (106 mH) were preincubated with PDEIs in the presence of 
cytochalasin B (5|ig ml-i) for 5 min (37°C) prior to stimulation with fMLP for 5 min 
(37’C). Results shown are mean±s.e.m % inhibition of control fMLP response of 8  
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Fig 4.5 Effect of IBMX (upper panel) and RO 20-1724 (lower panel) 
on PGE2-mediated inhibition of fMLP (10-7M )-stim ulated superoxide  
generation by human neutrophils. Neutrophils (106 ml-1) were simultaneously 
incubated with cytochalasin B (5jig ml-1), PGE2 +/-IBMX or RO 20-1724 (5 min, 37°C) 
prior to fMLP stimulation (5 min, 37°C). Results shown are mean±s.e.m % inhibition of 
the control fMLP response of 5 (IBMX) and 3 (RO 20-1724) separate experiments 
performed in duplicate. Inhibition by IBMX alone was 29.7±3.7% (3xl0*6M), 
50.6±4.3% (10-5M) and 64.0±7.2% (10-4M), and RO 20-1724 alone were 45.5±7.5% 
(10-7M), 62.3±6.7% (10-6M) and 65.7±10.1% (10-5M) respectively.
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PGE2 Treatment PGE2 p[A5o] Maximum % Inhibition
Control 7.37±0.16 91.413.3
+IBMX lxlO-^M 7.65±0.35 96.510.5
+IBMX 3xl0-*M 8 . 1 2 1 0 .0 2 ** 96.311.1
+IBMX Ixl0-5M 8.2410.12** 97.211.2
+IBMX lxlO^M 8.4110.11** 93.313.9
Control 7.0710.11 91.014.0
+RO 20-1724 Ixl0-7M 7.7610.24 91.014.0
+RO 20-1724 Ixl0-6M 8.3710.33* 91.713.5
+RO 20-1724 Ixl0-5M 8.3810.16* 95.713.2
Table 4.3 Effect of IBMX and RO 20-1724 on PGE2 inhibition of 
fMLP-stimulated 0 2 ~ generation by human neutrophils. Neutrophils (106 ml- 
i) were preincubated with PGE2+/-IBMX or RO 20-1724 in the presence of cytochalasin 
B (5pg mH) for 5 min (37*C) prior to stimulation with fMLP (10*7M) for 5 min (37*C). 
Results shown are meanisem % inhibition of the control fMLP response from 5 separate 
experiments for the effects of IBMX (shown in the upper part of the table) and 3 separate 
experiments for RO 20-1724 (in the lower part of the table), each performed in duplicate. 
Statistically significant changes compared with control data indicated by * for P<0.05 and 
** for P<0.01 (paired Student’s t-test).
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Treatment PGAi p[A50] Maximum % Inhibition
Control 6.93±0.15 89.012.4
+IBMX 3xlO-6M 7.20±0.20 93.511.5
+IBMX Ixl0-5M 7.3710.23* 94.312.9
Table 4.4 Effect of IBMX on PGAi inhibition of fMLP (10-7 M )-  
stimulated superoxide generation by human neutrophils. Neutrophils (106 ml- 
i) were preincubated with PGA1+/-IBMX in the presence of cytochalasin B (5pg ml-i)
for 5 min (37°C) prior to stimulation with fMLP (10-7M) for 5 min (37°C). Results 
shown are meanisem % inhibition of the control fMLP response from 3 separate 
experiments performed in duplicate.Statistically significant changes compared with 
control data indicated by * for P<0.05 (paired Student’s t-test).
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4.2.3 Effect of adenylate cyclase and protein kinase A inhibitors on superoxide 
generation by human neutrophils 
SQ 22356, the adenylate cyclase inhibitor (1(MM, Tamaoki et al., 1993), when pre­
incubated with the neutrophils for 20 min prior to addition of PGE2  or IBMX reduced the 
control fMLP O2” response by 15% and 22% in 2 donors. Unexpectedly, SQ 22356 did 
however left-shift the PGE2  inhibition curve PIA50] values in both experiments from 7.5 
to 8 . 1  and 7.0 to 8 . 2  with no effect on the PGE2  maximum (91% and 87% in the 
absence, 99% and 98% in the presence of SQ 22356). The IBMX inhibition curve was 
unaffected in one experiment (p[Aso] 5.1 and 5.0 in the absence and presence of SQ 
22356 respectively) and was right-shifted in the second experiment from 5.3 to 4.7 by 
SQ 22356.
H89, the protein kinase A inhibitor, had no effect on fMLP (10-7M)-stimulated 0 2 “ 
generation at 3xl0-6M, 10-5M and 3xl0-5M. These concentrations have a selective effect 
on protein kinase A dependent processes without affecting protein kinase G responses in 
intact cells (Chijiwa etal., 1990). The fMLP responses in the presence of H89 were 
109±2%, 108±5% and 99±6% of the control fMLP response respectively (n=3). There 
was, however, a concentration-dependent reversal of PGE2 (10-6M) and IBMX (3x10- 
5M) inhibition of fMLP-stimulated superoxide generation (Fig 4.6).
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3x10-6 10-5 3x10-5 IBMX 3x10-5M PGE2 10-6M
[H89] M 
vs control fMLP
Fig 4.6 Effect of protein kinase A inhibitor H89 on PGE2 (10*6M ) 
and IBMX (3xlO-5 M)-mediated inhibition of fMLP (10-7 M )-stim ulated  
superoxide generation by human neutrophils. Neutrophils (106 ml*1) were 
pretreated with H89 (20 min, room temperature) prior to the addition of PGE2 or IBMX 
(5 min, 37°C) and then stimulated with fMLP (5 min, 37eC). Effect of H89 on control 
fMLP-stimulated superoxide generation are shown by the filled bars on the left of the 
histogram. Results shown are meanis.e.m % inhibition of 3 separate experiments 
performed in duplicate. Statistical significance compared with control indicated by an 
asterisk representing P<0.05 as determined by Student’s t-test.
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4.2.4 Effect of divalent cation chelators and Ca2+ entry blockers on fMLP-
stimulated superoxide generation by human neutrophils
4.2.4.1 Effect of EDTA and EGTA
The presence of extracellular divalent cation chelators EDTA (Ca2+ and Mg2+ ions) or 
EGTA (Ca2+ ions only) attenuated O2" generation induced by fMLP (Fig 4.7). fMLP 
(10-7M)-stimulated O2 generation was reduced in the presence of EDTA and EGTA by 
48.6±5.1% and 62.1±4.6% respectively (n=3, p<0.05 for both), suggesting that fMLP- 
stimulated O2” generation is partially dependent on Ca2+ influx. However the fMLP 
p[A50] 7.8±0.1 was not significantly different in the presence of EDTA (ImM) or EGTA 
(0.95mM), 7.8±0.1 and 7.6±0.1 respectively (n=3, p>0.05).
In addition to this, PGE2 and the PDEIs (rolipram and RO 20-1724) inhibited fMLP- 
stimulated 0 2 “ generation in the presence of EGTA (Fig 4.8). Indeed, PGE2 was more 
potent against fMLP-stimulated O2 generation in the presence of EGTA. The PGE2  
p[A50] of 7.3±0.2 in the absence of EGTA was left-shifted in the presence of EGTA to 
8.1±0.2 (n=3, p<0.05), whilst the potency of the PDEIs were not significantly different 
in the absence or presence of EGTA. The p[Aso] of rolipram was 7.8±0.3 and 7.7±0.2, 
and RO 20-1724 was 7.1±0.1 and 6.9±0.2, in the absence and presence of EGTA 
respectively (n=3).
4.2.4.2 Effect of Ca2+ entry blockers; econazole and Ni2+ ions
The cytochrome P450 inhibitor, econazole, at 3xl0-6M and 10-5M potentiated O2" 
generation stimulated by lower concentrations of fMLP (2xl0*8M) by 37±13% and 
59±4% respectively, but did not inhibit the response to 10-7M fMLP (105±3% and 
90±2% of the control response) (mean±range of 2 separate experiments). Higher 
concentrations of econazole (3xl0-5M and 1CMM), blocked O2'  generation stimulated by
fMLP at both 2xlO*8M (79±17% and 81±12% respectively) and 10-7M (95±3% and 
95±2% respectively) (meanirange of 2 separate experiments).
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Ni2+ ions block receptor-mediated Ca2+ entry (RMCE) and voltage operated Ca2+ 
channels (VOQ. The addition of extracellular NiCl2 (3mM) as a source of Ni2+ ions, did 
not inhibit fMLP (KWM) stimulated O2" generation. There was however a degree of 
inhibition of the O2" response stimulated by lower concentrations of fMLP (10-gM) (Fig 
4.9).
4.2.4.3 The effect of inhibition of Ca2+ entry on thapsigargin-stimulated 
superoxide generation by human neutrophils 
Thapsigargin, the endoplasmic reticulum Ca2+-ATPase inhibitor (10-7M-10*6M), 
stimulated O2” generation by human neutrophils which was completely suppressed by the 
presence of ImM EGTA (Fig 4.10). Thapsigargin (lxlO-6M)-stimulated C>2“ generation 
(14.8±5.3 nmol O2" 1 0 6 neutrophils ■*) was partially inhibited by PGE2 (10-5M) and 
rolipram (10-6M) (Fig 4.11). Unlike fMLP, 0 2 “ generation stimulated by thapsigargin 
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Fig 4.7 Effect of divalent cation chelators EDTA and EGTA on fMLP- 
stimulated superoxide generation by human neutrophils. Neutrophils (106 ml- 
i) were preincubated with cytochalasin B (5pg mH)+/-EDTA (ImM) or EGTA 
(0.95mM) prior to stimulation with fMLP (10-9 -10-6M, 5 min, 37#C). Results shown are 
mean±s.e.m superoxide anion generation (nmol 0 2 “ 106 neutrophils*1) of 3 separate 
experiments performed in duplicate.
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Fig 4.8 PGE 2 (upper panel), rolipram (middle panel) and RO 20-1724 
(lower panel)-mediated inhibition of fMLP (10*7 M)-stimuIated superoxide 
generation by human neutrophils in the absence or presence of EGTA. 
Neutrophils (106 ml-1) were incubated with PGE2 , rolipram or RO 20-1724 (5 min,
37*C) in the presence of cytochalasin B (5|ig ml-1) +/- EGTA (0.95mM) prior to 
stimulation with fMLP (5 min, 37°C). Results shown are mean±s.e.m % inhibition of 
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Fig 4.9 Effect of extracellular N i2+ ions on fM LP-stim ulated  
superoxide generation by human neutrophils. Neutrophils (106 ml-1) were 
preincubated with NiCl2 (3mM) and cytochalasin B (5|Xg ml-1) for 5 min (37-C) prior to
fMLP stimulation (5min, 37°C). Results shown are mean±s.e.m fMLP responses 
normalised with respect to the control fMLP maximum response (=1) in the absence of 
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Fig 4.10 Thapsigargin-stim ulated superoxide generation by human 
neutrophils - effect of EGTA (0.95mM). Neutrophils (106 m l1) were 
preincubated with EGTA for 5 min (37#C) prior to stimulation with thapsigargin (10 min, 
37°C). Results shown are the mean±s.e.m of superoxide responses normalised with 



























Control Rolipram 10‘6MPGE2 10'5M
Fig 4.11 Effect of PGE2 (10 5M) and rolipram (10-6M) on thapsigargin 
(lO-^M )-stimulated superoxide generation by human neutrophils.
Neutrophils (106 m l1) preincubated with rolipram or PGE2 for 5 min (37°C) prior to
stimulation with thapsigargin (10 min, 37°C). Results shown are mean±s.e.m 
superoxide response normalised with respect to the thapsigargin control of 4 (PGE2) and 
3 (rolipram) separate experiments performed in duplicate.
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Fig 4.12 Effect of extracellular N i2+ ions on thapsigargin-stimulated 
superoxide generation by human neutrophils. Neutrophils (106 ml-i) were 
preincubated with NiCl2  (3mM) for 5 min (37°C) prior to thapsigargin stimulation 
(lOmin, 37°C). Results shown are mean±s.e.m thapsigargin responses normalised with 
respect to the control thapsigargin maximum response (=1) of 3 separate experiments 
performed in duplicate.
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4.2.5 Effect of cAMP elevation on fMLP and thapsigargin stimulated
increases in human neutrophil [Ca2+]i
4.2.5.1 fMLP-stimulated increases in [Ca2+]i in human neutrophils
The basal [Ca2+]i of the neutrophils was 32.9±1.6nM (n=6) in the presence of ImM 
CaCl2 - fMLP stimulated a biphasic increase in [Ca2+]i, characterized by a rapid 
‘transient* increase in [Ca2+]i of 207±80.9nM at 10-gM (n=3) and 214.6±30.7nM at 10- 
7M (n=6) respectively (peaking within 5 sec) which declined rapidly, followed by a 
protracted ‘second phase* of elevated [Ca2+]i with a lower plateau (Fig 4.13). The 
second phase remained above baseline even 5 min after stimulation.
4.2.5.2 Effect of rolipram and PGE2  on fMLP-stimulated increase in [Ca2+h
Maximally effective concentrations of PGE2  (10-5M) and rolipram (10-6M) against fMLP 
(10*7M)-stimulated O2 - generation had no effect on the peak increase in [Ca2+]i (‘first 
phase*) stimulated by fMLP (10-7M), which were 96.0±3.0% (n=6) and 95.3±5.8% 
(n=4) respectively of the control fMLP peak [Ca2+]i. Both PGE2 (10*5M) (Fig 4.14) and 
rolipram (10-8-10-6M) (Fig 4.15) reduced the duration of the ‘second phase*. Inhibition 
of fMLP-stimulated increase in [Ca2+]i 30s after fMLP addition was 53±4% for PGE2 
(10-5M, n=7), and for rolipram 17±10% (10*8M), 41±12% (10-7M) and 42±12% (10- 
6M) (n=3 for each).
4.2.5.3 fMLP-stimulated increases in [Ca2+]i using a Ca2+-re-addition protocol
The Ca2+-re-addition protocol was used to dissociate Ca2+ release from intracellular 
stores and Ca2+ influx. Extracellular Ca2+ ions were removed so that the increase in 
[Ca2+]i reflected release from intracellular stores. Ca2+ influx could also be studied 
independently in the same preparation of cells by the re-introduction of extracellular Ca2+
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ions. The basal [Ca2+]i levels were lower in the presence of IOOjiM CaCl2 and ImM 
EGTA but there was no difference in the onset time of the fMLP-stimulated ‘transient’. 
The response declined rapidly to a new baseline, the [Ca2+]i being approximately equal to 
that in the presence of ImM CaCh. Re-addition of 2mM CaCh (110s after fMLP 
stimulation) produced an immediate transient increase in [Ca2+]i which peaked 
approximately 130s after fMLP stimulation and slowly returned to basal [Ca2+]i levels 
(control basal in the presence of ImM CaCl2 ). In unstimulated cells, there was a similar 
but more transient and smaller increase in [Ca2+]i on re-addition of 2mM CaCh (Fig 4.16 
and 4.17), which also returned to control basal [Ca2+]i levels.
4.2.5.4 Effect of rolipram and PGE2 on fMLP-stimulated increase in [Ca2+]i using 
the Ca2+ re-addition protocol
Neither PGE2  (10-5M) and rolipram (10-6M) had any effect on the rate of onset or the 
peak (the magnitude) of the fMLP (10-7M)-stimulated Ca2+ ‘transient’. However, there 
was a more rapid rate of decay of this transient in PGE2 or rolipram pre-treated 
neutrophils (n=7) (Fig 4.16). In addition, PGE2 (10-5M) or rolipram (1(HM) both 
inhibited the magnitude of the increase in [Ca2+]i on re-addition of 2mM CaCl2 in fMLP- 
stimulated neutrophils by 78±2% and 70+5% respectively (measured at fMLP T+130s, 
n=3 for both) (Fig 4.16). The increase in [Ca2+h on re-addition of CaCl2 in unstimulated 
neutrophils was unaffected by these agents (Fig 4.17).
4.2.5.5 Effect of rolipram and PGE2 on thapsigargin-stimulated increase in 
[Ca2+]j using the Ca2+ re-addition protocol
Thapsigargin (10-6M) stimulated an increase in [Ca2+]i in the absence of extracellular 
Ca2+ ions, but unlike fMLP, the level did not return to basal levels (Fig 4.18). Re­
addition of 2mM CaCl2 160s after thapsigargin addition resulted in a further larger
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increase in [Ca2+]i. This second phase was larger than that observed with fMLP (10-7M), 
and did not return to basal levels. No consistent inhibition of this second phase of 
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Fig 4.13 fMLP (10*8M and 10*7M) stimulated [Ca2+]j elevation in 
human neutrophils. Fura-2-loaded neutrophils (5xl06 mH) were stimulated with 
fMLP in the presence of ImM MgCh and ImM CaCh- The trace shown is taken from a 
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Fig 4.14 Effect of PGE2 (10-5M) of fMLP (10-7M)-stimulated [Ca2+]i 
elevation in human neutrophils. Fura-2-loaded neutrophils (5 x 1 0 6  mi-i) were 
preincubated with PGE2 for 5 min (37°C) prior to stimulation with fMLP (indicated by 
the arrow). The traces shown are from a single experiment but are representative of 7 
other experiments. The inset shows the effect of PGE2 on fMLP-stimulated increase in
[Ca2+]j measured 30s after stimulation with fMLP (T+30s) indicated by an arrow on the 
ordinate axis of the trace. Results are shown are the meanis.e.m increase in [Ca2+]i 
























Fig 4.15 Effect of rolipram (10-8-10*6M) of fMLP (10*7M)-stiimilated 
[Ca2+]| elevation in human neutrophils. Fura-2-loaded neutrophils (5xl06 m l1)
were preincubated with rolipram for 5 min (37°C) prior to stimulation with fMLP 
(indicated by the arrow). The traces shown are from a single experiment but are 
representative of at least 2 other experiments The inset shows the effect of rolipram on 
fMLP-stimulated increase in [Ca2+]j measured 30s after stimulation with fMLP (T+30s) 
indicated by an arrow on the ordinate axis of the trace. Results are shown are the 
meanis.e.m increase in [Ca2+h compared to the control fMLP response of 3 separate 
experiments performed in duplicate.
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Fig 4.16 Effect of PGE2 (10-5M) (middle panel) and rolipram (KMM) 
(lower panel) on fMLP (10-7M)-stimulated elevation of [C a2+]i in human 
neutrophils using the ‘re-introduction of extracellular C a 2+’ protocol. 
Upper panel shows the effect of re-introducing extracellular Ca2+ on 
unstimulated and fMLP-stimulated human neutrophils. Fura-2-loaded 
neutrophils (5xl06 ml-1) were incubated with EGTA (ImM) in the presence of O.lmM 
CaCl2 , ImM MgCl2 and either PGE2  or rolipram for 5 min (37°C) prior to the addition of 
fMLP (or buffer), followed 110s later by the re-introduction of 2mM CaCl2 - The inset 
shows the effect of rolipram and PGE2 on the fMLP-stimulated increase in [Ca2+]i on re- 
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Fig 4.17 Lack of effect of rolipram (10*6M) on the [Ca2+]| elevation in 
unstimulated human neutrophils using the ‘re-introduction of extracellular 
C a2+’ protocol. Fura-2-loaded neutrophils (5xl06 ml-i) were incubated with EGTA 
(ImM) in the presence of 0.1 mM CaC^, ImM MgCl2 and rolipram for 5 min (37°C) 
prior to the addition of buffer, followed 110s later by the re-introduction of 2mM CaCl2 - 

































Fig 4.18 Effect of PGE2 (10'5M) (upper panel) and rolipram (10 6M) 
(lower panel) on thapsigargin (10*6M)-stimulated elevation of [Ca2+], in 
human neutrophils using the ‘re-introduction of extracellular Ca2+’ 
protocol. Fura-2-loaded neutrophils (5xl06 ml-i) were incubated with EGTA (ImM) 
in the presence of O.lmM CaCl2 , ImM MgCh and either PGE2 or rolipram for 5 min 
(37°C) prior to the addition of thapsigargin, followed 140s later by the re-introduction of 
2mM CaCh- The traces shown are from a single experiment but are representative of 2 
other experiments.
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4.2.6 Effect of cAMP-elevation on fMLP-stimulated Mn2+ influx as a measure
of Ca2+ influx
The effect of cAMP-elevation on fMLP-stimulated Ca2+ influx in human neutrophils was 
further investigated by measuring the influx of the Ca2+ surrogate, Mn2+ ion. The Mn2+ 
ion, unlike Ca2+ is not a substrate for Ca2+ pumps and is therefore not subject to efflux.
Measuring Mn2+ quenching of intracellular fura-2 (Xex 360nm) therefore represented ion
movement into the cell, allowing the discrimination between Ca2+ mobilisation and influx 
(Merritt et al., 1989).
4.2.6.1 Effect of MnC^ concentration on fMLP-stimulated Mn2+ influx
In inidal experiments using extracellular Mn2+ at ImM, there was a basal leakage of Mn2+ 
ions into the neutrophils as observed by the quenching of fura-2 in unstimulated 
neutrophil. fMLP (KWM) stimulation induced further Mn2+ influx; but pretreating the 
neutrophils with PGE2 (10-5M) or rolipram (10-6M) had no effect on the rate or degree of
fMLP-stimulated Mn2+ influx (107±14% and 107±4% respectively compared to the 
control fMLP response 100±8%, n=3 for both).
The insensitivity of fMLP-stimulated Mn2+ influx to cAMP-elevating agents could be 
interpreted in three ways. Firstly, Mn2+ ion and Ca2+ ion influx may be differentially 
regulated by cAMP, or possibly elevation of cAMP does not modulate divalent cation 
influx, but selectively potentiates the removal of cytosolic [Ca2+]i.
To exclude the possibility that the Mn2+ concentration used (ImM) was excessive and 
masking inhibition of stimulated Mn2+ influx, the effect of adding lower concentrations of 
MnCh to the extracellular medium was investigated.
Reducing the extracellular Mn2+ concentration from ImM to 0.3mM made no difference 
to Mn2+ leakage into unstimulated cells, nor was there a change in Mn2+ influx into fMLP
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(10-7M) or ionomycin (2xlO-6M)-stimulated neutrophils (Fig 4.19). Lowering the 
MnCl2 concentration to O.lmM, substantially reduced the leakage of Mn2+ ions into 
unstimulated cells compared to that in the presence of ImM MnC^. In contrast, fMLP 
(10-7M) and ionomycin (2xlO-6M) stimulated Mn2+ influx was identical to that observed 
in the presence of ImM MnCl2 (Fig 4.19).
4.2.6.2 Effect of rolipram and PGE2 on fMLP-stimulated Mn2+ (O.lmM) influx
fMLP (10-7M)-stimulated Mn2+ influx (O.lmM) into human neutrophils was 
concentration-dependendy inhibited by pretreating the neutrophils with rolipram (10-7-10- 
6M) or PGE2 (10-6-10-5M) (Fig 4.20) (n=3). The degree of inhibition of fMLP- 
stimulated Mn 2+ influx observed between experiments was variable, but rolipram was 
consistently more potent and effective than PGE2 (n=4 donors). However the 
combination of maximally effective concentrations of PGE2 (10-5M) and rolipram (10-
6M) resulted in an additive inhibition of fMLP (10-7M)-stimulated Mn2+ (O.lmM) influx 
(Fig 4.21), which was greater than either agent alone (n=4), but did not inhibit fMLP- 
stimulated Mn2+ (ImM) influx (n=3) (fig 4.22).
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Fig 4.19 Effect of M 11CI2 concentration on Mn2 + influx in 
unstimulated and fMLP (10*7M) or ionomycin (2xl(M M )-stim uIated  
human neutrophils. Fura-2-loaded neutrophils (5xl06 ml-1) were incubated with 
ImM MgCl2, O.lmM CaCh for 5 min (37°C) prior to the addition of buffer, fMLP or 
ionomycin (2xlO-6M) followed by the introduction of MnCh (0.1, 0.3 or ImM) 40s
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Fig 4.20 Effect of PGE2 (10-«-10-«M) and rolipram (10-7-10-<M) on 
fMLP (10-7M)-stimuIated Mn2+ (O.lmM) influx in human neutrophils 
(upper panel). Fura-2-loaded neutrophils (5xl06 ml-1) were incubated with buffer, 
PGE2  or rolipram for 5 min (37°C) in the presence of ImM MgCh, O.lmM CaCh prior 
to the addition of buffer, fMLP or ionomycin (2xlO-6M, positive control) followed by the 
introduction of MnCh (O.lmM) 40s later. Results shown are the effect of PGE2 and 
rolipram on fMLP-stimulated Mn2+ influx as mean±s.e.m % of the control fMLP 
response quantified as AUC. Statistical significance indicated by an asterisk representing 
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Fig 4.21 Effect of PGE2 (10*5M) and rolipram (10*6M) alone and in 
combination on fMLP (10*7M)-stimulated Mn2+ (O.lmM) influx in human 
neutrophils. Fura-2-loaded neutrophils (5xl06 ml-1) were incubated with PGE2 +/- 
rolipram in the presence of ImM MgCl2 and O.lmM CaCl2 for 5 min (37°C) prior to the 
addition of buffer or fMLP, followed by the introduction of MnCl2 40s later. The traces 
shown are from a single experiment but are representative of 3 other experiments. The 
inset shows PGE2 +/- rolipram-mediated inhibition of fMLP-stimulated Mn2+ (O.lmM)
influx as mean±s.e.m % of the control fMLP response quantified as AUC of 4 separate 
experiments. Statistical significance in the inset is indicated with the asterisk representing 
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Fig 4.22 Comparison of the ability of rolipram (10*6M) combined with 
PG E 2 (10-5M) to inhibit fMLP (10*7M)-stimuIated Mn2+ (O.lmM, upper 
panel) and (ImM, lower panel) influx in human neutrophils. Fura-2-loaded 
neutrophils (5xl06 m l1) were incubated with rolipram combined with PGE2 in the 
presence of ImM MgCl2 and O.lmM CaC^ for 5 min (37°C) prior to the addition of 
buffer or fMLP, followed by the introduction of MnCl2 40s later. The traces shown are 
from a single experiment but are representative of 2 other experiments. The inset shows 
the effect of rolipram combined with PGE2 on fMLP-stimulated Mn2+ influx as 
mean±s.e.m % control fMLP response quantified as AUC, from the time of MnCl2 
addition at 80s to 340s, of 3 separate experiments. Statistical significance in the inset is 
indicated by an asterisk representing P<0.05 as determined by Student’s t-test.
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4.3 DISCUSSION
The data presented in this chapter suggest that:-
1. Non-selective (IBMX) and type IV-selective (rolipram) PDEIs inhibited fMLP- 
stimulated O2’ generation, although they stimulated little increase in neutrophil cAMP 
levels. PGE2  was a potent and effective stimulus of cAMP elevation at concentrations 
which inhibited fMLP-stimulated O2” generation in the absence or presence of PDEIs.
2. PGE2  inhibition of fMLP-stimulated O 2’ generation was potentiated by IBMX or 
RO 20-1724, which suggests that cAMP elevation is a common mechanism. Further 
evidence for cAMP elevation as the transduction mechanism was the reversal of IBMX 
and PGE2 inhibition of fMLP-stimulated O2" generation by the protein kinase A inhibitor 
H-89.
3. fMLP-stimulated O2" generation was partially inhibited by the chelation of 
extracellular Ca2+ ions suggesting that Ca2+ influx was involved in fMLP-stimulated 
human neutrophil activation. As rolipram and PGE 2 suppressed fMLP-induced increases 
in [Ca2+]j; inhibition of Ca2+ influx may account in part for their inhibitory effect on 
neutrophil activation.
4. Neither rolipram nor PGE2 inhibited fMLP-induced mobilisation of Ca2+ ions
from intracellular stores; but both agents attenuated fMLP-stimulated Ca2+ (and Mn2+) 
influx.
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4.3.1 Effect of PDEIs and PGE2 on cAMP levels and superoxide generation in
human neutrophils
The isoenzyme selectivity and potency order of the PDEIs tested in this study as 
inhibitors of fMLP-stimulated 02~ generation suggests that the predominant 
phosphodiesterase activity in human neutrophils is the type IV isoform:-
*rolipram > *RO 20-1724 > *IBMX > ^milrinone 
type IV type IV non-selective type III
(♦Wright et a l, 1990) (#Lindgren et a l , 1990)
These results are in agreement with published data on phosphodiesterase activity isolated 
from human neutrophils, PDEI-stimulated elevation of neutrophil cAMP levels and 
modulatory activity on O2" generation (Nielson et al, 1990, Ho et al., 1990, Schudt et al., 
1991).
However, in this study, rolipram and IBMX induced little elevation of neutrophil cAMP 
levels in either unstimulated or fMLP-stimulated human neutrophils, at concentrations 
which clearly inhibited fMLP-stimulated 0 2 “ generation. The levels of cAMP were, 
higher in fMLP-stimulated neutrophils pre-treated with rolipram but not with IBMX. The 
discrepancy between the two PDEIs on fMLP-stimulated neutrophil cAMP levels has 
been reported by others (Schudt etal., 1991). One possibility is that phosphodiesterase 
inhibition reveals potentiation of adenylate cyclase activation by endogenously generated 
adenosine by fMLP (Iannone eta l., 1989). This effect of fMLP on neutrophil cAMP 
levels was abolished by adding adenosine deaminase to inactivate endogenous adenosine 
or IBMX which is an adenosine receptor antagonist (Iannone et al., 1989).
Consequently, the ability of PDEIs to stimulate cAMP elevation in naive or fMLP- 
stimulated neutrophils is not easily reconciled with their ability to inhibit neutrophil 
function, in terms of potency or efficacy. The results of the PDEI experiments on cAMP- 
elevation and neutrophil activation described in this chapter suggest that inhibition of
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fMLP-stimulated O2" generation is exquisitely sensitive to modulation by cAMP- 
dependent processes or they are working through a cAMP-unrelated mechanism. It is 
clear however that small or undetectable increases in total cAMP content are sufficient to 
inhibit the respiratory burst. Furthermore, total cellular cAMP levels may not correlate 
well with the inhibitory effect of cAMP-elevating agents. Measurement of localised or 
regional increases in cAMP may provide more accurate correlation with the observed 
changes in neutrophil function.
In contrast to the PDEIs, PGE 2  stimulated cAMP elevation in human neutrophils at 
concentrations which inhibited fMLP-stimulated O f  generation and the results in chapter 
3 suggest that they are mediated by the same prostanoid EP receptor. Nonetheless, 
although PGE2 -induced cAMP elevation and inhibition of neutrophil activation may be 
causally related, this alone is not sufficient evidence for cAMP elevation as the signal 
transduction pathway via which PGE2 modulates neutrophil function.
Forskolin, the direct activator of adenylate cyclase, did not stimulate high levels of cAMP 
accumulation (in the presence of IBMX) above basal compared to PGE2 , which may be 
related to the poor inhibitory activity .of forskolin on superoxide generation observed in. 
chapter 3.
However, on comparing the effects of PDEIs and PGE2 alone and in combination on 
human neutrophil function, the findings presented in this study suggest that they share a 
common transducer molecule - cAMP. Most notably, PGE2-stimulated cAMP elevation 
and inhibition of fMLP-stimulated O2" generation by human neutrophils was enhanced by 
the presence of PDEIs. The p[Aso] for PGE2 -inhibition of fMLP-stimulated O2" 
generation was concentration-dependently shifted leftward by IBMX and RO 20-1724; 
which is evidence that PGE2 inhibition of fMLP-stimulated O2" generation is mediated via 
cAMP elevation. IBMX also produced a leftward shift of PGAi inhibition of fMLP- 
stimulated O f  generation, demonstrating that this effect of PDEIs was not restricted to
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PGE2 but extended to other EP receptor agonists. A similar interaction was demonstrated
by Kenakin & Beek (1984), who described IBMX potentiation of ^-adrenergic agonist
(isoprenaline)-induced positive ionotropy in guinea-pig papillary muscles, and producing 
a ten-fold increase in the isoprenaline p[Aso].
There were also many similarities between PDEI and PGE2 effects on human neutrophil 
function, for instance PGE2-stimulated cAMP elevation was augmented by the presence 
of fMLP, as was rolipram. In addition, the ability of the protein kinase A inhibitor, H89, 
to concentration-dependently reverse both PGE2 and IBMX inhibition of fMLP- 
stimulated O2" generation by human neutrophils also suggests that both agents act via 
cAMP-elevation.
The adenylate cyclase inhibitor, SQ 22356, failed to attenuate PGE2-mediated inhibition 
of fMLP-stimulated O2” generation. However, SQ 22356 attenuated IBMX-mediated 
inhibition of fMLP-stimulated O2 - generation in two experiments, contrary to the 
reported adenylate cyclase inhibitory activity of this compound at the same concentration 
(1(MM) on PGE2 -mediated inhibition of fMLP-stimulated O2” generation in human 
neutrophils reported by Talpain etal. (1994). It is unclear why there is a discrepancy 
between the effects of SQ 23356 described in the present study and that of Talpain et al.> 
other than a difference in preincubation time for SQ 22356 with the neutrophils prior to 
addition of PGE2 . A 20 min preincubation time was used in the present study whilst 
Talpain & Armstrong used 2 min, but considering the requirement for SQ 22356 to enter 
the cells to reach the site of action, adenylate cyclase, the longer preincubation period 
would have been more likely to ensure optimum equilibration time.
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4.3.2 Effect of rolipram and PGE2 on fMLP-stimulated increases in
neutrophil [Ca2+]j
The results in this study showed that fMLP-stimulated O2" generation was partially 
reduced by chelation of extracellular Ca2+ ions; implying that fMLP-mediated neutrophil 
activation involved Ca2+ influx. Indeed, other functions such as fMLP-stimulated human 
neutrophil chemotaxis and adhesion, are suppressed in the presence of EGTA (Merritt et 
al., 1991 and Davies etal., 1990, respectively). In addition to this, fMLP-stimulated 
neutrophil degranulation and O2" generation were completely abolished by simultaneously 
depleting the intracellular Ca2+ stores and buffering [Ca2+]i with intracellular Ca2+ ion 
chelators such as BAPTA (O’Flaherty et al., 1991); demonstrating that increases in 
[Ca2+]i were required for fMLP-activation of neutrophils. However, the same study
showed that Ca2+-depleted human neutrophils were still able to degranulate and generate 
O2" anions albeit at a lower level, on stimulation with fMLP in spite of the absence of an 
increase in [Ca2+]i.
The preliminary experiments in this study measuring fMLP-stimulated increases in 
[Ca2+]i found that the response was biphasic with the characteristics described in other 
publications in the literature (Sage et al., 1990, Demaurex et al., 1992). Their studies 
showed that fMLP stimulated increase in [Ca2+]j involved the release of Ca2+ ions from
intracellular stores and the opening of plasma membrane Ca2+ channels allowing the 
influx of extracellular Ca2+ ions.
In the present study, rolipram or PGE 2, at concentrations which were maximally effective 
against fMLP (10-7M)-stimulated O2" generation, modulated fMLP-stimulated increase in 
[Ca2+]i in human neutrophils. As neither agent had any effect on the onset or the size of 
the first phase of the increase in [Ca2+]i, the ‘Ca2+ transient’; inhibition of the 
mobilisation of intracellular Ca2+ stores seemed an unlikely mechanism of action (Schudt
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etal., 1991 and Hecker etal., 1990 respectively). Furthermore, othercAMP-elevating 
agents such as PGD2 and the cell-permeable cAMP analogue, dibutyryl cAMP, also have
no effect on the fMLP-stimulated ‘Ca2+ transient’ (Simpkins et al., 1990, Ney & Schror, 
1991).
However, in the present study, the duration and amplitude of the ‘second phase’ 
(resulting from Ca2+ influx - see introduction) of the fMLP-stimulated increase in [Ca2+]i 
in human neutrophils pre-treated with either rolipram or PGE2 was reduced. The 
selective diminution of this protracted increase in [Ca2+]j by PDEIs and PGE2  is similar 
to that noted by Schudt et al. (1991) and Hecker et al. (1990) respectively. These data 
suggest that cAMP-elevation reduced [Ca2+]j by inhibiting Ca2+ influx and/or promoting
Ca2+ sequestration.
The Ca2+ re-addition protocol was adopted to temporally dissociate the two phases of 
increase in [Ca2+]i; and enabled the study of rolipram and PGE2 on fMLP-stimulated 
Ca2+mobilisation independently of Ca2+ influx and vice versa. As indicated earlier in this 
discussion, in the absence of extracellular Ca2+ ions, rolipram or PGE2 did not delay the 
onset of Ca2+ mobilisation nor did they suppress the peak increase in [Ca2+]i. However, 
both agents accelerated the decay of this ‘Ca2+ transient’ suggesting that cAMP-elevation 
may increase the rate of removal of cytosolic free Ca2+ ions.
In the same neutrophil preparation, the re-introduction of Ca2+ ions after the mobilisation- 
dependent increase in [Ca2+]i returned to basal levels resulted in an additional influx- 
dependent increase in [Ca2+],. Both rolipram and PGE2  reduced the magnitude of the 
fMLP-stimulated influx-dependent increase in [Ca2+]j to almost unstimulated levels. 
Although the Ca2+ entry induced increase in [Ca2+]j was almost completely abolished by 
rolipram or PGE 2 ; it was unclear from these Ca2+ re-addition experiments whether this 
was achieved by inhibiting Ca2+ channel opening or promoting Ca2+ sequestration and/or
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efflux.
PDEIs exhibited a similar inhibitory effect on fMLP-stimulated increases in [Ca2+]i in 
fura-2 loaded human neutrophils in the presence of thimerosal (Schudt et al., 1991) 
which prolonged and increased the magnitude of the second phase of fMLP-stimulated 
increase in [Ca2+]i. Although they observed inhibition of this influx component by 
PDEIs, the inhibition was difficult to quantitate as the use of thimerosal did not 
differentiate between inhibition of Ca2+ influx per se and potentiation of Ca2+ efflux. 
Another complication was that the mechanism of action by which thimerosal prolonged 
and increased the fMLP-stimulated influx was unknown. Thimerosal itself induced a 
small rise in [Ca2+]i (even in the absence of extracellular Ca2+ ions) but did not affect the
function of the plasma membrane Ca2+ pump. These observations suggested that 
thimerosal may prevent repletion of the intracellular Ca2+ stores depleted by fMLP 
activation of the neutrophil (Hatzelmann et al., 1990).
Hecker et al. (1990) used 45Ca uptake as an index of Ca2+ influx, and showed that PGE2
inhibited fMLP-stimulated 45Ca uptake by human neutrophils. However the response 
was small, and the experimental protocol used made it impossible to determine whether 
the uptake of 4^Ca represented purely influx, or if there was a component of binding of 
45Ca to cellular protein.
Thus, many different approaches have been adopted in order to demonstrate that putative 
neutrophil inhibitors have a direct effect on Ca2+ influx as a mechanism of action but to 
date, there has been little progress in this area of research. However, rolipram and PGE2 
mediated inhibition of fMLP-stimulated Mn2+ (Ca2+ surrogate) influx in human 
neutrophils as described in this chapter are the first direct demonstrations of PDEI and 
PGE2  inhibition fMLP-stimulated Ca2+ influx in human neutrophils. However the 
disparate effect of rolipram and PGE2 on Mn2+ influx may be explained by a possible 
effect of Mn2+ accumulation on adenylate cyclase activation. The human neutrophil
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adenylate cyclase isoform(s) have not been identified although at least 8 different 
mammalian isoforms have been characterized (Kruprinski et al., 1992), some of which 
are activated by Mn2+ions in the mM concentration range leading to approximately 2-fold 
increase in enzyme activity (Jakobs et al., 1984). It is possible then that Mn2+ ions 
become concentrated within the neutrophil cytosol and may actually compete with the 
PGE2-receptor complex for activation of adenylate cyclase. PGE2 normally causes a 8-
10 fold increase in human neutrophil cAMP levels; if Mn2+ ions reduce PGE2-stimulated 
cAMP levels this would result in a reduction in the inhibitory effect of the expected degree 
of inhibition of Mn2+ influx. If this were the case, rolipram would be potentially more 
effective as by preventing the breakdown of cAMP stimulated by the effect of Mn2+ ions 
on adenylate cyclase potentiates the inhibitory effect of cAMP elevation on Mn2+ influx.
M n 2 +  ions are not the only divalent cations which can influence adenylate cyclase activity, 
some isoforms of adenylate cyclase are inhibited by C a2+  ions (Kruprinski etal.t 1992). 
Thus changes in [Ca2+]i could also affect adenylate cyclase activation in the human 
neutrophil just as cAMP levels modulate [C a2+ ]; which suggest that these two signal 
transduction molecules interact intimately to regulate neutrophil function. Mn2+ ions may 
also affect the function of the type IV phosphodiesterase, as there appears to be an 
absolute functional requirement for divalent cations. EDTA treatment inactivates the type 
IV PDE and catalytic activity is only restored by the addition of Mg2+, Mn2+ or Zn2+ but 
not C a2+  ions. This effect of Mn2+ ions on PDE activity may affect the ability of cAMP- 
elevating agents to inhibit Mn2+ influx. Relatively high concentrations of rolipram were 
required to inhibit fMLP-stimulated Mn2+ influx compared with 0 2 “ generation and the 
second phase of increase in [C a 2+]j, and may be explained by the higher concentration of
rolipram required to overcome the stimulatory effect of Mn2+ ions accumulating in the 
neutrophils. PGE2-stimulated increases in cAMP are mediated by activating adenylate 
cyclase, however the accumulation of Mn2+ ions within the cell may stimulate PDE
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activity attenuating the increase in cAMP and abrogating the inhibitory effects of PGE2 on
Mn2+ influx. The variability of the inhibition of Mn2+ influx by PGE2 and rolipram
observed may reside at the level of phosphodiestase activity in each neutrophil 
preparation. Consequently, the effect of rolipram and PGE2 on fMLP-stimulated
neutrophil Mn2+ influx may underestimate their modulation of Ca2+ influx.
The role of Ca2+ influx in cell activation has been questioned (Clapham, 1995) - is it just 
a physiological mechanism to refill intracellular stores or does it have a more direct role in 
cell activation? The latter is a distinct possibility as many cellular enzymes and processes 
occur in association with the plasma membrane. In the neutrophil this includes adenylate 
cyclase, the NADPH-oxidase, phosphodiesterase and obviously Ca2+ influx channels. 
Thus the main neutrophil functions and biochemical processes studied in this thesis are 
located at the plasma membrane and suggest that they are physically in close proximity. 
This would allow highly regulated interactions between these cellular processes and 
emphasises the complexity of neutrophil activation regulation which can occur at many 
levels.
The evidence in the literature suggests that in human neutrophils, fMLP-stimulated Ca2+. 
and Mn2+ influx have identical kinetics (Sage et al., 1990) and is closely linked to the 
emptying of the intracellular stores (Demaurex e ta l ., 1992). Intuitively then, Ca2+ 
influx, and therefore Mn2+ influx, in the human neutrophil is closely associated with the 
filling state of the intracellular stores of Ca2+ ions (Demaurex et al., 1992).
Nevertheless, the ion channels through which Ca2+ and Mn2+ ions permeate the plasma 
membrane to enter the neutrophil have not been elucidated. However, patch-clamping 
studies on human neutrophils have established the presence of a non-specific cation 
channel, which is activated by increases in [Ca2+]i and is permeable to Ca2+ ions (von
Tschamer et al., 1986). However, it is unclear whether Mn2+ ions could permeate this 
channel, or if this non-specific cation channel is inhibited by rolipram and PGE2 . cAMP-
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modulated ion fluxes have been reported in the neutrophil including that of Schumann et 
al., (1992), describing dibutyryl cAMP and adenosine agonist (NECA) inhibition of a 
fMLP-stimulated non-specific cation current in whole cell voltage-clamped human 
neutrophils.
The characterization of Ca2+ permeable channels in the neutrophil plasma membrane has 
so far depended on indirect evidence such as the channel blocking activity of divalent 
(N i2+ and Co2+) and trivalent (La3+) cations (Andersson et al., 1986). Human 
neutrophils do not possess voltage-operated Ca2+ channels, as Ca2+ influx is not 
stimulated by depolarisation by gramicidin D or K+ ions (Andersson eta l., 1986) and the 
temporal characteristics of fMLP-stimulated Ca2+ influx are not those of a receptor- 
operated Ca2+ channel, but are more like second messenger-operated channels (SMOC) 
(Pittet et al., 1989). It is impossible, however, to conclusively characterize the Ca2+ 
channels present without further neutrophil patch-clamping studies. Unfortunately there 
are however few published patch-clamping studies on human neutrophils; and without 
them it is difficult to demonstrate that cAMP elevation can modulate the function of 
specific Ca2+ channels.
4.3.3 Additional sites of action for rolipram and PGE2 inhibition of human
neutrophil activation
In spite of this, it is evident from the present study that rolipram and PGE2 have a limited 
effect on fMLP-stimulated Mn2+ influx in human neutrophils, even at concentrations 
which almost completely inhibited Ca2+ influx-dependent increases in [Ca2+]i and O2" 
generation. The indications are that in addition to inhibiting Ca2+ entry, cAMP elevation 
may also promote the removal of cytosolic free Ca2+ ions by plasma membrane and 
possibly endoplasmic reticular Ca2+ pumps. The observations from the experiments 
conducted in the absence of extracellular Ca2+ ions described in this study support this 
idea, such as the decline of the fMLP-stimulated Ca2+ transient (mobilisation of
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intracellular stores) was more rapid in rolipram or PGE2 pre-treated cells.
The neutrophil plasma membrane Ca2+ pump is stimulated by protein kinase C and 
calmodulin (Lagast etal., 1984a and 1984b) but there is no evidence for its sensitivity to 
modulation by cAMP. Interestingly, protein kinase C increases the velocity of the pump, 
whereas calmodulin increases both the velocity and the Ca2+ ion affinity of the pump. 
However, there are at least 4 genes encoding plasma membrane Ca2+ pumps (PMCA1-4) 
with different tissue gene-splice variants of the most abundant type PMCA1 whose 
function exhibits differential sensitivity to cyclic nucleotide regulation; for example, in 
erythrocyte ghosts PKA-dependent phosphorylation increases the velocity and the affinity 
of the pump for Ca2+ ions (James et al., 1989).
The Ca2+-ATPases (pumps) on endoplasmic or sarcoplasmic reticulum differ from those 
in the plasma membrane. The intracellular Ca2+-pumps are of three types; SERCA1, 
SERCA2 and SERCA3 (Grover & Khan, 1992). SERCA1 and SERCA2 pumps are 
regulated by cAMP dependent phosphorylation of phospholamban, whilst SERCA3 is 
regulated by cAMP-dependent protein kinase (PKA). The dephosphorylated form of 
phospholamban inhibits the SERCA pump, and phosphorylation of phospholamban by 
PKA would therefore lessen the restraint on Ca2+ pump activity. It is not surprisingly 
therefore that the SERCA2b isoform has been detected in human neutrophils (Stendahl et 
al., 1994). In adherent non-phagocytosing neutrophils the Ca2+ATPase was evenly 
distributed throughout the cytosol; during the early stages of phagocytosis the distribution 
was concentrated adjacent to the forming phagosome; and after complete ingestion, the 
Ca2+ATPase was focussed around the periphery of phagosomes. The regional and 
temporal changes in the distribution of SERCA2b pumps suggests that they may regulate 
local changes in [Ca2+]j during neutrophil activation, and that cAMP elevation does
modulate neutrophil endoplasmic reticulum Ca2+ pump function. Furthermore, fMLP 
inhibits the uptake of Ca2+ ions by a Ca2+-ATPase (pump) in human neutrophil 
lysosomes which has a high affinity for Ca2+ (Km=107nM) and therefore is active at
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resting [Ca2+]i (Klempner, 1985) and these intracellular pumps may have a physiological 
role in maintaining a low normal resting [Ca2+]j.
In addition to the inhibition of fMLP-stimulated increases in [Ca2+]i, cAMP elevation may 
also have other modulatory sites of action. With regard to O2” generation, there is some 
evidence that the assembly and function of the O2’ generating enzyme complex, NADPH- 
oxidase, may itself be regulated by cAMP-elevation. Protein kinase A phosphorylation of 
the Rap-IA regulatory protein inhibits Rapl A binding to the cytochrome bsss component 
ofNADPHoxidase (Quilliam eta l., 1991 and Bokoch eta l.t 1991). Cytochromeb558 is 
the terminal carrier of the electron transfer chain of the oxidase complex, and activation of 
this complex requires the association of cytochrome bsss to p47Pho*, p67ph°*, an 
NADPH-binding protein and a GTP-binding protein. In some forms of chronic 
granulomatous disease where cytochrome bsss is absent; the neutrophils are unable to 
generate O2' anions which underlines the importance of cytochrome bsss in the oxidase 
system (Morel et al., 1991).
The discrepancy in the weakness of PGE2 as an inhibitor of fMLP-stimulated Mn2+ 
influx, compared with its potency and efficacy as an inhibitor of fMLP-stimulated 
increase in [Ca2+]i and O2" generation contrasts to the consistency of the inhibitory effects
of rolipram. This difference, in addition to the possible effects of Mn2+ ions on adenylate 
cyclase and PDE function may relate to differences in the mechanism and also to the 
spatial localisation of cAMP elevation stimulated by PGE2  and rolipram. Most 
measurements of cAMP increases are of total cellular cAMP content and do not reflect 
regional localised increases in cAMP (Barsony & Marx, 1990) which are likely to be 
different as PGE2 stimulates adenylate cyclase whilst rolipram inhibits the metabolism of 
cAMP by the phosphodiesterase. Any temporal differences between PGE2  and rolipram 
stimulated increases in cAMP are unlikely to result in the differences in inhibitory activity 
on Mn2+ influx as they had identical effects on the fMLP-stimulated increases in [Ca2+]i
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which occurred over the same time-course as the Mn2+ influx experiments. Furthermore, 
inhibition of Ca2+ influx is not the only mechanism employed by cAMP-elevating agents, 
and effects on other intracellular activation pathways cannot be excluded.
Thus, cAMP elevation modulates receptor-activated (i.e. fMLP) Ca2+ entry, although the 
effect is relatively small compared with the inhibition of increases in [Ca2+]i and 0 2 “
generation. However attenuation of Ca2+ entry represents only one mechanism of action; 
whilst the body of evidence suggests that there are additional modulatory sites where 
cAMP can exert its inhibitory effects on neutrophil activation.
4.3.4 Comparison of thapsigargin and fMLP-stimulated superoxide
generation and increase in [Ca2+]i by human neutrophils
In the present study, thapsigargin-stimulated 0 2 “ generation by human neutrophils was 
completely abolished in the presence of EGTA suggesting that the response was entirely 
dependent on Ca2+ influx. In contrast, fMLP-stimulated O2” generation was only
partially reduced by the removal of extracellular free Ca2+ ions. These data suggest that 
there are differences in the signal transduction pathways utilised by these two stimuli.
Furthermore, the addition of extracellular Ni2+ ions had no effect on fMLP-stimulated O2” 
generation but completely inhibited thapsigargin-stimulated 0 2 ~ generation; indicating 
additional differences in the types of Ca2+ channels they activate in the human neutrophil. 
However, Ni2+ ions have been reported to suppress fMLP-stimulated human neutrophil 
chemotaxis (Merritt etal., 1991) but not fMLP-stimulated neutrophil adhesion (Davies et 
al., 1990).
Although these two stimuli activate neutrophils by different mechanisms, fMLP (via a 
plasma membrane receptor) and thapsigargin (inhibition of endoplasmic Ca2+-ATPase); 
they are reported to induce identical kinetics for depletion of intracellular Ca2+ stores and 
Ca2+ (and Mn2+) influx in human neutrophils (Demaurex, 1992). In which case, the
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characteristics of their functional responses may be expected to be similar. However, 
with regard to O2" generation, this is clearly not so.
The kinetics of thapsigargin and fMLP-stimulated Ca2+ movements may be similar, but 
their profiles are different which may account for their functional differences. fMLP, as a 
receptor-operated stimulus elicits a rapid depletion of endoplasmic reticulum Ca2+ stores, 
and the signal initiated by fMLP interacting with its receptor is transient, and the emptying 
of the Ca2+ stores are corresponding transient. The stores emptied on fMLP stimulation 
are subsequently repleted by the Ca2+-ATPase present on the endoplasmic reticulum.
Thapsigargin, in contrast, exerts its effects by inhibiting this same Ca2+-ATPase 
preventing the physiological refilling of the Ca2+ stores eventually completely depleting 
the stores. Ca2+ influx in the human neutrophil is closely associated with the filling state 
of the intracellular stores of Ca2+ ions (Demaurex et al., 1992). Thus, thapsigargin, by 
blocking repletion of the intracellular stores, signals the opening of Ca2+ channels in an 
effort to increase [Ca2+]j and as the stores are never repleted, the signal is not terminated, 
the channels remain open and the Ca2+ influx does not cease.
Thus, the differences in sensitivity of thapsigargin and fMLP-stimulated O2” generation 
may reflect the differences in the time course of their Ca2+ responses and also that Ca2+ 
permeable channels with different sensitivities to Ni2+ permeability may be activated by 
the two stimuli. In which case, the effect of Ni2+ ions on human neutrophil chemotaxis is 
more difficult to interpret in light of the lack of effect on 0 2 “ generation. Although 
experimental differences cannot be excluded, such as different time courses for these two . 
functions (5 min for superoxide and 2 hours for chemotaxis). The blockade of Ca2+ 
influx for a long period of time, such as 2  hours may cause depletion of the intracellular 
stores. Intracellular Ca2+ stores will have been discharged by fMLP during the first few 
minutes of stimulation; and Ni2+ ions will prevent the uptake of Ca2+ ions required to 
replete the stores and maintain a sufficiently raised [Ca2+]i level to maintain chemotaxis
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over this time period.
Finally, fMLP via activation of its membrane receptor activates signal transduction 
mechanisms some of which lead to elevation of [Ca2+]i or are Ca2+-dependent whilst
other pathways are Ca2+insensitive such as protein kinase C activation. Therefore, fMLP 
can activate human neutrophils in the absence of increases in [Ca2+]i, whilst thapsigargin- 
stimulation of neutrophils is completely dependent on increased [Ca2+]i. Taken in
consideration with thapsigargin being a non-physiological stimulus (no termination of the 
activation signal); results obtained using this substance as a cell activator should be treated 
with care as they may not reflect normal cell responses, for instance thapsigargin 
stimulated increases in [Ca2+]i are not sensitive to cAMP-elevating agents. However, 
thapsigargin-stimulated O2" generation was inhibited by high concentrations of rolipram 
and PGE2 ; which suggests that cAMP-elevating agents can inhibit neutrophil activation 
downstream of increases in [Ca2+],.
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CHAPTER 5
PGE2 AS A MODULATOR OF HUMAN AND
RABBIT NEUTROPHIL ACTIVATION, AND 
THE DISTRIBUTION OF THE ‘EPn’ RECEPTOR
IN HUMAN MONOCYTES AND THE HUMAN 
PROMYELOCYTIC CELL LINE (HL-60)
5.1. INTRODUCTION
5.1.1 PGE2-mediated modulation of human neutrophil activation
Neutrophils respond to stimuli with a range of responses, for instance; respiratory burst 
(O2", Gryglewski et al., 1987), degranulation (Ham et al., 1983 and Hecker et al. , 
1990), 5-lipoxygenase activation (Ham etal., 1983 and Hecker et al., 1990), chemotaxis 
(Harvath etal., 1991) and adhesion (Chopra & Webster, 1988). The modulatory effects 
of E-type prostaglandins are not restricted to inhibition of fMLP as a stimulus nor to O2" 
generation as a function. Prostaglandins of the E-series attenuate neutrophil responses to 
many soluble (fMLP and PAF) and particulate (opsonised zymosan) stimuli, (Hecker et 
al., 1990 and Gryglewski et al., 1987 respectively).
The release of azurophilic granule contents (degranulation), such as p-glucuronidase, 
lysozyme and N-acetylglucosamine, from human neutrophils is inhibited by cAMP 
elevating agents, such as p-adrenergic agents, E-type prostaglandins, PDEIs and the cell
permeable cAMP analogue dibutyryl cAMP (Ignarro etal., 1974, Ham etal., 1983 and 
Lad et al., 1985). The activation of 5-lipoxygenase (5-LO) and subsequent generation of. 
LTB4  and 5-HETEs in neutrophils however appears to more sensitive than degranulation 
to inhibition by PGE2 (Ham et al., 1983 and Hecker et al., 1990).
Thus, PGE2 and other cAMP elevating agents may show selectivity in their ability to 
modulate different neutrophil functions; and may also differentially attenuate the 
responses to various stimuli. In this study, the potency and efficacy of PGE2  as an 
inhibitor of fMLP- and opsonised zymosan-stimulated O2” generation by human
neutrophils has been compared with PGE2-mediated inhibition of fMLP-stimulated p-
glucuronidase release and IL-8 -stimulated shape change.
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5.1.2 Rabbit neutrophil prostanoid receptors
The rabbit is one species in which prostaglandins have been demonstrated to have both 
pro-inflammatory and anti-inflammatory effects in vivo (Rampart and Williams, 1986). 
PGE2  when co-injected with directly-acting permeability-inducing factors such as 
histamine and bradykinin, acts as a vasodilator potentiating plasma protein leakage into 
the injection sites. The enhancement of oedema by the vasodilator activity of PGE2 is 
also observed with agents which stimulate neutrophil-dependent vascular permeability, 
such as LTB4  and fMLP (Wedmore & Williams, 1981). This neutrophil-dependent 
increase in vascular permeability is abolished by rendering the rabbits neutropaenic with 
nitrogen mustard or anti-neutrophil serum (Wedmore & Williams, 1981).
Systemically administered prostaglandins have a selective inhibitory effect on neutrophil- 
dependent skin oedema in the rabbit (Rampart & Williams, 1986). These experiments 
were performed using infusions of PGI2 (prostacyclin) and subcutaneously administered 
15-methyl PGEi, a stable analogue of PGEi. However, although these findings suggest 
that rabbit neutrophils may express inhibitory prostanoid IP and/or EP receptors, PGEi is 
not a selective EP receptor agonist and its effects are not easily attributed to either 
receptor. In addition, agonist activity for PGEi has been described at the IP receptor on 
guinea-pig platelets (Eglen & Whiting, 1988). Thus, from these observations, it is 
unclear which prostanoid receptors are present on rabbit neutrophils. The 
characterization of the prostanoid receptors present on rabbit neutrophils, therefore, is an 
important issue to address.
In vitro studies (Fantone et al., 1984) demonstrated that 15-methyl PGEi inhibited rabbit 
neutrophil (elicited from the peritoneal cavity) degranulation and O2" stimulated by fMLP, 
OZ and PMA. In addition, PGE2 and PGI2 also inhibited degranulation and to a similar 
extent suggesting that rabbit neutrophils may express inhibitory prostanoid EP and IP 
receptors. If the rabbit neutrophil EP receptor is similar to that on the human neutrophil, 
the rabbit may prove to be a suitable species for the demonstration of anti-inflammatory
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activity of selective agonists for this receptor. Furthermore, the characterization of rabbit 
EP receptors in general, would generate information on the species distribution of the 
‘EPn’ receptor and therefore provide evidence that the human neutrophil EP receptor was 
either a human homologue of the classical EP2 receptor, originally characterized in the cat 
trachea (Coleman et al., 1987) or was a novel EP receptor subtype.
5.1.3 PGE2  receptors on mature human peripheral blood monocytes
The immunomodulatory effect of PGE2 on leukocyte function is not confined to the 
neutrophil, but extends to the monocyte (Gordon et al., 1976, Endres et al., 1991) and 
lymphocyte (Gordon et al., 1979, van Tits et al., 1991). These mononuclear cells are 
more long-lived than neutrophils; and have more orchestrative roles in the inflammatory 
response even though monocytes and neutrophils share the same progeny. Mononuclear 
cells are generally considered more important in chronic inflammatory disorders than 
polymorphonuclear leukocytes such as neutrophils, and so modulation of monocyte and 
lymphocyte activation may have greater therapeutic potential.
The role of PGE2 on monocyte function is more complex than with neutrophil activation. 
PGE2 not only regulates monocyte responses to inflammatory stimuli (Gordon et al.,' 
1976, Scales et al., 1989); but is also a major product of monocyte activation (Gordon et 
al., 1976). In contrast, most human neutrophil-derived eicosanoids are generated via the 
lipoxygenase pathway; whilst cyclo-oxygenase products are minor products (Stenson & 
Lobos, 1982) compared to 5-lipoxygenase metabolites. The ability of exogenous PGE2 
to selectively inhibit LPS-stimulated TNFa but not IL-1 generation by human monocytes
(Endres et al., 1991) suggests that monocyte function pathways may be differentially 
regulated. Type IV PDEIs exhibit a similar profile of activity to PGE2 , such as inhibition 
of LPS-stimulated TNFa generation and inhibition of fMLP-stimulated O2” generation
(Elliott & Leonard, 1989). Thus, it is possible that PGE2  may also elevate cAMP levels 
in human monocytes and therefore share a common mechanism of action with PDEIs; as
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appears to be the case with human neutrophils (chapter 4).
Monocyte responses such as TNFa generation, generally follow a longer time-course
than neutrophils; hence the effect of inhibitors is not always as easily interpreted as their 
chemical stability may be critical in their activity. Thus, the human monocyte prostanoid 
EP receptor may be more easily characterized by determining the more rapid effects of the 
agonists and antagonists on cAMP accumulation. Characterization of the monocyte 
prostanoid EP receptor would also provide more knowledge about the distribution of the 
‘EPn* receptor amongst human leukocytes, and the more general anti-inflammatory and 
immunomodulatory potential of agonists at this receptor.
5.1.4 Characterization of PGE2 receptors present on undifferentiated HL-60 cells
The human promyelocytic leukaemic cell line, HL-60, represents a common progenitor 
cell which monocytes and neutrophils share. There are other monocyte-like leukocytic 
cell lines, for instance, U937, THP-1 and mono mac-6 , but these are committed cell lines 
which can only be matured into monocyte-like cells, which suggests that the HL-60 cell 
represents a more immature promyelocyte. In their undifferentiated form, HL-60 cells 
are unable to mount a functional response to inflammatory stimuli as a consequence o f ' 
there being few receptors for the stimuli and/or poor coupling of the receptors to effector 
mechanisms (Collins et al., 1979, Newburger e ta l ., 1984). HL-60 cells can be 
differentiated into neutrophil-like or monocyte-like cells by using different maturation 
conditions (Collins et al., 1979) and are then functionally competent to respond to 
stimuli.
HL-60 cells have been used in numerous studies as a source of neutrophilic and 
monocytic cells for biochemical and pharmacological studies. Their expression of 
prostanoid receptors was investigated in this study as a potentially useful cell line for the 
characterization of prostanoid receptors and screening of novel prostanoid agonists. The 
advantage of the HL-60 cell line would be the lack of inherent variability associated with 
neutrophils (or monocytes) from donors caused by natural variability of the receptor
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density, and possibly also in the multiple types of prostanoid receptors expressed in 
human neutrophils (chapter 3). Thus, human leukocytes possess a multitude of 
prostanoid receptors such as DP coexisting with ‘EP2y ,EPn’ receptors in neutrophils and 
DP, IP coexisting with ‘EP2 ’, ‘EPn’ or ‘EP4 ’ receptors in monocytes respectively. The 
relative numbers of each receptor type expressed differ between individuals, which 
obviously causes problems in receptor characterization using these cells.
It is evident that even in their undifferentiated form, HL-60 cells respond to PGE2  and 
other prostanoid EP agonists with an elevation in cAMP levels. Hollingsworth & De 
Vries, (1992), suggested that the receptor responsible was the EP2 subtype. However, 
the characterization was based on the potency order of misoprostol and 11-deoxy PGEi 
compared to PGE2 , and the inactivity of sulprostone. The EP receptor characterization in 
the HL-60 is therefore incomplete as selective EP2 agonists and prostanoid receptor 
antagonists were not used and warrants more thorough classification.
5.1.5 Aims
The aims of this chapter were to:-
1 . Profile the inhibitory activity of PGE2 on human neutrophil activation by 
comparing its potency and efficacy as an inhibitor of O2" generation stimulated by soluble 
and particulate stimuli, and as an inhibitor of neutrophil degranulation and shape change.
2. Characterize the prostanoid EP receptor on rabbit neutrophils to determine the 
species diversity of the EPn receptor originally characterized on the human neutrophil (in 
chapter 3).
3. Characterize the prostanoid EP receptor present on human peripheral blood 
monocytes and undifferentiated HL-60 cells to determine the distribution of the EPn 
receptor on human leukocytes.
180
5.2 RESULTS
5.2.1 Effect of PGE2 on human neutrophil activation
5.2.1.1 Effect of PGE2 on superoxide generation by human neutrophils 
stimulated by soluble and particulate stimuli
C5a and fMLP have a similar potency as stimuli of O2” generation by human neutrophils 
(Fig 5.1), either agent (10-7M) stimulated approximately 90% of the maximum response 
(n=2 and n=3 respectively). However, in some donors fMLP was the more efficacious 
stimulus, fMLP and C5a (10-7M) stimulated the generation of 26.4±2.1 and 12.0±0.1 
nmol O2 " 1 0 6 neutrophils*1 respectively (n=3, p<0.05). PGE2 was an equieffective 
inhibitor of C5a and fMLP-stimulated O2” generation by human neutrophils (Fig 5.2). 
The comparative p[A5 o] values for PGE2 against C5a and fMLP were 7.7±0.3 and 
7 .1±0.1 respectively (p>0.05, n=3), and the maximum inhibitions observed were 
similar, 85.0±7.9% and 93.3±1.5% respectively (p>0.05, n=3).
Opsonised zymosan concentration-dependently stimulated superoxide generation by 
human neutrophils (Fig 5.4). A concentration of lmg ml- 1 opsonised zymosan (15 min' 
stimulation period) was chosen to investigate the effect of inhibitors which stimulated 
23.7±2.6 nmol O2” 106 neutrophils-1, similar to that stimulated by fMLP (see above).
PGE2 was a poor inhibitor of opsonised zymosan (OZ)-stimulated (lmg ml-1) O2"
generation by human neutrophils (21.0±1.8% inhibition at 3xlO-5M, n=4), (Fig 5.3). 
None of the other prostanoid agonists evaluated against fMLP. misoprostol, AH13205, 
11-deoxy PGEi or sulprostone, were able to inhibit OZ-stimulated O2" generation (Table 
5.1). The selective type IV PDEI, RO 20-1724 also proved to be a poor inhibitor of OZ- 
stimulated O2" generation, the maximum inhibition observed was 24.3±10.9% at 10-5M 
(n=4, Fig 5.3). Combination of PGE2 and RO 20-1724 pretreatment of neutrophils 
resulted in an additive inhibition of OZ-stimulated O2” generation, maximum inhibition
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observed was 53.0±6.0% (Fig 5.3). These data suggest that OZ-stimulated O2" 
generation by human neutrophils, in contrast to soluble stimuli, is relatively insensitive to 
inhibition by cAMP-elevating agents.
PAF (2x10*7 M) primed fMLP (2xlO*8 M)-stimulated O2 ” generation by human 
neutrophils, but was unable to prime opsonised zymosan-stimulated O2” generation even 
at low levels of stimulation (Fig 5.4). PGE2 was an effective and potent inhibitor of 
fMLP-stimulated O2" generation in PAF-primed neutrophils, with a PIA50] of 7.5±0.1 
and maximum of 86.3±3.3% inhibition at 3xlO-5M, (n=3, Fig 5.5). The potency and 
efficacy of PGE2-inhibition of PAF-primed fMLP (2xlO*8M) O2” generation (22.8±6.4 
nmol O2” 106 neutrophils-1) was comparable to inhibition of fMLP (10-7M)-stimulation in 
the presence of cytochalasin B (5jig ml-1) (Fig 5.5).
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Fig 5.1 fMLP (upper panel) and C5a (lower panel)-stim ulated  
superoxide generation by human neutrophils. Neutrophils (106 ml-1) were 
preincubated with or without cytochaiasin B (5|ig ml-1) for 5 min (37°C) prior to 
stimulation with fMLP (5 min, 37°C), or with cytochaiasin B (5pg ml-1) for 5 min 
(37°C) prior to stimulation with C5a (5 min, 37°C). The lower panel also includes fMLP 
(10-7M) in the same experiments as C5a for comparison. Results shown are mean±s.e.m 
(fMLP) and mean±range (C5a) superoxide generation (nmol O2" 106 neutrophils-1) of 3 
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Fig 5.2 Concentration-effect curves for PGE2 -mediated inhibition of 
C5a (10-7M) and fMLP (10~?M) stimulated superoxide generation by 
human neutrophils. Neutrophils (106 ml-i) were incubated with PGE2 in the
presence of cytochaiasin B (5pg ml-i) prior to stimulation of superoxide generation with 
C5a or fMLP (5 min, 37#C). Results shown are the meanis.e.m % inhibition of the 
respective control responses of 3 separate experiments performed in duplicate.
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Fig 5.3 Effect of PGE2 and the PDEI, RO 20-1724, alone (upper 
panel) and in combination (lower panel), on opsonised zymosan (lm g ml- 
i)-stimulated superoxide generation by human neutrophils. Neutrophils (106 
ml-i) were preincubated with PGE2 +/- RO 20-1724 for 5 min (37°C) prior to stimulation
with OZ (37’C) for 15 min. Results shown are the meanis.e.m of 4 experiments for 
PGE2 , 3 experiments for RO 20-1724 and 2  experiments for the combination of PGE2
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Fig 5.4 Effect of PAF (2xlO-7 M) priming (5 min preincubation) on 
fMLP (upper panel) and opsonised zymosan (lower panel) stimulated 
superoxide generation by human neutrophils. Neutrophils (106 ml*1) were 
preincubated with PAF (5 min, 37°C) prior to stimulation with fMLP (5 min) of 
opsonised zymosan (0 .1 -3 mg ml-1, 15 min, 37°C) Results shown are the meanis.e.m 
superoxide generation (nmol 0 2 “ 106 neutrophils-1) of 4 (fMLP 2xlO-8M), 3 (fMLP 10- 
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Fig 5.5 P G E 2 inhibition of fMLP (2xlO*8M)-stimuIated superoxide 
generation by PAF (2xlO-7M)-primed human neutrophils. Neutrophils (106 
ml-1) were simultaneously incubated with PAF+/-PGE2  (5 min, 37’C) prior to- 
stimulation with fMLP (5 min, 37°C). Results shown are the mean±s.e.m of 3 
experiments performed in duplicate, and compared to the effect of PGE2  inhibition (5
min, 37°C) of fMLP (10-7M)-stimulated superoxide generation (5 min, 37*C) by 
cytochaiasin B (5pg ml-1) treated neutrophils.
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-10 -7±4 -7±4 -3±2 2±7 -18±15
-9 -6±3 -29±14 -10±4 2±5 -22±18
-8 -3±3 -17±7 -8±6 -2±6 -14±17
-7 3±3 -9±12 -15±7 3±10 -9±17
-6 13±3 -25±19 -9±19 8±3 14±11
-5 15±5 -22±10 26±3 9±5 18±8
-4.5 21±2 -21±14 15±14 26±2 31±3
n 6 4 3 3 4
Table 5.1 Effect of prostanoid agonists on OZ (lm g ml*i) stimulated  
superoxide generation by human neutrophils. Neutrophils (106 ml-1) were 
preincubated with prostanoid agonists for 5 min (37°C) prior to stimulation with OZ for 
15 min (37°C). Results are mean±s.e.mean % inhibition of control OZ response, n 
represents the number of experiments performed for each agonist in duplicate.
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5.2.1.2 Effect of PGE2 on human neutrophil degranulation
PGE2  inhibited fMLP (10-7M)-stimulated neutrophil degranulation measured as the
release of p-glucuronidase. PGE2 was equipotent (ptAso] =7.0±0.1, n=4) as an
inhibitor of fMLP-stimulated degranulation and O2" generation, although the maximum
inhibition of p-glucuronidase release was significantly lower (pcO.OOl), 61.0±3.7%
inhibition at 3xlO-5M, n=4) (Fig 5.6) compared to O2” generation (91.2%, n=5 cited in 
chapter 4).
5.2.1.3 Effect of PGE2  on human neutrophil shape change
Neutrophil shape change (polarisation) is functionally related to chemotaxis (Wymann ex 
al., 1990) as both require changes in the cytoskeleton. fMLP (1(HM0-8M) and IL- 8  
(10*10-10-8M) stimulated an increase in the proportion of polarised neutrophils (Fig 5.7), 
quantified manually and by flow cytometry respectively.
PGE2  (10-9-l(MM) inhibited human neutrophil polarisation stimulated by submaximal
concentrations of IL- 8  (3xl0-i°M and 10-9 M) as quantified by flow cytometry (n=3- 
donors) (Table 5.2). The degree of inhibition was dependent on the strength of the 
stimulation, less inhibition was observed with 10-9M IL- 8  than with 3xl0*10M IL-8 . 
Similarly, PGE2 ( 1 0  5M) inhibited fMLP (10-9M)-stimulated polarisation by 45.3±5.0%
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Fig 5.6 P G E 2 -mediated inhibition of fMLP (10-7 M )-stim ulated P-
glucuronidase release from human neutrophils. Neutrophils (10* ml-i) were 
incubated with PGE2  and cytochaiasin B for 5 min (37*C) prior to stimulation with fMLP
(5 min, 37*C). Results shown are the mean±s.e.m % inhibition of fMLP-stimulated p-
glucuronidase release of 4 separate experiments performed in duplicate. The basal release 
of p-glucuronidase was 0.5±0.3% and fMLP stimulated the release of 32.5±4.1% of
total P-glucuronidase content as estimated by 0.1% triton X-100 induced release.
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Fig 5.7 IL-8 -stimulated human neutrophil shape change (polarisation) 
measured by flow cytometric analysis of forward light scatter (upper 
panel) and fMLP-stimulated human neutrophil shape change (polarisation) 
measured manually (lower panel). Neutrophils (106 ml-i) were stimulated with 
IL- 8  or fMLP (30 min, 37°C), and fixed with glutaraldehyde (1.25%) prior to analysis. 
Results shown are meanis.e.m of % polarisation of 3 separate experiments performed in 
duplicate.
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Log [PGEJ M % Inhibition IL- 8  SxlO-iOM
% Inhibition 
IL- 8  10-9M
- 8 4±8 7±1
-7 20±15 10±4
- 6 26±10 17±8
-5 40±12* 19±4
-4 53±18* 18±10
Table 5.2 P G E 2 inhibition of IL - 8  stim ulated human neutrophil 
polarisation analysed by flow cytometry (Coulter Elite Flow Cytometer).
Neutrophils (106 ml-1) were preincubated with the PGE2 for (room temperature) prior to
addition of IL- 8  and incubated for 30 min (37’C). The neutrophils were fixed with 
glutaraldehyde (1.25%) (30 min, room temperature) and shape change (polarisation) 
quantified by measuring forward light scatter using flow cytometry. Results are 
expressed as mean±s.e.m % inhibition of the respective IL- 8  control polarisation 
responses in 3 separate experiments performed in duplicate. Statistically significant 
(P<0.05, Student’s t-test) inhibition is indicated by an asterisk.
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5.2.2 Characterization of rabbit neutrophil prostanoid EP receptors
5.2.2.1 Prostanoid EP receptors on rabbit peritoneal neutrophils
The potency order for inhibition of fMLP-stimulated 0 2 “ generation by rabbit neutrophils 
elicited from the peritoneal cavity was PGE2>PGl2>BW245C^PGD2 (Fig 5.8) and 
summarised in Table 5.3. None of the prostanoid receptor agonists or the adenosine 
receptor agonists, adenosine and NECA, were able to inhibit fMLP-stimulated O2" 
generation by more than 60% (Fig 5.8). The E/[A] curves of the prostanoid receptor 
agonists were not easily defined and shallow, and p[A5o] values could not be estimated 
for PGD2 , PGI2 and BW245C. The p[Aso] for PGE2  was 7.3±0.2 as estimated from 
experiments with well-defined E/[A] curves (n=5), which was similar to the p[Aso] of
7.210.1 (n=30) for PGE2 inhibition of fMLP-stimulated human neutrophil 0 2 “ 
generation (chapter 3).
5.2.2.2 Prostanoid receptors on rabbit peripheral blood neutrophils
Since elicited peritoneal neutrophils had been activated, they may have been 
physiologically and morphologically altered and respond differently compared to naive, 
circulating neutrophils. Therefore the ability of PGE2 to modulate rabbit peripheral blood 
neutrophil function was also determined.
fMLP-stimulated similar levels of 0 2 “ generation by rabbit blood-derived and peritoneal 
neutrophils, i.e. 10.3±1.6 and 10.3±1.1 nmol 0 2 “ 106 neutrophils- 1 respectively. PGE2  
was a poor inhibitor of fMLP-stimulated 0 2 “ generation by rabbit neutrophils isolated 
from peripheral blood. The maximum inhibition by PGE2 was approximately 40% at 10-
5M and 10-*M, lower than that observed with peritoneal neutrophils (Table 5.3) and the 
E/[A] curve was not well defined.
Prostanoid EP receptor activation was determined using cAMP accumulation (in the 
presence of 5xl0^M  IBMX) as an alternative assay method. The basal levels of cAMP
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were 239±21 fmol cAMP 106 neutrophils*1 (n=3). PGE2 (lO-MO^M) stimulated cAMP 
accumulation by rabbit peripheral blood neutrophils (Fig 5.9). A well-defined E/[A] 
curve was established with a maximum at 10*5M (2,237±1,068 fmol cAMP 106 
neutrophils*1 and an estimated p[Aso] of 6.9±0.2 (n=3), although there was a further 
increase in cAMP levels at 1(MM PGE2  (3,184±1,036 fmol cAMP 106 neutrophils*1, 
n=3). The EP2  selective agonists, AH 13205 (p[A5o]=5 .8 ±0 .2 , 563±355 fmol cAMP 
106 neutrophils*1, n=3) and butaprost (p[A5o]=5 .4 ±0 .3 , 2,044±863 fmol cAMP 106 
neutrophils*1, n=3) were also able to stimulate cAMP accumulation (Fig 5.9), thus 
suggesting that rabbit neutrophils express *EP2-like* receptors positively-coupled to 
adenylate cyclase activation. AH 6809 (2xl0-5M) had no effect on unstimulated levels of 
cAMP (22Q±57 fmol cAMP 106 neutrophils*1, n=3), and antagonised PGE2-stimulated
cAMP accumulation in one out of three rabbit neutrophil preparations (DR=2.0 
logiounits, Fig 5.10). The inconsistent antagonism of PGE2-stimulated cAMP 
accumulation by AH 6809 indicated that rabbit neutrophils may have a heterogenous 
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Fig 5.8 Effect of PGD2 , PGE2 , PGI2 and the prostanoid DP receptor 
agonist BW 245C (upper panel), and the effect of adenosine and the 
adenosine receptor agonist, NECA, (lower panel) on fMLP (10-7M )-  
stim ulated superoxide generation by rabbit peritoneal neutrophils.
Neutrophils (2xl06 ml-i) were incubated with inhibitors and cytochalasin B (5|ig ml-i) 
for 5 min (37°C) prior to fMLP stimulation (5 min, 37#C). Results shown are the 
mean±s.e.m % inhibition of the control fMLP responses of the number of experiments 
indicated in the legends each performed in duplicate.
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Logio [A] M % Inhibition
p g e 2
% Inhibition






p g e 2
-9 1 1 ± 2 4±4 8 ± 2 7±3 15±4
- 8 18±4 5±3 10±3 11±3 20±5
-7 33±4 11±4 18±9 19±7 25±4
- 6 46±5 18±5 25±9 38±6 32±3
-5 57±4 27±5 3Q±7 57±3 30±4
-4 N.D. N.D. N.D. N.D. 37±4
n 6 5 4 5 4
Table 5.3 Summary of the inhibitory effects of prostanoid receptor 
agonists and on fMLP (10-7 M)-stimulated superoxide generation by rabbit 
peritoneal neutrophils or rabbit peripheral blood neutrophils (in bold).
Rabbit neutrophils (2xl06 ml-1) were preincubated with inhibitors and cytochalasin B 
(5pg ml*1) for 5 min (37*C) prior to stimulation with fMLP for 5 min (37’C). Results 
shown are the meanis.e.mean % inhibition of the control fMLP response, n represents 
the number of experiments performed in duplicate and N.D. denotes not determined. 
Rabbit peritoneal neutrophils and peripheral blood neutrophils generated 10.3±1.1 nmol 
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Fig 5.9 P G E 2 , AH 13205 and butaprost stim ulated  cAM P  
accumulation by rabbit peripheral blood neutrophils. Neutrophils (5x103 per 
determination) were preincubated with IBMX (5xlO*4 M, 5 min, 37*C) prior to 
stimulation with the prostanoid EP agonists (5 min, 37°C). Results shown are 
mean±s.e.m cAMP increases normalised with respect to the 10-5M PGE2  response of 3 
separate experiments performed in duplicate.
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Fig 5.10 P G E 2-stimulated cAMP accumulation by rabbit peripheral 
blood neutrophils in the absence and presence of AH 6809 (2xlO-5M ).
Neutrophils were preincubated with AH 6809 for 30 min (room temperature) prior to 
PGE2 stimulation of cAMP accumulation (5 min, 37’C) performed in the presence of.
IBMX (5xlO-4M). Upper middle and lower panels each show the results obtained from 






































































5.2.3 Characterization of prostanoid EP receptor-mediated stimulation of cAMP 
accumulation in human monocytes
Donor variability was observed in the absolute amounts of cAMP generated by human 
monocytes both in terms of the basal levels of cAMP generation in unstimulated human 
monocytes of 2.9±0.6 pmol cAMP 106 monocytes*1 (n=8 ), and monocytes stimulated 
with prostanoids.
PGE2  (10-M(MM) stimulated cAMP accumulation with a p[Aso] was 6.5±0.1 (n=7), 
calculated from the maximum cAMP increase at 10-5M (50.9±3.4 pmol cAMP 106 
monocytes*1), although there was a further increase at lO^M (65.7±9.8 pmol cAMP 106  
monocytes1) (Fig 5.11).
The selective EP 2-receptor agonists, AH13205 and butaprost, were also able to stimulate 
cAMP accumulation which suggests that an EP2 -(like) receptor is present on human
monocytes (Fig 5.11). AH13205 appeared to be a partial agonist with an a  of
0.56±0.09 (compared to the PGE2 Emax at 10-5M) and p[Aso] of 5.3±0.3 (n=4), whilst
butaprost ( 1 0 *5M) reached a similar maximum to PGE2 , oc =1.02±0.24, with a p[A5o] of'
5.6±0.1 (n=4). The E/[A] curve however for butaprost was considerably steeper than 
either PGE2 or AH13205.
To further characterize the EP receptor, the prostanoid receptor antagonists BW A8 6 8 C 
(DP selective, 1(HM), AH 6809 (DP/EP^Pn, 10-5M) and AH23848B (TP/EP4 ,10-5M) 
were tested against PGE2-stimulated cAMP accumulation. BW A8 6 8 C had no effect on 
PGE2-stimulated increases in cAMP, except at the highest concentration of PGE2  tested 
(10-4M, n=4) (Fig 5.12). The presence of DP receptors were demonstrated by PGD2 - 
stimulated cAMP accumulation (36.2±15.6 pmol cAMP 106 monocytes*1) with a pJAso] 
of 6.7±0.1 (n=4) which was completely abolished by BW A8 6 8 C (Fig 5.12) suggesting
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that PGE2 (<10-5M) did not activate prostanoid DP receptors.
AH 6809 (10*5M) produced a parallel rightward shift of PGE2-stimulated cAMP 
accumulation in human monocytes with a DR=1.5±0.1 logio units (n=7), and was 
unaffected by the presence of BW A8 6 8C (10-7M, n=3) (Fig 5.13) suggesting that AH 
6809 antagonism of PGE2 was not mediated at the prostanoid DP receptor.
AH23848B was tested against PGE2 at a relatively low concentration of 10*5M compared 
to its EP4 receptor pA2 value of 4.9-5.4 (Coleman et al., 1994b), as Milne et al. (1994) 
reported that 3xl0*5M AH23848B completely abolished PGE2 stimulated increases in 
cAMP in human monocytes. A dose ratio of approximately 0.5 logio units for 
AH23848B (10-5M) against PGE2 would have been predicted from its EP4 receptor pA2 
value. Although the observed shift was not inconsistent with the literature pA2 at the EP4 
receptor; it was not parallel, suggesting that AH23848Bwas non-competitive (n=7) (Fig 
5.14).
To determine the selectivity of AH 6809 and AH23848B as EP-receptor antagonists, they 
were tested against cicaprost (selective IP receptor agonist) and compared to their effects 
on the PGE2 E/[A] curve. Cicaprost was the most potent and efficacious prostanoid
cAMP-stimulating agent, with a p[Aso] of 7.8±0.2 and 221.1±53.5 pmol cAMP 106
monocytes-i (n=8). Neither AH 6809 nor AH 23848B (both at 10-5M) had any effect on 
cicaprost-stimulated cAMP accumulation (n=4) shown in Fig 5.15 and summarised in 
Table 5.4, suggesting that both agents were selective antagonists of PGE2-stimulation of 
adenylate cyclase in human monocytes.
Thus, the results suggest that human peripheral blood monocytes possess prostanoid IP 
receptors, lower numbers of DP receptors and at least 2 EP receptors. There appear to be 
‘EP2 ’-like receptors as determined by the activity of AH 13205 and butaprost (EP2- 
selective agonists). However, as PGE2 was antagonised by AH 6809, this 4EP2*-like
201
receptor may be the same subtype as characterized in the human neutrophil (chapter 3) as 
EP4 receptors are not antagonised by AH 6809 (personal communication by Simon 
Lydford). The presence of EP4  receptors, as suggested by PGE2 antagonism by 
AH23848B, the EP4  receptor antagonist, albeit non-competitively, cannot be excluded.
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Fig 5.11 P G E 2 , AH 13205 and butaprost stim u lated  cAM P  
accumulation by human peripheral blood monocytes. Prostanoid agonist 
stimulated cAMP accumulation by. human peripheral blood monocytes (105 per. 
determination) was measured over a 5 min period (37’C) in the presence of IBMX (5x10- 
4M). Results are expressed as a fraction of the PGE2  cAMP response at 10-5M of each
respective experiment, with each point representing the meanis.e.m of the data from 7 
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Fig 5.12 Effect of BW A8 6 8 C (lO-^M) on PGE2 (upper panel) and 
PG D 2  (lower panel) stimulated cAMP accumulation by human peripheral 
blood monocytes. Monocytes (1x105 per determination) were preincubated with BW 
A8 6 8 C for 30 min (room temperature) prior to stimulation with the prostanoids for (5 
min, 37#C) in the presence of IBMX (5x10*^). Results were expressed as a fraction of 
the PGE2 10-5M response and the PGD2 maximum response respectively. The data 















•3•7 6 5 ■4-10 9 8
[PGE2] (log10 M)
BW A868C 10-7M
BW A868C 10-7M/AH 6809 10-5M
1 0 *tu 1 ,u0 
0.
r  ° -8 - 8>IAa
1 0.6-
.c




-10 9 8 ■7 5 36 4
[PGE2] (fog-| o M)
Fig 5.13 AH 6809 (10*5 M) antagonism o f PGE2 -stim uIated cAMP 
accumulation by human peripheral blood monocytes in the absence (upper 
panel) and presence of BW A8 6 8 C (10-7 M) (lower panel). Monocytes 
(1x10s per determination) were preincubated with the antagonists for 30 min (room 
temperature) prior to stimulation with the prostanoids for (5 min, 37#C) in the presence of 
IB MX (5xlO-4M). Results were expressed as a fraction of the control PGE2 10-5M
response of each respective experiment and shown as the mean±s.e.m of 7 and 3 separate 
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Fig 5.14 Effect of AH23848B (10-5M) on PGE2 -stim ulated  cAMP 
accumulation by human peripheral blood monocytes. Monocytes (1x10s per 
determination) were preincubated with AH23848B for 30 min (room temperature) prior, 
to stimulation with the prostanoids for (5 min, 37*C) in the presence of IBMX (5x10- 
4 M). Results were expressed as a fraction of the PGE2 105M response and shown as 
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Fig 5.15 Effect of AH 6809 (10-5M) (upper panel) and AH23848B 
(10-5 M) (lower panel) on cicaprost-stimulated cAMP accumulation by 
peripheral blood monocytes. Monocytes (105 per determination) were preincubated 
with the antagonists for 30 min (room temperature) prior to stimulation with cicaprost for 
(5 min, 37*C) in the presence of IBMX (5x10-^). Results were expressed as a fraction 
of the cicaprost maximum cAMP response and shown as the mean±s.e.m of 4 separate 
experiments performed in duplicate.
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Cicaprost Cicaprost p[Aso] Max increase in cAMP 
pmol 1 0 6 monocytes- 1
Control 7.46±0.18 286±95
AH 6809 10-5M 7.54±0.04 265±80
AH23848B 10-5M 7.49±0.13 248±82
Table 5.4 Cicaprost (selective IP receptor agonist)-stimuIated increase 
in cAMP by human peripheral blood monocytes in the absence and 
presence of AH 6809 (10-5 M). or AH23848B (10-5M). Monocytes were, 
incubated with the antagonists for 30 min (room temperature) prior to stimulation of 
cAMP accumulation by cicaprost (5 min, 37°C) in the presence of IBMX (5x10-^ ). 
Results shown are the mean±s.e.mean data from 4 separate experiments performed in 
duplicate.
208
5.2.4 Characterization of prostanoid EP receptor-mediated stimulation of cAMP 
accumulation in undifferentiated HL-60 cells
The basal cAMP levels were found to be 8.0±1.2 pmol/106 HL-60 cells (n=22). PGE2 
(10-9-1(MM) increased cAMP levels accumulated over a 10 min period by 270.7±19.2 
pmol/106 HL-60 cells with a PIA50] of 6.7±0.1 (n=9) (Fig 5.16). Neither PGD2 nor
cicaprost stimulated cAMP accumulation in undifferentiated cells suggesting that 
prostanoid DP and IP receptors were not present or not functionally coupled to adenylate 
cyclase on undifferentiated HL-60 cells (data not shown). In addition to AH 6809 and 
BW A8 6 8 C, SC 19220 (EPi selective, pA2 5.8) were also tested at lO^M for antagonist 
activity against PGE2 stimulated increases in cAMP.
AH 6809 (10-5M) had no effect on basal cAMP levels, 8.4±1.2 pmol/106 HL-60 cells 
compared to control HL-60 cells, 7.1±0.6 pmol/106 HL-60 cells (n= ll) and caused a 
parallel rightward shift of the PGE2 curve by 1.3±0.1 logio units (n=9) (Fig 5.17). The 
selective DP receptor antagonist BW A868C (10*7M) had no effect on the PGE2 cAMP 
curve, theptAso] was 6.7±0.1 compared to the control PGE2 PIA50] of 6 .6±0.1  (n=3, 
Fig 5.17) suggesting that PGE2 was not acting at DP receptors. The EPi receptor 
selective antagonist, SC 19220 (10-4M), did not antagonise PGE2 stimulated cAMP 
accumulation, p[Aso]=6.8  (range 6 .8-6 .8 , n=2 ) compared to the control PGE2 p[Aso] of 
6 .8  (range 6 .8-6.8  n=2), but increased the maximum PGE2-stimulated cAMP to 127% 
and 119% of the control PGE2 maximum (n=2 ) (Fig 5.17).
The specificity of AH 6809 was investigated on cAMP generation stimulated by the 
adenylate cyclase stimulator forskolin. Forskolin was a poor stimulus of cAMP 
accumulation in undifferentiated HL-60 cells compared to PGE2 (Fig 5.18). In addition
to this, forskolin-stimulated cAMP generation was not antagonised by AH 6809 (10-5M) 
(n=2 ).
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A range of prostanoid EP agonists were tested as stimulators of cAMP accumulation, 
AH13205 (EP2  selective), 11-deoxy PGEi, misoprostol and PGAi. The potency order 
of these agonists compared to PGE2 was similar to that described for the human
neutrophil cAMP increases (chapter 3), although their a  values (maximum responses
compared to full agonist PGE2 = 1 ) are not the same as those observed for cAMP 
responses in the neutrophil (Fig 5.19). However on applying the Operational Model to 
both sets of data (Leff et al., 1990), similar agonist potency orders were obtained (Fig 
5.19) suggesting that the agonist potency order for these agonists is consistent with the 
EP2 receptor subtype. The EP1/EP3 selective agonist sulprostone however did not 
stimulate cAMP accumulation in undifferentiated HL-60 cells. The levels in the presence 
of lxlO-^M sulprostone were 7.5±1.4 pmol (106 HL-60)-1 compared to basal levels 




A—  Misoprostol 
■—  PGA! 
• —  AH 13205














7 6 5 3-10 9 8 4
[Prostanoid agonist] (log-io M)
Fig 5.16 cAMP accumulation stimulated by PGE2 and prostanoid 
receptor agonists 11-deoxy PG Ei, misoprostol, PGAi and AH13205 by 
undifferentiated HL-60 cells. HL-60 cells (106 per determination) were stimulated 
with the prostanoid receptor agonists for (10 min, 37°C) in the presence of IB MX (5x10* 
4M). Results shown represent the mean±s.e.m cAMP increase normalised with respect 
to the PGE2 maximum (=1) of 5 separate experiments performed in duplicate.
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Fig 5.17 Effect of AH 6809 (10-5M) (upper panel), BW A8 6 8 C (10- 
?M) (middle panel) and SC 19220 (10-4 M) (lower panel) on PGE2 - 
stimulated cAMP accumulation by undifferentiated HL-60 cells. HL-60 
cells (106 per determination) were preincubated with the antagonists for 30 min (room 
temperature) prior to stimulation with PGE2 for (10 min, 37*C) in the presence of IBMX 
(5x1 O^M). Results shown are the mean±s.e.m cAMP response normalised with respect 
to the control PGE2 maximum cAMP increase of 9 (AH 6809), 3 (BW A8 6 8 C) and 
mean±range of 2 (SC 19220) separate experiments performed in duplicate.
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Fig 5.18 Forskolin-stimulated cAMP accumulation by undifferentiated 
HL-60 cells in the absence (upper panel) and presence of AH 6809 (10- 
5M) (lower panel). HL-60 cells (106 per determination) were preincubated in the 
absence or presence of AH 6809 for 30 min (room temperature) prior to stimulation with 
forskolin (10 min, 37°C) in the presence of IBMX (5x10-%!). Results shown are the 
meanis.e.m cAMP increase normalised with respect to the PGE2 maximum (as a 
comparison) of 3 separate experiments (upper panel) and meanirange of 2 separate 
experiments (lower panel) performed in duplicate.
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Experimental
Neutrophil PGE2  > PGAi > AH 13205 > 11-Deoxy PGEi > Misoprostol
P[A50l 6.8 6.3 5.8 5.6 5.2
s.e.m ±0 .1 ±0.2 ±0.1 ±0.2 ±0.2
a 1.0 0.62 0.34 1.0 1.0
HL-60 p g e 2 > 11-deoxy PGEi * PGAi > Misoprostol > AH13205
p[A50] 6.8 5.7 5.7 5.5 5.5
s.e.m ±0.1 ±0.1 ±0.1 ±0.1 ±0.1
a 1.0 0.73 0.62 
Simulated
0.62 0.57
Neutrophil p g e 2 > 11-deoxy PGEi ® PGAi > Misoprostol * AH13205
p[A50] 8.8 7.6 7.6 7.2 6.9
s.e.m ±0.1 ±0.2 ±0.1 ±0.2 ±0.2
a 1.0 1.0 1.0 1.0 1.0
HL-60 p g e 2 > 11-deoxy PGEi * PGAi > Misoprostol « AH13205
p[A50] 8.8 7.6 7.5 7.2 7.2
s.e.m ±0.1 ±0.1 ±0.1 ±0.1 ±0.1
a 1.0 1.0 1.0 1.0 1.0
Fig 5.19 Comparison of the potency orders of prostanoid EP agonists 
mediating cAMP accumulation by human neutrophils (data from chapter 3) 




The results presented in this chapter suggest that:-
1 . PGE2 selectively inhibits the activation of human neutrophils, and is not a global 
modulator of neutrophil function. PGE2 inhibited fMLP- and C5a-stimulated O2” 
generation; but was a poor inhibitor of OZ-stimulated O2" generation. Although PGE2 
was a potent and efficacious inhibitor of fMLP-stimulated O2” generation, fMLP-
stimulated P-glucuronidase release was inhibited by a lower degree but with similar
potency. In addition, PGE2 was a poor inhibitor of IL-8 - and fMLP-stimulated 
neutrophil polarisation; the degree of inhibition was inversely proportional to the 
concentration of IL-8 and fMLP, suggesting functional antagonism.
2. Rabbit neutrophils (peritoneal exudate) possessed inhibitory prostanoid EP and IP 
receptors and a lower number of DP receptors; as observed by the low potency and 
comparative efficacy of PGD2 and the selective DP receptor agonist BW 245C, against 
fMLP-stimulated superoxide generation. Rabbit peripheral blood neutrophils also 
expressed EP receptors, which appeared to be ‘I^V-like as both AH13205 and butaprost 
stimulated cAMP accumulation. Further characterization as determined by sensitivity to 
AH 6809 antagonism, was inconclusive, as antagonism of PGE2 was observed in only 
one of three rabbits.
3. Characterization of the prostanoid receptors on human peripheral blood 
monocytes mediating cAMP elevation suggests that monocytes possess a prostanoid EP 
receptor which is similar to that on human neutrophils. The EP receptor agonist 
(butaprost and AH13205 both active) and antagonist (BW A868C-no antagonism and AH 
6809-antagonism) profiles in the human neutrophil and monocyte were similar. 
However the non-competitive nature of AH23848B antagonism of PGE2 means that the 
presence of EP4 receptors on human monocytes cannot be excluded. In addition to this,
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HL-60 cells which can be differentiated into either neutrophilic or monocytic cells, also 
express functional prostanoid EP receptors with similar agonist potency orders and 
sensitivity to prostanoid receptor antagonists to the human neutrophil.
5 .3 .1  PGE2 - an inhibitor of human neutrophil activation
PGE2 is not a global inhibitor of human neutrophil activation. Even within a single 
functional assay, 0 2 “ generation, PGE2 differentially inhibited human neutrophil 
activation by soluble stimuli, fMLP and C5a, but not particulate stimuli, opsonised 
zymosan (OZ). Similar selectivity was exhibited by the PDEI RO 20-1724, which 
attenuated fMLP but not opsonised zymosan-stimulated O2” generation, thus suggesting 
that cAMP-elevation was a common mechanism of PGE2 and PDEIs. However, OZ- 
stimulated LTB4 formation by human neutrophils was inhibited by PGE2 and other 
<EP2*-selective agonists (Wheeldon & Vardey, 1993), with similar potency and efficacy 
as inhibitors of fMLP-stimulated O2” generation. These observations may reflect 
divergence of post-receptor signal transduction pathways which allows selective 
inhibition of responses, for instance, LTB4 formation but not O2” generation, elicited by 
a single stimulus, OZ. Thus, modulation of neutrophil activation is determined by the 
way stimulatory and inhibitory signal transduction mechanisms interact
The potentiation of OZ-stimulated O2” generation by sulprostone (EP1/EP3 selective 
agonist) is of interest, as Wheeldon & Vardey (1993) similarly reported sulprostone 
potentiated OZ-stimulated LTB4 generation by human neutrophils. These observations 
suggest that pro-inflammatory EP3 receptors are present on human neutrophils which 
potentiate OZ-activated neutrophil activation possibly via the MAC-1 (CDllb/CD18) 
integrin receptor which bind the C3bi particles of opsonised zymosan. Additional 
evidence to support this mechanism of action is a report by Armstrong (1992) of 
sulprostone and other prostanoid EP agonists with activity at EP3 receptors stimulated 
neutrophil adhesion to filters in chemotaxis assays.
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The modulatory effect of PGE2 on human neutrophils is not limited to inhibition of 0 2 “ 
generation but extends to attenuation of degranulation and polarisation. PGE2 , in this
study, was a potent, albeit less effective inhibitor of fMLP-stimulated p-glucuronidase
release than an inhibitor of fMLP-stimulated 0 2 “ generation. This observation suggests a 
divergence of signal transduction mechanisms and sensitivity to PGE2  inhibition in the 
human neutrophil controlling degranulation and NADPH-oxidase activation.
The effects of PDEIs and prostanoid EP agonists on neutrophil chemotaxis and adhesion 
(Harvath et al., 1991, Armstrong, 1992) are more complex. In previous studies, neither 
type of agent was an efficacious inhibitor of fMLP-stimulated chemotaxis, and lower 
concentrations of EP agonists, most notably EP3 selective agonists, stimulated neutrophil 
adhesion to the chemotaxis filters (Armstrong, 1992). In addition, simultaneous 
treatment of neutrophils with type IV selective PDEIs and EP agonists failed to potentiate 
inhibition of fMLP-stimulated chemotaxis (Armstrong, 1992). However, Harvath eta l., 
(1991) showed that forskolin, isoprenaline and PGEi were more effective inhibitors of 
human neutrophil chemotaxis stimulated by fMLP and LTB4  in the presence of the non- 
selective PDEIIBMX.
The activation state of neutrophils in individuals with inflammatory conditions, are more 
likely to be primed by endogenous agents, for example, TNFa, GMCSF and PAF
(Nathan, 1987, Ho et al., 1990); or activated by stimuli such as LTB4, complement 
factors (C5a and C3) and chemokines (IL-8 ) prior to drug treatment. In this study, PGE2  
was as potent and efficacious an inhibitor of PAF-primed fMLP-stimulated O2" 
generation as it was of unprimed human neutrophils. This observation suggests that 
PGE2  (or another EP receptor agonist) would be effective as an inhibitor of neutrophil 
activation in inflammatory conditions where an individual’s neutrophils would already 
primed prior to exposure to PGE2 . PDEIs (Ho e ta l ., 1990) were also potent and 
effective inhibitors of O2” generation by human neutrophils primed with PAF or TNFa.
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This is as would be expected if PDEIs and PGE2 share a similar profile of activity, as a 
consequence of the same transducer molecule - cAMP. However, one study reported that 
the ability of exogenous adenosine to inhibit asthmatics’ neutrophils was diminished 
(Sustiel et al., 1989), which suggests that in chronic inflammatory disorders, attenuation 
of leukocyte activation may be more difficult to achieve. However, in the same study 
there was little difference in PGE2 inhibition of neutrophil activation between normals 
and asthmatics. Thus, a selective prostanoid EP receptor agonist may be more clinically 
effective in the treatment of chronic inflammatory conditions, such as asthma, than 
adenosine agonists.
5.3.2 Prostanoid receptors on rabbit neutrophils
The results suggest that rabbit neutrophils isolated from peripheral blood or collected 
from casein-induced peritoneal exudate express prostanoid receptors. As is the case with 
human neutrophils, the prostanoid receptors on rabbit neutrophils are not a homogenous 
population, but unlike human neutrophils, inhibition of O2” generation by rabbit 
neutrophils was not a suitable assay to assess the activity of prostanoids. The inhibition 
curves of the prostanoids in the rabbit neutrophils were shallow making interpretation of 
the data difficult.
PGE2-stimulated cAMP increase in rabbit neutrophils (isolated from peripheral blood) 
produced better defined E/[A] curves than obtained using the O2” assay. The p[Aso] 
values were similar to that obtained with PGE2-stimulated cAMP increases in the human 
neutrophil (chapter 3) and the activity of the ‘EP2 ’-selective agonists butaprost and 
AH13205 all provide evidence of this rabbit neutrophil EP receptor resembling the EP2  
receptor. However, the inconsistent antagonism of PGE2-stimulated increases in cAMP 
by AH 6809 (only one of three rabbits) may suggest that the EP receptor present on the 
rabbit neutrophil is an ‘EP2 ’-receptor similar to that described in the cat trachea (Coleman 
etal., 1987) and is not sensitive to antagonism by AH 6809. An alternative explanation
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may be that the EP receptors present on rabbit neutrophils are not a homogeneous 
population and that there is considerable variability in the expression of individual 
subtypes as exists in the rabbit jugular vein (Lawrence & Jones, 1992). The latter may 
explain the results presented in this present study as only a small number of animals were 
used and obviously warrants more work.
5.3.3 Prostanoid EP receptors on human peripheral blood monocytes
As with most early work on prostaglandins and inflammatory cells, the EP receptor on 
monocytes has been presumed to be the EP2 subtype on the basis of the ability to 
stimulate cAMP elevation. The most detailed pharmacological characterization to date 
was that of Milne et al., (1994), where the effect of EP receptor agonists and AH23848B 
(EP4 receptor antagonist) on cAMP elevation by human monocytes was studied. They 
concluded that the EP agonists stimulated cAMP elevation by activating EP4 receptors, on 
the basis that AH13205 (EP2-selective agonist) was inactive and AH23848B antagonised 
PGE2. An apparent pA2 value of 5.6 was estimated from the rightward-shift of the 
PGE2 curve observed in the presence of 10-5M AH23848B as 3x 10-5M completely 
abolished the PGE2 cAMP response. •
In the present study, contrary to the findings of Milne etal. (1994), both AH13205 and 
butaprost, the EP2-selective agonists, stimulated cAMP accumulation suggesting the 
presence of an ‘EP2 ’-like receptor. Practical differences may account for the different 
findings presented in this study and that of Milne et al. The cell preparations used in the 
respective studies are themselves different; in the present study die monocyte preparations 
(90% pure) were isolated by centrifugation and the assay performed on fresh monocyte 
preparations (< 2 hours after final preparation) and measured total cAMP levels. 
However, in Milne’s study, the monocyte population was prepared from a mixed 
mononuclear cell suspension, and the monocytes were isolated by adherence overnight. 
The generation of cAMP was consequently performed on adherent cells, the supernatants
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removed after stimulation and only cellular cAMP assayed.
The cAMP levels measured in the monocyte suspensions in the present study with all 
treatments were higher than those reported by Milne etal., and may therefore have been 
more sensitive to detect the levels of cAMP stimulated by AH13205 or butaprost which 
were lower than that stimulated by PGE2 . In addition to this, cAMP can be released from 
cells into the supernatant as has been demonstrated with human neutrophils (Harvath et 
al., 1991). The amount released can represent a substantial proportion of the total 
amount of cAMP generated, for instance in the human neutrophil (Harvath etal., 1991). 
Thus, another explanation for the different findings may be that Milne et al. only 
measured unreleased cAMP and not total cAMP generation stimulated by the EP agonists. 
However, the amount of cAMP retained and released by each stimulus in the monocyte 
may not be identical.
Yet another possible explanation is that adherent and suspended monocytes may respond 
differently to stimulation. The EP4 receptor may be functionally coupled to adenylate 
cyclase in adherent and suspended monocytes; whilst the AH 6809-sensitive ‘EPn* 
receptor may only be functionally coupled to adenylate cyclase in non-adherent 
monocytes. A similar situation exists in human neutrophils with TNFa which can only
stimulate 0 2 ~ generation in adherent neutrophils and not in neutrophil suspensions 
(Nathan, 1987).
The present studies with prostanoid DP and EP receptor antagonists suggest that PGE2 
was selectively acting at EP receptors except at the highest concentration (lO^M). 
Selective antagonism by AH 6809 and AH23848B (10-5M for both antagonists) of 
PGE2 -stimulated cAMP elevation was concluded on observing no antagonism of the 
cAMP response of the prostanoid IP receptor agonist cicaprost. AH 6809 (10-5 M) 
produced a parallel rightward displacement of the PGE2 E/[A] curve suggesting that AH 
6809 was behaving as a competitive antagonist; whilst AH 23848B (10-5M) caused a
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collapse of the PGE2 curve indicating that the antagonism was non-competitive.
The antagonism by AH 6809 of PGE2 has been observed in human neutrophils 
(inhibition of O2" generation and cAMP generation), whilst the non-competitive nature of 
AH23848B has been described in Jurkat cells (human T-lymphocyte cell line) (De Vries 
et al.9 1995) with a range of AH23848B concentrations. The Jurkat cells did not respond 
to AH13205 with an increase in cAMP levels suggesting that this human T-cell line did 
not possess *EP2*-like receptors; whilst the non-competitive depression of the PGE2 
curve by AH23848B they suggested was evidence of an atypical EP receptor. However, 
the non-competitive nature of AH23848B antagonism of PGE2 has been observed in EP4 
receptor-containing tissues, such as the rabbit saphenous vein (personal communication 
from Simon Lydford, Astra Chamwood) indicating that non-competitive antagonism by 
AH23848B of PGE2 is not inconsistent with an EP4 receptor. Thus, the EP receptor 
present on Jurkat cells may actually be an EP4 receptor, and the human monocyte 
possesses two EP receptors; an EP4 receptor and an ‘EPn’ receptor.
The monocyte preparations contained a significant number of platelets (1 monocyte: 2-8 
platelets), however, it is unlikely that these platelets contributed significantly to the cAMP- 
accumulation on stimulation with PGE2. Platelets do not possess EP receptors positively 
coupled to adenylate cyclase and any effect of PGEi and PGE2 are mediated via the 
prostanoid IP receptor (Myers etal., 1985). Although platelets express prostanoid DP 
and IP receptors, platelets made only a minor contribution to the levels of cAMP 
generated in these preparations on stimulation with PGD2 or cicaprost (Darius et al., 
1994).
5.3.4 Prostanoid EP receptors of the human promyelocytic leukaemic cell line
HL-60
Undifferentiated HL-60 cells responded to the prostanoid EP agonists with an elevation 
of cAMP levels. The agonist profile was consistent with the EP2 subtype and the agonist
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potency order was similar to that of human peripheral blood neutrophils discussed in 
chapter 3. Further similarities with the neutrophil *EPn* receptor included AH 6809 
antagonism of the PGE2 stimulated increase in cAMP, the lack of antagonism of PGE2 
by the selective DP receptor antagonist BW A8 6 8C or the EPi receptor antagonist SC 
19220. The location of the PGE2 E/[A] curve in the HL-60 cells was similar to that of the 
human neutrophil, although the E/[A] curve was steeper in HL-60 cells (2-3 log 10 units) 
than the human neutrophil (3-3.5 log 10 units) suggesting that HL-60 cells expressed a 
more homogeneous population of prostanoid EP receptors. The PGE2 superoxide 
inhibition E/[A] curves were also generally more shallow, suggesting that neutrophil 
prostanoid EP receptors were a heterogeneous population.
In a binding study recently published by Matthews et al. (1995) using the membranes of 
HL-60 cells differentiated into macrophage-like cells, showed that specific binding of 
[3H] PGE2 had two components. Only one of these binding sites was well-characterized 
as the second was not saturated by 10-7M radiolabelled ligand. The higher affinity site 
had a Kd of 3.5x10-9M, and [3H] PGE2 binding at this site was displaced by AH23848B 
(Kj of approximately 1.9xl0-5M), but not by the EP2 selective agonists butaprost and. 
AH13205, or the EP1/EP3 selective agonist sulprostone. AH 6809 (10-5M) did not 
displace PGE2 binding, and cicaprost, the high potency IP agonist, showed only low 
potency as an inhibitor of PGE2 binding. Thus, the data from the Matthews et al. study 
suggests that the high affinity PGE2 binding site on macrophage-like HL-60 membranes 
was the EP4 receptor, and therefore undifferentiated HL-60 cells must also be able to 
express EP4 receptors. However, it is evident from the location of the PGE2 cAMP 
stimulation curve in undifferentiated HL-60 cells (and peripheral blood monocytes), 
p[A50] *7.0, that the prostanoid EP receptor responsible for the cAMP elevation is not 
the EP4 subtype but is mediated via a lower affinity binding site. This would obviously 
brings into question the functional role of the EP4 receptor on monocytes and
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macrophage-like HL-60 cells.
Prostanoid EP agonists inhibit a variety but not all neutrophil functions, and therefore 
may reduce acute inflammation. Furthermore, monocyte activation may also be 
modulated by EP receptor agonists; as cAMP-elevating agents such as phosphodiesterase
inhibitors, PGE2 and p-adrenergic agents, inhibit monocyte function in vitro. This
suggests that prostanoid EP agonists may modulate certain aspects of chronic 




6.1 Characterization of Prostanoid Receptors
Pharmacological characterization of the prostanoid EP receptors mediating inhibition of 
human neutrophil activation in the present study suggests that the receptor is similar to the 
classical EP2 subtype on the basis of agonists potency ratios (chapter 3). These findings are 
in agreement with other published studies (Wheeldon & Vardey, 1993; Talpain et al., 1994). 
Additional evidence of the similarity of the neutrophil and the classical EP2  subtype arose 
from the neutrophil cAMP studies with prostanoid EP agonists (chapter 3). The agonist 
potency order for elevation of cAMP of EP agonists was similar to that of inhibition of 
fMLP-stimulated superoxide generation; and cAMP elevation is believed to be the signal 
transduction pathway of EP2 receptors (Yeardley et al., 1993).
However, further characterization of the human neutrophil EP receptor with prostanoid 
receptor antagonists (chapter 3) showed that AH 6809 antagonised EP2 receptor mediated 
responses, in contradiction to the existing classification. Antagonism by AH 6809 was 
observed against PGE2-mediated inhibition of superoxide generation and PGE2-stimulated 
cAMP elevation. Doubt had been cast on the specificity of AH 6809 as an antagonist in the 
human neutrophil (Talpain et al., 1994), but the antagonism of AH 6809 by PGE2 in the 
human leukocytes observed in the present study showed specificity and selectivity.
However, the degree of antagonism by AH 6809 (10-5M) of PGE2 in the human neutrophil
superoxide assay using a large pool of donors was variable (chapter 3), but may be explained 
by the presence of heterogenous populations of prostanoid EP receptors some of which may 
not be sensitive to AH 6809 antagonism. The relative proportions of these receptors on 
neutrophils may differ between individuals as would the apparent sensitivity of PGE2 to AH 
6809 antagonism. Such a situation would result in an apparent “wall” effect as described in 
chapter 3, preventing AH 6809 (10-5M) producing as large a rightward shift of the PGE2
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E/[A] curve as would have been predicted from the pA2  value estimated from the early O2’ 
experiments. Alternatively, the estimate of the pA2 value for AH 6809 was conducted on 
relatively few donors, and may not represent the true pA2 value, which would only be 
realised from using a larger population of donors.
EP receptors are the only prostanoid receptors with clear pharmacological evidence for 
subdivision, but rigorous pharmacological characterization of ‘EP2 *-receptors in human 
tissues and those of other species is lacking. Therefore, the findings presented in this thesis 
are not conclusive evidence for the neutrophil EP receptor either being a AH 6809-sensitive 
human homologue of the classical EP2-receptor or a novel prostanoid EP receptor subtype. 
However, the findings presented in this thesis suggest that the existing classification shown 
in Table 3.1 may require revision to take into account the antagonism of the human EP2  
receptor by AH 6809, termed ‘EPn\  (Table 6.1). In addition, the use of AH 6809 as a 
selective prostanoid DP/EPi receptor antagonist receptor should be reevaluated as antagonism 
of prostanoid EP2  receptors may be an additional property. AH 6809 antagonises prostanoid 
DP, EPi and EP2 responses over a similar concentration range (10-6M-10-5M), and should
be regarded as a less selective prostanoid receptor antagonist. Furthermore, AH 6809 has 
been omitted from the 1995 edition of the Trends in Pharmacological Studies (TIPS) annual 
compendium of receptor classification, suggesting that AH 6809 is no longer regarded as a 
selective prostanoid DP/EPi receptor antagonist.
However the classification to date has relied upon the use of tissues, mainly smooth muscle 
preparations from a range of species, such as the guinea pig ileum (EPi), cat trachea (EP2 ), 
guinea pig vas deferens (EP3 ) and piglet saphenous vein (EP4 ). Thus the characterization of 
prostanoid receptors in any tissue from any species is subject to a degree of uncertainty as 
species differences may exist in their sensitivity to different agonists and antagonists. One 
example of this is another prostanoid receptor, the thromboxane (TP) receptor. Most TP
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receptor antagonists have 1 0 -fold higher pA2 value in the aorta and platelets of humans, rats 
and dogs compared to the corresponding rabbit tissues (Lumley et a l., 1989 and Tymkewycz 
etal.y 1991). Other pharmacological parameters, for instance, TP agonist potency orders 
were similar in human, rat, dog and rabbit tissues, suggesting that the differences in 
antagonist potency between rabbit and the other species’ tissues were unlikely to be due to 
TP receptor subdivision. A more likely explanation is differences in the affinity of 
antagonists for TP receptors between species.
Species differences in the potency of antagonists at prostanoid EP receptors may also apply 
to human tissue. There is a limited supply of normal human tissue except for blood derived 
cells (platelets and leukocytes), which is the main difficulty associated with the classification 
of human prostanoid receptors. However, there are many human cell lines which may 
represent a useful source of human ‘tissue’ for pharmacological studies. One such cell line is 
the human promyelocytic leukaemic cell line (HL-60), in which the prostanoid EP receptor 
was characterized in the present study (chapter 5). HL-60 cells which may be differentiated 
into either neutrophil-like or monocyte-like cells, expressed prostanoid *EP2 *-like receptors 
as determined by agonist potency orders. Furthermore, the HL-60 EP receptor appeared to 
be sensitive to AH 6809 antagonism (chapter 5), as described in the human neutrophil 
suggesting it is the ‘EPn’ receptor (chapter 3).
The presence of a AH 6809-sensitive ‘EP2 ’-like receptor mediating cAMP elevation was also 
demonstrated in human peripheral blood monocytes (chapter 5) suggesting that the ‘EPn’ 
receptor is present on many human leukocytes. Whether the same EP receptor subtype is 
expressed by other human leukocytes, such as eosinophils and lymphocytes remains to be 
discovered. Knowledge of the distribution of the ‘EPn’ receptor would throw light on the 
immunomodulatory and anti-inflammatory potential of selective agonists for this receptor for 
the treatment of acute and chronic inflammation.
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Prostanoid EP receptor classification is however impeded by a lack of selective and potent 
antagonists for the receptor subtypes. It is clear from the experiments with AH 6809 and 
AH23848B in the human neutrophil, that both EP receptor antagonists have other activities in 
leukocytes not directly associated with their prostanoid receptor antagonist properties (chapter 
3; Talpain et al., 1994). These activities interfere with leukocyte functional assays such as 
superoxide generation, and have limited their use as antagonists and hampered the 
interpretation of their antagonism of prostanoid agonists.
In view of the less than ideal potency and selectivity of prostanoid EP receptor agonists and 
antagonists, as well as the additional problems of human prostanoid receptor classification, 
additional evidence with respect to receptor classification may be provided by recent advances 
in molecular biology. The first human prostanoid TP receptor was cloned (Hirata e ta l. , 
1991) from cDNA libraries of cultured megakaryocyte leukaemia cells and human placenta 
obtained from partial amino acid sequences of purified protein from the membranes of human 
platelets. The murine prostanoid TP receptor was then cloned (Namba et al., 1992) and used 
as a hybridisation probe to clone the murine EP3 receptor by homology screening (Sugimoto 
et al., 1992). Subsequently murine (Honda et al., 1993), rat (Sando et al., 1994), and human 
(An et al., 1993, Bastien et al., 1994) ‘EP2 ’ receptors were also cloned.
The cloned murine EP receptor which was initially designated the ‘EP2 ’ subtype on the basis 
that PGE2 stimulated a cAMP increase (Honda et al., 1993), was consequently re-assigned 
the EP4  notation. The basis for this was the observation that butaprost, the EP2  selective 
receptor agonist, did not displace PGE2  binding of the cloned receptor expressed in COS 
cells (Nishigaki et al., 1995). This illustrates that demonstration of a functional response 
mediated by a transfected cloned receptor is insufficient confirmational evidence of receptor 
identity, and that pharmacological characterization and evaluation of functional data is 
essential. Many publications detailing the successful cloning of prostanoid receptors lack
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pharmacological evaluation of the functional agonist and antagonist data, thus precluding 
confirmation of the transfected (cloned) receptor as being identical to the naturally-occurring 
receptor which was the target of the initial cloning strategy.
Prostanoid receptors are expressed by most if not all mammalian cell types, as would have 
been expected from the ubiquitous distribution of prostaglandins throughout the body. 
Consequently finding a suitable mammalian cell line which does not constitutively express 
prostanoid receptors in which to transfect cloned prostanoid receptors has been difficult. 
Even if this is achieved, there is no guarantee that the transfected receptor will be expressed 
in the same way, for instance differences in the folding of the protein and glycosylation 
patterns. A functional response may not be detectable, as the transducer molecules may be 
different, for instance G protein types and numbers or different isoforms of adenylate cyclase 
may differ. In addition, alternative splice variants at the carboxy-terminal of transfected 
cloned bovine (Namba etal., 1993), human (Regan et al., 1994b), murine (Sugimoto et a l. , 
1993) and rabbit (Breyer et al., 1994) prostanoid EP3 subtypes have been identified. 
Normally EP3 receptors are negatively coupled to adenylate cyclase via Gi, however some 
alternative splice variants were able to couple to G s instead of Gi and activated adenylate 
cyclase, but all the splice variants exhibit similar agonist potency orders for binding. 
However, no splice variants have been found for any of the other EP receptor subtypes, TP 
or FP receptors. The constitutive expression of prostanoid receptor splice variants in normal 
cells is unclear, as is their physiological significance in dictating tissue responses to agonists 
and antagonists.
Cloned receptors have been successfully transfected into non-mammalian cells such as 
Xenopus oocytes (human TP receptors, Hirata et al., 1991), bacteria such as Escherishia coli 
(E. coli) and insect cell lines e.g. Spodoptera frugiperda (Sf-9) cells. The stable transfection
of adenylate cyclase linked (3-adrenergic receptors into insect Sf-9 cells has been achieved
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(MouiUac et al., 1992, Kleymann et al., 1993, Ravet et al., 1993), overcoming the problems 
of phylogenic differences. These insect cells may be prove to be suitable for transfection 
with prostanoid receptors such as those identified in human neutrophils and monocytes. 
Cloned prostanoid EP3 receptors have also been successfully transiently transfected into 
insect Trichoplusia ni (MG1) cells (Huang & Tai, 1994). These reports provide evidence 
that it may be feasible transfect cloned prostanoid EP receptors which normally couple to 
adenylate cyclase into Sf-9 cells.
The human prostanoid ‘EP2 * receptor, Hup-4, cloned from human placenta, when 
transfected into COS-7 cells was found to be positively coupled to adenylate cyclase. The 
pharmacological prostanoid agonist profile in binding studies (displacing 1251 labelled PGE2  
binding) and functional studies (cAMP generation) was consistent with the ‘EP2 * receptor 
(Regan e ta l ., 1994a). As no antagonists were tested in the Hup-4 transfected cells, it is 
unclear whether Hup-4 is the ‘EPn’ receptor characterized in the human neutrophil. Northern 
blotting has shown that Hup-4 is present in HL-60 cells, and as PGE2 -stimulated cAMP 
accumulation is AH 6809-sensitive in undifferentiated HL-60 cells (chapter 5), suggesting 
that ‘EPn’ and Hup-4 are the same receptor. The only proof would come from blocking the 
expression of Hup-4 in HL-60 cells, for example by the use of the antisense approach and 
confirming this at the message and protein level, then using these modified cells in 
experiments to evaluate the effect of AH 6809 on PGE2 . In addition, AH 6809 antagonises 
PGE2  binding to Hup-4 and PGE2-stimulated cAMP generation in Hup-4 transfected COS-7 
cells (Woodward, personal communication). The results presented in this thesis on the EP- 
receptor pharmacology of human neutrophils and HL-60 cells support such speculation. 
Furthermore, the pharmacology of the human monocyte ‘EP2-like* receptor is also similar to 
that of the human neutrophil and HL-60 cells (which can be differentiated into monocyte-like 
cells or neutrophil-like cells).
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The Hup-4 amino acid sequence is distinctly different to the other two human ‘EP2 ’ receptor 
clones (An e ta l ., 1993 and Bastien e ta l ., 1994). However, the degree of homology 
between them and Hup-4 was similar to that between Hup-4 and human EPi or EP3 
receptors. In contrast, there was close homology between these human ‘EP2 ’ receptors and 
the human EPi or EP3 receptors (-80%) and the murine *EP2 * and renamed EP4  receptor. 
The receptors were cloned from human peripheral blood polymorphonuclear leukocytes and a 
human lung cDNA library respectively using reverse transcription and with cDNA primers 
prepared from mouse EP3 and human thromboxane A 2  receptors (An et al.* 1993) and the 
murine EP2  receptor sequences (Bastien et a l., 1994). The amino acid sequence between 
these two clones as almost identical as was the distribution of their mRNA expression in 
human tissue, i.e. strongly expressed in lung, kidney, small intestine and thymus. The 
pharmacology of these two ‘EP2 ’ receptors is different to Hup-4. PGE2 stimulated cAMP 
generation via the transfected ‘EP2 ’ receptors (An etal.* 1993 and Bastien et a l., 1994), but 
butaprost was unable to displace radio-labelled PGE2 binding to the same transfected EP2 
receptors (Bastien etal.* 1994) which is not consistent with the pharmacology of the classical 
EP2 receptor. As would have been predicted from the lack of pharmacological analysis in 
these studies, the designation of the ‘EP2 * notation was premature as the limited 
pharmacology presented in those studies suggest that they may actually represent the EP4  
subtype.
The expression of these two human ‘EP2 * receptor clones in thymus, spleen and leukocytes, 
and the fact that An et al. (1993) used polymorphonuclear leukocytes, which are 
predominately neutrophils, to generate the cDNA primers, would suggest that there may be 
EP4  receptors expressed by these leukocytes. However, the pharmacology of PGE2  and
other prostanoid EP receptor agonists and antagonists in human neutrophils does not reflect 
the presence of an EP4 receptor. Possible explanations may be the comparatively low
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expression of EP4  receptors by human neutrophils compared to the other EP receptors 
present, or that EP4 receptors are only weakly coupled to effector mechanisms. An 
alternative explanation is that the stringency of the primers used may have favoured the 
detection and isolation of the EP4 receptor from either neutrophils or possibly other 
contaminating leukocytes in the polymorphonuclear cell preparation such as monocytes, 
lymphocytes or eosinophils. The study of An et al. (1993) did not report the purity of the 
cell preparation, in which case the detection of EP4  in the mRNA of peripheral blood 
leukocytes may reflect its presence in other leukocytes. As human monocytes express EP4  
receptors (chapter 5; Milne etal. (1994)), monocytes may be the source of the EP4  receptor 
mRNA. In which case, the cloning of the EP4 receptor from a human polymorphonuclear 
cell preparation by An et al. (1993) may have been mistakenly interpreted as the neutrophil 
EP2  receptor.
However, only the demonstration of Hup-4 expression by human neutrophils and 
monocytes, and AH 6809 antagonism of PGE2 binding and/or cAMP generation mediated 
via the transfected Hup-4 receptor, would conclusively show that Hup-4 was identical to 
‘EPn\  Hup-4 is present in many tissues, for instance, the placenta, and knowledge of its 
distribution in additional human tissues would allude to possible in vivo effects of agonists 
for this receptor. Thus, it may be feasible to synthesise agonists for the Hup-4 receptor with 
selective anti-inflammatory effect on neutrophils and monocytes. Not only would such 
agonists represent a novel anti-inflammatory strategy, but lead to the re-evaluation of the 
classification of prostanoid EP receptors.
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Receptor Subtype Selective Agonist Selective Antagonist pA2












EP. S ulprostone/GR63799X None
EP/ None AH23848B 5.4
Table 6.1 Modification of the existing classification of prostanoid EP 
receptor subtypes, selective agonists and antagonists. The data presented as 
shown in Table 3.1 with the inclusion of the prostanoid EP receptor data from this thesis 
shown as the ‘EPn’ subtype. HAH 6809 is also a prostanoid DP receptor antagonist (see 
Table 1.1).
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6.2 Prostanoid EP receptors: effects on leukocyte intracellular signalling and activation
Although it is generally accepted that prostanoid EP receptor-mediated inhibition of leukocyte 
activation utilizes cAMP as a transducer molecule, the precise mechanism of action is not well 
understood. The effects of PGE2 and PDEIs on neutrophil activation, cAMP elevation and
[Ca2+h presented in this thesis (chapter 4) suggest that there are multiple sites of interaction 
between these two signal transducer molecules. Consequently, interpretation of the effects of 
cAMP elevation and changes in [Ca2+h on neutrophil activation is not easy. These 
difficulties reflect the limitations of the methods used to determine the effects of inhibitors 
and stimuli of cell activation on cAMP levels and [Ca2+]j.
cAMP levels in this present study, as in most studies, were measured in the presence of a 
phosphodiesterase inhibitor and/or at particular time points and therefore do not reflect 
temporal or regional changes in cellular cAMP levels which accompany cell activation. 
Compartmentalisation of cellular cAMP has been postulated in human neutrophils (Bourne, 
1972), and demonstrated in other cell types by Barsony & Marx (1990) with E-type 
prostaglandins, isoprenaline and PDEIs. These agents stimulated intracellular localised 
cAMP increases which changed with time; cAMP levels were initially increased in the 
periphery close to the plasma membrane; and gradually the fluorescence became more 
widespread within the cell. Forskolin, in contrast, showed a different distribution of cellular 
cAMP increase; initial increases were found to be perinuclear. These regional increases in 
cAMP suggest that the receptor-activated adenylate cyclase is closely associated with the 
plasma membrane, as is protein kinase All (ubiquitous) and the type IV phosphodiesterase 
(reviewed by Houslay et al., 1995). In human neutrophils and HL-60 cells, forskolin was a 
poor stimulus of cAMP elevation compared to PGE2 (chapter 4 and 5 respectively). 
Forskolin was also a weak inhibitor of fMLP-stimulated 0 2 “ generation in human neutrophils 
compared to PGE2 . The difference between agonist-receptor stimulated increases in cAMP
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and those induced by forskolin may reflect the differential ability of forskolin to stimulate 
different isoforms of adenylate cyclase. Forskolin may preferentially activate cytosolic or 
perinuclear adenylate cyclases rather than plasma membrane bound isoforms.
An additional complicating factor is that some of the cAMP generated is extruded from the 
cell and found extracellularly (Bourne, 1972 and Harvath etal., 1991). This may represent 
another mechanism employed by the neutrophil to regulate perimembrane cAMP levels in 
addition to the activity of phosphodiesterases. The extrusion mechanism involved has not 
been identified and the physiological relevance of the extruded cAMP puzzling as cAMP is 
membrane impermeable and all targets for cAMP are intracellular. Comparison of the effects 
of neutrophil stimuli and inhibitors on cellular cAMP by measuring total cAMP levels may be 
subject to compartmentalisation and extrusion of cAMP and may not correlate well with their 
effects on neutrophil activation.
The type IV PDE isoforms found in human neutrophils were A2, A4 and A7, the former is 
located at the plasma membrane. Houslay et al. (1995) proposed that type IV PDEs were 
located close to other members of the cAMP modulatory pathway such as adenylate cyclase, 
PKA and AKAP (type A kinase anchoring protein), to compartmentalise and localise cAMP 
increases to certain regions. In the neutrophil, cAMP may regulate cell activation by 
modulating the function of plasma membrane Ca2+ pumps, NADPH oxidase, secretory 
granules and cytoskeletal components and adhesion molecules involved in chemotaxis and 
adhesion.
The perimembrane localisation of the components of the cAMP system in the neutrophil are 
well placed to interact with components of the Ca2+ system such as Ca2+ channels through 
which Ca2+ influx occurs from the extracellular medium and the plasma membrane Ca2+ 
pumps promoting the extrusion of cytosolic Ca2+ ions. The function of the RaplA and 
cytochrome bsss components of the active NADPH oxidase are affected by cAMP-mediated
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phosphorylation, are also closely associated with the plasma membrane (see general 
introduction, chapter 1 ).
Thus, cAMP and Ca2+ and NADPH oxidase; the signal transducer pathways and functional 
response of the neutrophil studied in this thesis, are physically in close proximity and 
perfectly placed for intimate interactions (Fig 6.1).
The distribution of SERCA2b, the cAMP-dependent phospholamban-activated intracellular 
Ca2+ATPase, is closely associated with the F-actin in activated human neutrophils and 
thereby well-placed to regulate [Ca2+]i at sites of phagocytosis (Stendahl era/., 1994).
Downey et al. (1991) showed that neutrophil microfilament assembly is sensitive to 
modulation by cAMP and F-actin polymerisation is required for chemotaxis, shape change 
and adhesion. SERCA2b may also be localised at sites of pseudopodia formation and 
adhesion where focal increases in [Ca2+]j are also required. Stimulation of SERCA2b by 
cAMP may contribute to PGE2 and PDEI mediated inhibition of OZ-stimulated superoxide 
generation by human neutrophils (chapter 5). Neutrophil stimulation by OZ requires 
phagocytosis of OZ mediated by binding the C3bi (MAC1 integrin) receptor, which also 
mediates neutrophil adhesion. Stimulation of SERCA2b by cAMP would attenuate the rise in 
[Ca2+]j required for these functions as would other cAMP-dependent mechanisms which
decrease [Ca2+]i already described. These include the stimulation of plasma membrane Ca2+
pumps such as the cAMP-stimulated plasma membrane Ca2+ pumps are present in human 
platelets (Johansson et a l., 1992), erythrocytes (James et al.y 1989) and smooth muscle 
(Khan & Grover, 1991). PGE2 and PDEI attenuation of fMLP-stimulated increase in [Ca2+]i
by accelerating the decay of the Ca2+ transient and reducing the magnitude of the protracted 
influx-dependent increase in [Ca2+]i (chapter 4) may be mediated either or both of these 
mechanisms. Furthermore, human neutrophil nonselective cation channels are regulated by
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cAMP (Schumann etal., 1992) as is Ca2+ and Mn2+ influx as observed in this present study 
(chapter 4) suggesting that cAMP does indeed regulate ion channel function.
Cross-talk not only exists between cAMP and Ca2+, but also occurs between cAMP and 
other classical signal transducer molecules for instance protein kinase C (reviewed by 
Houslay, 1991). NADPH-oxidase function may be regulated by protein kinase C (Tauber, 
1987) and cAMP (via RaplA), as may [Ca2+]i as the plasma membrane Ca2+ pump is
activated by phorbol esters (Lagast et al., 1984b) and fMLP-stimulated increase in [Ca2+]i is 
attenuated by cAMP-elevating agents as has been shown in this thesis (chapter 4) and by 
others.
As the cAMP-dependent protein kinase phosphorylates RaplA, a member of the more 
recently discovered group of low-molecular-weight GTPases (LMWG), cAMP may also 
interact with LMWG such as the Rac2 protein (Knaus et al., 1991) which has been identified 
as a regulatory protein of NADPH-oxidase. As Rac and other LMWG also regulate 
cytoskeletal changes (reviewed by Bokoch, 1995), this represents another possible site of 
interaction with cAMP. PGE2 -mediated inhibition of IL- 8  and fMLP-stimulated human 
neutrophil polarisation (chapter 5), a response which involves cytoskeletal rearrangement, 
may involve such a mechanism. As chemotaxis is not dependent on extracellular Ca2+ ions 
(Merritt era/., 1991), the effects of cAMP elevating agents (Harvath etal., 1991) may also 
implicate a similar LMWG mechanism.
Other signal transduction pathways involved in neutrophil activation are beginning to be 
elucidated, for instance, phosphatidylinositol 3-kinase (PI3K) and tyrosine kinases. How 
these pathways interact with cAMP and other classical signal transducer molecules, such as 









Fig 6.1 Schematic illustration of the possible mechanisms of action 
of cAMP-elevating agents regulating [Ca2+]| and superoxide generation in 
the human neutrophil.
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6.3 Prostanoid EP receptor agonist-mediated inhibition of human leukocyte activation: 
implications to acute and chronic inflammation
In the present study the leukocytes responses to stimuli such as fMLP, and inhibitors like 
prostaglandins, were variable between donors (chapter 3). These observations highlight the 
versatile nature and role of these leukocytes in host defence, which is to respond rapidly and 
effectively to the constantly fluctuating demands of the immune system. Leukocytes must 
protect the body from all types of insult, in any part of the body, whether it be local or 
systemic to eliminate the injurious agent, limit tissue damage and initiate repair. However, 
the immunological status of an individual is constantly changing, so even one leukocyte 
phenotype from an individual donor taken at different times may respond differently. 
Neutrophils undergo rapid turnover (circulating 1 1/2 12 hours, McAfee et al., 1976), which is 
an inherent variable to aid the rapid reaction and adaptability of the immune system to ever 
changing demands.
It is not surprising perhaps that the effects of prostanoid agonists and antagonists on 
leukocyte functional assays are more variable than pharmacologists would like to see and 
expect. However, much in vitro pharmacological research is based upon work performed on 
isolated tissues obtained from genetically constrained strains of animals kept in tightly 
controlled environments, and so may give a misleadingly high expectation of the consistency 
of agonist effects in tissues which from less controlled sources. As humans are different, 
their inherent variability may be the reason for the range of drug efficacies in the clinic, and 
why some individuals are more susceptible to certain side effects than others.
A range of cell types, such as epithelial cells (Churchill et al., 1989), fibroblasts (Carley et 
al., 1992), monocytes/macrophages (MacDermot et al., 1984) and smooth muscle cells 
(Haye-Legrand etal., 1986) are capable of releasing PGE2  which inhibits human leukocyte 
activation. Such a mechanism may physiologically modulate leukocyte function preventing
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inappropriate or excessive activation. These cell types are located in areas where leukocytes 
will come into close contact during normal trafficking and during inflammation. The local 
synthesis of prostaglandins may suppress the activation state of the leukocyte to prevent 
damage to the host tissue as a self-protective mechanism. Tissue monocytes/macrophages 
release chemotactic agents such as IL- 8  in addition to PGE2 ; and may regulate neutrophil 
infiltration and activation in inflammatory sites by the release of such cocktails of neutrophil 
stimulatory and inhibitory agents. Synovial cells also have the capacity to synthesise and 
release chemokines, IL- 8  for example (Watson etal., 1988a and b) and PGE2 (McGuire- 
Goldring et al., 1983) and may serve a similar role in inflammation of the joint.
Misoprostol is one of the few prostanoid EP agonists which has been used clinically. 
Rheumatoid arthritis patients treated with NSAIDs are prone to gastric ulceration, and 
misoprostol has been used in conjunction with NSAIDs to prevent NSAID-induced 
gastropathy (reviewed by Garris & Kirkwood, 1989). Misoprostol was as effective as 
histamine H 2 receptor antagonists in the prevention of gastric ulceration, but increased the 
incidence of diarrhoea 3 fold. Part of the efficacy of misoprostol may be due to restoration of 
the gut cytoprotective effect of endogenous prostaglandins abolished by NSAID treatment. 
Leukocyte adherence is believed to play a role in the pathogenesis of NSAID-induced 
ulceration (Wallace et al., 1991), and misoprostol by inhibiting leukocyte adhesion may 
attenuate the accumulation of leukocyte at ulcerogenic sites. However, the results of the 
misoprostol/NSAID cotreatment clinical trial suggested that misoprostol had no advantage 
over established anti-ulcer therapy, and had undesirable side effects in a high proportion of 
people. In addition, as prostaglandins are abortifacients the use of misoprostol is 
contraindicated in women of child-bearing age. The problems observed in these patients may 
be due to the lack of selectivity of misoprostol as an EP receptor agonist, which has similar 
potency at prostanoid EP2/EP3 and EP4  receptors (Coleman et al., 1994b). However, the 
development of more selective prostanoid EP receptor agonists may overcome such
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problems, and be useful for the treatment of gastro-intestinal inflammation and other 
inflammatory conditions such as asthma, ARDS, arthritis, and psoriasis.
Orally administered misoprostol has been shown to inhibit neutrophil, eosinophil and 
monocyte accumulation in allergic cutaneous inflammation induced in atopic volunteers 
(M am etal., 1993), suggesting that inhibitory prostanoid EP receptors are present in these 
leukocytes. Misoprostol selectively inhibited the late (leukocyte infiltration-dependent) but 
not early inflammatory response. Leukocytes from misoprostol-treated individuals showed a 
reduction in leukocyte activation (eosinophils and lymphocytes) (Alam et al., 1993), with a 
decrease in eosinophil survival in culture and decrease in GMCSF generation by 
lymphocytes. Systemically administered prostaglandins may therefore be therapeutically 
beneficial for the treatment of allergic inflammatory diseases such as asthma and also 
psoriasis and other inflammatory skin conditions.
Inhaled prostanoid agonists may also be beneficial for the treatment of inflammation of the 
airway. Inhaled PGE2 inhibited the early and late phases of allergen-induced 
bronchoconstriction and hyperreactivity in human asthmatics (Pavord et a l., 1992), 
suggesting that lung inflammation may represent another therapeutic target for selective EP 
agonists. AH13205, the prostanoid EP2  receptor agonist, however produced no relief from 
bronchoconstriction in humans and induced cough (Nials etcd., 1993). The lack of potency 
of AH13205 as an EP receptor agonist further highlights the need for more potent selective 
agonists for EP2  and other relaxant EP receptors to evaluate the antiinflammatory effects of 
prostanoid EP agonists in the lung and other inflammatory sites. Furthermore, the 
characterization of the prostanoid receptors which mediate cough warrants further 
investigation as it is an undesirable effect of EP agonists which may be avoided if cough and 
bronchodilation are mediated by different receptors.
The anti-inflammatory effects of prostanoid EP receptor agonists involving inhibition of
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leukocyte activation could be useful in the treatment of inflammatory disease. Indeed, 
Gordon et al. (1976) showed that lymphocyte activation was inhibited by local PGE2 , which 
was the earliest demonstration of an anti-inflammatory effect of a prostanoid EP receptor 
agonist. However the use of prostanoid agonists in humans is limited by their lack of 
selectivity, such as the diarrhoeagenic activity and abortifacient potential of misoprostol, and 
the tussive effect of AH13205. These problems can only be overcome by the development of 
more selective agonists for prostanoid EP receptors which mediate inhibition of leukocyte 
activation. This, in turn, depends on the characterization of these leukocyte receptors which 
has been attempted in the study presented in this thesis. Further progress can only be 
achieved by the combining molecular biology and pharmacological techniques to characterize 
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Inhibition by prostanoid EP receptor agonists of formyl-methionyl-leucyl-phenylalanine ( FMLP ) stimulated neutrophil superoxide production and 
relationship to increases in cAMP
S.W. Li, N.K. Boughton-Smith, K. McKechnie, A. Blackham & P. Leff, Department of Pharmacology, Fisons pic, Pharmaceutical Division, Research 
and Development Laboratories, Bakewell Road, Loughborough, Leicestershire, LEI 1 ORH.
Prostaglandins of the E series suppress a variety of neutrophil functions, such as superoxide production by a mechanism that involves increases in cAMP 
formation ( Hecker et al., 1990; Ney & Schror, 1991 ). However, the coupling between cAMP and neutrophil modulation has not been analysed 
pharmacologically, either to verify whether the two functional responses are mediated by the same receptor, or to determine the quantitative relationship 
between them. In this study we have used PGEo and some other EP receptor agonists to define this relationship.
Human neutrophils were isolated from venous blood by centrifugation with Polymorphprep ( Nycomed). Neutrophils ( 106 cells mb1) were preincubated 
( 37°C ) with cytochalasin B ( 5|ig m l1 ) and prostanoids or vehicle ( < 0.25% ethanol) for 5 min in phosphate buffered saline ( containing 0.9mM 
CaCl2, 0.5mM MgCl2 and llmM glucose ) prior to stimulation with FMLP ( submaximal concentration, 1 0 7M ) for 5 min at 37°C. Superoxide 
production was measured as the reduction of cytochrome C ( 0.08mM, A550nm). The cAMP generation was determined from 2xl07 cells m l1 pretreated 
for 5 min with isobutylmethyl xanthine ( 500|iM) and stimulated for 5 min with the EP receptor agonists or vehicle ( < 0.25% ethanol). After addition 
of perchloric acid (5  % final concentration, 4°C) and centrifugation ( 30s at 10,000g) cAMP was extracted using tri-n-octylamine/Freon, and assayed by 
3H-RIA ( Amersham).
All the agonists tested behaved as full agonists against FMLP ( 107 M ) stimulated superoxide production (9.9 ± 0.5nmol 106 cells1) whereas two of the 
agonists, PGAj and AH 13205, behaved as partial agonists of cAMP formation, a  and pEC50 values obtained by fitting a logistic equation to 
concentration-effect data are shown in the Table 1.
Table 1
pECcn ( and a  values for cAMP 1 for PGEo. 11-deoxv PGEi. misoprostol. PGA, and AH 13205 in superoxide and cAMP assays 
Agonist PGE2 11-deoxy PGEi Misoprostol PGA, AH 13205
Superoxide 7.210.1 ( n=30 ) 6.110.2 ( n=7 ) 6.310.4 ( n=3 ) 62±D2 ( n=3 ) 5 ,5+0,2 ( n=7 )
cAMP 6.810.1 ( a  =1, n=21 ) 5.610.2 ( a  =1, n=4 ) 5.2 ( a  =1, n=4 ) 6.310.2 ( a  =0.62, n=3 ) 5.810.1 ( a  =0.34, n=3 )
Analysis of the two sets of data using operational model-fitting ( Leff et al., 1990) showed that they differ only in terms of the receptor reserve operating 
in the two assays. It is concluded, therefore, that the receptors subserving cAMP elevation and superoxide inhibition are the same. Additionally, affinity 
and efficacy values could be estimated for PGAj and AH 13205 demonstrating that cAMP measurement provides a more quantitative analysis of agonist 
effects than inhibition of superoxide production.
AH 13205 and misoprostol were gifts from Glaxo and Searle respectively.
Hecker, G., Ney, P. & Schror, K. ( 1990 ). Naunyn - Schmiedeberg’s Arch Pharmacol., 341. 308 - 315.
Leff, P., Prentice, D.J., Giles, H., Martin, G.R. and Wood, J. ( 1990). Journal of Pharmacol Methods, 23, 225 - 237.
Ney, P. & Schror, K.( 1991). Eicosanoids, 4 ,2 1 -2 8
COMPARISON OF PROSTANOID EP AGONIST cAMP RESPONSES IN HUMAN 
NEUTROPHILS AND HL-60 CELLS
S.W. Li. K.C.W. McKechnie, U. Westwick & N.K. Boughton-Smith
Department of Pharmacology, Fisons Pharmaceuticals, Bakewell Road, Loughborough, 
LEI 1 ORH, U.K and School of Pharmacy and Pharmacology, University of Bath, Claverton 
Down, Bath, BA2 7AY, U.K.
Prostanoid EP receptor agonists inhibit FMLP stimulated superoxide generation and 
increase cAMP in human neutrophils (Li et al., 1993). Human promyelocytic leukaemic 
HL-60 cells can be differentiated to become neutrophil-like and appear to express EP2 
receptors (Armstrong & Talpain, 1992, Hollingsworth & De Vries, 1992). This study 
compares cAMP responses of EP agonists in undifferentiated HL-60s and human 
neutrophils to determine whether they are mediated by the same receptor subtype. The HL- 
60s when stimulated with PGE2 (p[Aso] = 6.8±0.1, n=5) generated 30-50 fold more cAMP 
than human neutrophils (p[Aso] = 6.8±0.1, n=21). The EP agonists; 11-deoxy PGEi, 
Misoprostol, PGAi and AH13205 stimulated cAMP production in HL-60s (mean p[Aso] 
values were 5.7±0.1, 5.5±0.1, 5.7±0.1 and 5.5±0.1 respectively, n=4-5) and human 
neutrophils (mean p[Aso] values were 5.6±0.2, 5.2±0.2, 6.3±0.2 and 5.8±0.1 respectively, 
n=3-4) but did not all reach the same maximum response in both cell types. Analysis of the 
two sets of data using operational model fitting (Leff et al., 1990) showed that the same 
agonist potency order existed in both cell types i.e. PGE2> 11-deoxy PGE! * PGA! > 
Misoprostol > AH 13205. Therefore these data suggest that the same EP receptor subserves 
cAMP elevation in human neutrophils and undifferentiated HL-60 cells.
AH13205 and Misoprostol were gifts from Glaxo and Searle respectively.
Armstong, R. & Talpain, E. (1992) Brit. J. Pharmacol. 107, 91P 
Hollingsworth, N. & De Vries, G.W. (1992) Faseb 6(5) ,  A1849 
Leff, P. et a\. (1990) Journal of Pharmacol Methods 23, 225-237 
Li, S.W. et al. (1993) Brit. J. Pharmacol. 109, IP
cAMP-elevating agents inhibit Ca2+ entry but not mobilisation in human neutrophils
S.W. Li, N.K. Boughton-Smith & J. Westwick1, Department of Pharmacology, Fisons 
Pharmaceuticals pic, Research & Development Laboratories, Bakewell Road, 
Loughborough, Leicestershire, LE11 ORH, U.K. and iSchool of Pharmacy and 
Pharmacology, University of Bath, Claverton Down, Bath, BA2 7 AY, U.K.
Prostaglandin E2 (PGE2) (Hecker et al., 1990) and selective type IV phosphodiesterase 
inhibitors (PDEI’s), such as rolipram (Schudt eta l., 1991), inhibit FMLP-stimulated 
superoxide (O2") generation by human neutrophils. FMLP-stimulated increase in 
cytosolic free Ca2+ ([Ca2 +]i) in human neutrophils is also inhibited by PGE2 and 
rolipram. Both agents elevate cAMP levels, PGE2 by activating adenylate cyclase which 
catalyses the formation of cAMP from ATP, and PDEI’s by inhibiting cAMP 
metabolism. It is unclear whether cAMP-elevating agents inhibit human neutrophil 
activation by attenuating [Ca2+]i and if they do, whether this is mediated by modulating 
Ca2+-mobilisation and/or entry.
In this study, we investigated the effect of cAMP elevation on Ca2+ release from 
intracellular stores and Ca2+ influx in fura-2 loaded human neutrophils (5xl05 ml-i) by 
measuring [Ca2+]i and Mn2+ (a Ca2+ surrogate) influx. Chelation of extracellular Ca2+ 
with EGTA (ImM) inhibited FMLP (O.lpM)-stimulated O2" generation by human 
neutrophils (62.1+3.8%, n=3), as did PGE2 (IOjiM, 89.2±3.2%, n=4) and rolipram 
(l|iM , 7Q.7±3.0%, n=4). These maximally inhibitory concentrations of PGE2 and 
rolipram did not reduce the FMLP (O.lfiM)-induced peak increase in [Ca2+]i (release 
from intracellular stores) but reduced the duration of the increase in [Ca2+]i (influx from 
extracellular medium). Neither PGE2 nor rolipram inhibited the FMLP peak Ca2+ 
transient when extracellular Ca2+ ions were chelated with EGTA (ImM), but the increase 
in [Ca2+liOn re-addition of 2mM CaCl2 (Ca2+ influx) was inhibited by PGE2 (IOjjM, by 
77.7±11.3%, n=3) and rolipram (l(iM, by 72.8±6.3%, n=3). However Mn2+ influx 
stimulated by FMLP (0.1 pM) was unaffected by either agent, and there was no 
measurable FMLP-stimulated Ba2+ (another Ca2+ surrogate) influx over unstimulated 
levels.
These data demonstrate that cAMP-elevating agents, such as PDEI’s and PGE2 , inhibit 
FMLP-stimulated increase in [Ca2+]i and provides evidence for this as a mechanism of 
inhibiting human neutrophil activation. This is mediated by inhibiting Ca2+-entjy and/or 
promoting Ca2+-efflux/sequestration. In addition, Ca2+ and Mn2* permeable ion channels 
may be differentially regulated by increases in cAMP. It will be interesting to determine 
whether thapsigargin-induced superoxide generation, Ca2+ and Mn2+ influx are similarly 
modulated by cAMP-elevating agents.
Hecker, G., Ney, P., & Schror, K., 1990, Naunyn-Schmiedeberg’s Arch. Pharmacol., 
341, 308-315.
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Prostanoid antagonist AH 6809 antagonises PGEj inhibition of human neutrophil activation
S.W.Li, K.McKechnie, R.J.Griffiths1, N.K.Boughton-Smith, A.Blackham 
& P.Leff, Department of Pharmacology, Fisons pic, Pharmaceutical 
Division, Research and Development Laboratories, Bakewell Road, 
Loughborough, Leicestershire, LEI 1 ORH.
The potency order of prostaglandin E (EP) receptor agonists and activity of 
AH13205 (EP2 selective agonist) on neutrophil superoxide production and 
cAMP levels, suggest the EP receptors on human neutrophils are of the EP2 
subtype (Wheeldon & Vardey, 1993 and Li et al., 1993). There are, 
however, no selective antagonists for the EP2 receptor. AH 6809 has been 
described as an antagonist for EP! and DP receptors (pA2 values of 6.6-7.0, 
Coleman etal., 1987, and 5.3, Keery & Lumley, 1988, respectively) and it 
has been stated that it is a weak or inactive antagonist (pA2 < 5.0) at EP2 
receptors in the cat trachea and chick ileum (Coleman et al., 1985). In the 
present study we have evaluated AH 6809 as an antagonist of PGEj in human 
neutrophils and compared it to other EPj (SC 19220, pA2=5.4-5.7, Coleman 
etal., 1987) and DP (BW A8 6 8 C, pA2=9.26, Giles etal., 1993) receptor 
antagonists.
Human neutrophils were isolated from venous blood by centrifugation (450- 
470 g) with Polymorphprep (Nycomed) and pre-incubated with antagonists at 
room temperature (60 min) in phosphate buffered saline containing 0.9mM 
CaCl ,^ 0.5mM MgCl2 and llmM glucose. Cytochalasin B (5pg ml *) and the 
agonists or vehicle were added and incubation continued for a further 5 min 
(37°C). Superoxide production (5 min, 37°C) was stimulated by the addition 
of FMLP (10 7 M) and measured as superoxide dismutase (90 U m l1) 
inhibitable reduction of ferri-cytochrome C (0.08mM). PGE2 inhibition of 
FMLP stimulated superoxide production (pEC50=6 . 9  ± 0 .1 , mean ± 
s.e.mean, n=12) was antagonised by AH 6809 (pA2=7.04±0.06, 
slope=1.06±0.07, n=5 experiments) but not by SC 19220 (10*4 M). BW 
A8 6 8 C (10-7 M) also failed to antagonise PGE  ^a concentration which caused 
a 2.3810.09 log™ unit rightward-shift (mean ± s.e.mean, n=5) of the PGD2 
concentration-enect curve. Furthermore, the shift of the PGE2 curve by AH
6809 (10-5 M) was unaffected by the presence of BW A8 6 8 C (10 7 M, n=3). 
AH 6809 (10-5 M) did not antagonise inhibition of superoxide production 
mediated by the adenosine receptor agonist NECA or the adenylate cyclase 
activator forskolin (both n=3).
The results demonstrate a selective effect of AH 6809 on PGE2-induced 
suppression of human neutrophil activation, an effect that cannot be attributed 
to an action on DP receptors. The EP receptor on human neutrophils, like 
those mediating relaxation of the cat trachea and chick ileum, is classified as 
EP, on the basis of agonist potency order. However its sensitivity to AH 
6809 appears to distinguish it from those receptors. While it is tempting to 
suggest that these data provide evidence for a receptor subtype, the lack of 
detailed information in the literature on the action of AH 6809 in EP, receptor 
containing tissues means that experimental differences cannot be excluded.
AH 6809, SC 19220 and BW A8 6 8 C were gifts from Glaxo, Searle and 
Wellcome respectively.
Current address: Department of Immunology, Pfizer Central Research, 
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HUMAN NEUTROPHIL & MONOCYTE RESPONSES TO PGE2 ARE 
INHIBITED BY THE PROSTANOID ANTAGONIST AH 6809
S.W.Li. N.K. Boughton-Smith, K. McKechnie, A. Blackham & P.Leff. Department of 
Pharmacology, Fisons Research & Development Laboratories, Leics LEI 1 ORH. U.K.
Prostaglandin E (EP) receptor agonist potency order suggests that human neutrophils and 
monocytes have EP2 receptors. However, there are no selective antagonists for the EP2 
receptor. The activity of the EP1/DP receptor antagonist AH 6809 on responses to PGE2 
in human neutrophils and monocytes has therefore been evaluated. The inhibition by 
PGE2 (pECso=6.9) of fMLP (0.1 p.M) stimulated superoxide generation by isolated 
neutrophils was antagonised by AH 6809 (pA2=7.0, slope=l.l±0.1) but not by 
antagonists for EPi (SC 19220) or DP (BW A868C) receptors. AH 6809 (10|iM) did 
not affect inhibition of neutrophil superoxide generation by the adenosine receptor agonist 
NECA or by forskolin. In addition, elevation of cAMP levels by PGE2 in both isolated 
neutrophils (pECso=6.8) and monocytes (pEC5o=6.5) were also antagonised by AH 
6809 (DR=1.3 & 1.6 log units, respectively). Whether this sensitivity to AH 6809 on 
neutrophils and monocytes, compared with other EP2 tissues, is due to experimental 
differences or receptor divergence is unclear.
Comparison of prostanoid DP-receptors in the rabbit isolated saphenous vein and human neutrophil.
S.J. Lydford, S.W. Li & K.C.W. McKechnie. Department of Pharmacology, Astra Charnwood, Bakewell Road, Loughborough, Leics, LE11 ORH.
Prostanoid receptors have been designated DP, EP, FP, IP and TP-receptors 
on the basis of agonist and antagonist data and furthermore, EP-receptors 
have been subclassified into four distinct subtypes (Coleman et al., 1994). It 
has also been postulated that there may be subtypes of the DP-receptor 
(Woodward et al., 1993). In the present study we have examined the effects of 
selective DP-receptor ligands in the rabbit saphenous vein (RbSV) and human 
neutrophil (PMN).
Isolated rings of saphenous vein from male NZW  rabbits were prepared as 
described previously (Lydford etal., 1994) with 10pM GR32191B in the buffer. 
Human PMNs were prepared according to Li etal., 1993, for measurement of 
fMLP stimulated superoxide production. In both preparations, concentration- 
effect (E/[A]) curves to DP-receptor agonists were constructed in the absence 
and presence of appropriate antagonists. Data are presented as mean ±  s.e (n 
> 3 ).
In the RbSV, the DP-receptor agonists BW245C, ZK 118.182 and PGD2 
caused concentration-dependent relaxations with mean potencies (p[A50]) of 
7.58 ± 0 .1 1 , 7.36 ± 0.05 and 7.00 ± 0.07 respectively.
The potent DP-receptor antagonist BW A868C (0.01 - 100 pM), caused a 
rightward displacement of BW245C E/[A] curves in a manner consistent with a 
two receptor system (Lemoine and Kaumann, 1983). Analysis of the data 
using their model yielded two pKB estimates of *8.50 ±  0.07 and 4.89 ±  0.08. 
The higher estimate corresponds to an activity at DP-receptors, the latter to 
EP4-receptors (Lydford et al., 1994). The putative DP-receptor antagonist ZK 
138.357 (Thierauch etal., 1995) was without significant effect on BW245C  
E/[AJ curves at a concentration of 1 pM however at 30pM, a three-fold shift of 
BW245C E/[A] curves was observed. In addition, E/[A] curves to BW245C  
were antagonised by the EP/DP-receptor antagonist AH6809 (3 - 30 pM).
In human PMNs, the p[A50]s for inhibition of superoxide production by 
BW245C, ZK 118.182 and PGD2 were 8.69 ±  0 .10 ,7 .92  ±  0.12 and 7.73 ±
0.14 respectively.
BW A868C (0.1 pM), ZK 138.357 (1 pM) and AH6809 (3 - 30 pM) inhibited 
these responses with antagonist potencies similar to previously published 
estimates for DP-receptor blockade (Table 1).
Table 1. Antagonist potencies against BW245C (pA2 or *pKB)
Antagonist: B W A 868C  ZK 138.357 A H 6809
RbSV *8.50 ± 0 .0 7  t5 .0 5 ± 0 .1 2  5.93 ± 0.05
PMN t9 .46  ±  0.27 17.25 ± 0.03 6.59 ± 0.19
1 E stim ates ob ta ined  from a  sing le  concentration  of an tagon ist
Whilst the agonist potency order is the same in both preparations: BW245C > 
ZK 118.182 > PG D2; data obtained with a range of DP-receptor antagonists 
appears to indicate differences between the DP-receptors on the RbSV and 
human PMN. Possible interpretations of the antagonist data is that the 
differences are due to species variation or interactions with other prostanoid 
receptors. However, the change in antagonist potency orders between the 
two preparations may indicate activities at different receptor subtypes.
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